Complementary therapies for acne vulgaris

Huijuan Cao1, Guoyan Yang1, Yuyi Wang2, Jian Ping Liu1, Caroline A Smith3, Hui Luo1, and Yueming Liu4

1Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China

2Department of Dermatology, Chongqing Municipal Hospital of Traditional Chinese Medicine, Chongqing, China

3National Institute of Complementary Medicine (NICM), University of Western Sydney, Sydney, Australia

4c/o Cochrane Skin Group, The University of Nottingham, Nottingham, UK

Abstract

Background—Acne is a chronic skin disease characterised by inflamed spots and blackheads on the face, neck, back, and chest. Cysts and scarring can also occur, especially in more severe disease. People with acne often turn to complementary and alternative medicine (CAM), such as herbal medicine, acupuncture, and dietary modifications, because of their concerns about the...
adverse effects of conventional medicines. However, evidence for CAM therapies has not been systematically assessed.

**Objectives**—To assess the effects and safety of any complementary therapies in people with acne vulgaris.

**Search methods**—We searched the following databases from inception up to 22 January 2014: the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 1), MEDLINE (from 1946), Embase (from 1974), PsycINFO (from 1806), AMED (from 1985), CINAHL (from 1981), Scopus (from 1966), and a number of other databases listed in the Methods section of the review. The Cochrane CAM Field Specialised Register was searched up to May 2014. We also searched five trials registers and checked the reference lists of articles for further references to relevant trials.

**Selection criteria**—We included parallel-group randomised controlled trials (or the first phase data of randomised cross-over trials) of any kind of CAM, compared with no treatment, placebo, or other active therapies, in people with a diagnosis of acne vulgaris.

**Data collection and analysis**—Three authors collected data from each included trial and evaluated the methodological quality independently. They resolved disagreements by discussion and, as needed, arbitration by another author.

**Main results**—We included 35 studies, with a total of 3227 participants. We evaluated the majority as having unclear risk of selection, attrition, reporting, detection, and other biases. Because of the clinical heterogeneity between trials and the incomplete data reporting, we could only include four trials in two meta-analyses, with two trials in each meta-analysis. The categories of CAM included herbal medicine, acupuncture, cupping therapy, diet, purified bee venom (PBV), and tea tree oil. A pharmaceutical company funded one trial; the other trials did not report their funding sources.

Our main primary outcome was 'Improvement of clinical signs assessed through skin lesion counts’, which we have reported as 'Change in inflammatory and non-inflammatory lesion counts’, 'Change of total skin lesion counts’, 'Skin lesion scores’, and 'Change of acne severity score’. For 'Change in inflammatory and non-inflammatory lesion counts’, we combined 2 studies that compared a low- with a high-glycaemic-load diet (LGLD, HGLD) at 12 weeks and found no clear evidence of a difference between the groups in change in non-inflammatory lesion counts (mean difference (MD) −3.89, 95% confidence interval (CI) −10.07 to 2.29, P = 0.10, 75 participants, 2 trials, low quality of evidence). However, although data from 1 of these 2 trials showed benefit of LGLD for reducing inflammatory lesions (MD −7.60, 95% CI −13.52 to −1.68, 43 participants, 1 trial) and total skin lesion counts (MD −8.10, 95% CI −14.89 to −1.31, 43 participants, 1 trial) for people with acne vulgaris, data regarding inflammatory and total lesion counts from the other study were incomplete and unusable in synthesis.

Data from a single trial showed potential benefit of tea tree oil compared with placebo in improving total skin lesion counts (MD −7.53, 95% CI −10.40 to −4.66, 60 participants, 1 trial, low quality of evidence) and acne severity scores (MD −5.75, 95% CI −9.51 to −1.99, 60 participants, 1 trial). Another trial showed pollen bee venom to be better than control in reducing numbers of skin lesions (MD −1.17, 95% CI −2.06 to −0.28, 12 participants, 1 trial).
Results from the other 31 trials showed inconsistent effects in terms of whether acupuncture, herbal medicine, or wet-cupping therapy were superior to controls in increasing remission or reducing skin lesions.

Twenty-six of the 35 included studies reported adverse effects; they did not report any severe adverse events, but specific included trials reported mild adverse effects from herbal medicines, wet-cupping therapy, and tea tree oil gel.

Thirty trials measured two of our secondary outcomes, which we combined and expressed as 'Number of participants with remission'. We were able to combine 2 studies (low quality of evidence), which compared Ziyin Qinggan Xiaocuo Granule and the antibiotic, minocycline (100 mg daily) (worst case = risk ratio (RR) 0.49, 95% CI 0.09 to 2.53, 2 trials, 206 participants at 4 weeks; best case = RR 2.82, 95% CI 0.82 to 9.06, 2 trials, 206 participants at 4 weeks), but there was no clear evidence of a difference between the groups.

None of the included studies assessed 'Psychosocial function'.

Two studies assessed 'Quality of life', and significant differences in favour of the complementary therapy were found in both of them on 'feelings of self-worth' (MD 1.51, 95% CI 0.88 to 2.14, P < 0.00001, 1 trial, 70 participants; MD 1.26, 95% CI 0.20 to 2.32, 1 trial, 46 participants) and emotional functionality (MD 2.20, 95% CI 1.75 to 2.65, P < 0.00001, 1 trial, 70 participants; MD 0.93, 95% CI 0.17 to 1.69, 1 trial, 46 participants).

Because of limitations and concerns about the quality of the included studies, we could not draw a robust conclusion for consistency, size, and direction of outcome effects in this review.

**Authors’ conclusions**—There is some low-quality evidence from single trials that LGLD, tea tree oil, and bee venom may reduce total skin lesions in acne vulgaris, but there is a lack of evidence from the current review to support the use of other CAMs, such as herbal medicine, acupuncture, or wet-cupping therapy, for the treatment of this condition. There is a potential for adverse effects from herbal medicines; however, future studies need to assess the safety of all of these CAM therapies. Methodological and reporting quality limitations in the included studies weakened any evidence. Future studies should be designed to ensure low risk of bias and meet current reporting standards for clinical trials.

**PLAIN LANGUAGE SUMMARY**

**Complementary therapies for acne vulgaris**

**Background**—Acne is a chronic skin disease, which causes spots to occur simultaneously on several areas of the body, including the face, neck, back, and chest. Besides the current commonly used treatments, complementary and alternative medicines (CAM) are of increasing interest to people who often use them in addition to conventional treatments as additive or single therapies to treat acne.

**The review question**—Can any complementary therapies improve the clinical symptoms of acne vulgaris?

**Study characteristics**—We searched relevant databases and trials registers up to 22 January 2014. We identified 35 randomised controlled trials, with 3227 participants, which
used 6 kinds of CAM (herbal medicine, acupuncture, wet cupping, diet, purified bee venom, and tea tree oil). A pharmaceutical company funded one trial; the other trials did not report their funding sources.

**Key results**—For our primary outcome, we combined two studies that compared a low- with a high-glycaemic-load diet (LGLD, HGLD), but found no clear evidence of a difference between the 2 groups at 12 weeks for a change in non-inflammatory lesion counts. Only one of these two trials provided usable data to show potential benefit of LGLD for reducing inflammatory and total skin lesion counts. Tea tree oil and pollen bee venom were found to reduce total skin lesion counts in single trials, respectively. The remaining 31 included trials gave mixed results about whether complementary therapies might reduce the total number of skin lesion counts.

Twenty-six trials reported adverse events. The herbal medicine group found some mild side-effects, such as nausea, diarrhoea, and stomach upset. The acupuncture group found some itch or redness and pain following needle insertion. Participants who used tea tree oil reported itchiness, dryness, and flaking of the skin. None of the trials reported severe adverse effects.

For our secondary outcome, there was no clear evidence of a difference in the number of participants with remission between Ziyin Qinggan Xiaocuo Granule and minocycline according to a meta-analysis of two studies.

**Quality of the evidence**—There is some low-quality evidence from single trials that a low-glycaemic-load diet, tea tree oil, and bee venom may reduce skin lesions in acne vulgaris, but there is a lack of evidence from the current review to support the use of other CAMs. Methodological and reporting quality limitations in the included studies weakened any evidence.

**BACKGROUND**

Please see the glossary in Table 1 for an explanation of the terms we have used.

**Description of the condition**

Acne is a chronic inflammatory condition. It most commonly affects areas where the sebaceous glands are largest and most abundant - for example, the face, anterior trunk, and upper back (Simon 2005). It is a skin disease that causes spots to occur simultaneously on several areas of the body, including the face, neck, back, and chest. Comedones, also known as blackheads, which are dilated pores with a plug of keratin, characterise mild acne. Whiteheads (small, cream-coloured, dome-shaped papules), red papules, pustules, or cysts may be found with moderate or severe acne. Scars, both those on the skin and emotional scars, can last a lifetime (Oberemok 2002a; Webster 2002).

Acne is a common condition affecting 80% of adolescents (most commonly from 12 years of age), but it may also affect 54% of adult women and 40% of adult men (including those in their early- or mid-20s) (Ramos-e-Silva 2009). Two surveys suggest that the age of onset of
acne has fallen, with a mean age of onset of 11.6 years from a survey period between 2006 to 2008 and a mean age of 11.92 years from a survey period between 1991 to 1993 (Sørensen 2010).

Bacterial colonisation, sebum, hormone production, follicular hyperkeratinisations, and inflammation all contribute to acne causation (Friedlander 2010). According to the lesion type, acne can be classified into four main categories: non-inflammatory (purely comedone acne), mild papular, scarring papular, and nodular; the latter three are inflammatory acne lesions (Webster 2002). Besides the obvious skin lesions, acne may produce permanent scarring and have significant psychosocial consequences (Fried 2010; Oberemok 2002).

**Description of the intervention**

Acne treatment aims to lessen the inflammatory or non-inflammatory acne lesions, improve appearance, prevent or minimise potential adverse effects, and minimise any scarring (Oberemok 2002a). Ignoring prescribed drugs, many people still rely on herbal medications, skin hygiene routines, and dietary modifications (Webster 2002).

Complementary and alternative medicine (CAM) usually refers to therapies that are used in addition to conventional treatment, and many such therapies remain unproven (Verhoef 1999). ’Complementary therapy’ is usually used in addition to conventional treatments, while ’alternative therapy’ is often used instead of conventional treatment. In 1992, the US Office of Alternative Medicine classified complementary therapies, using the classification established by congressional mandate at the National Institutes of Health (Workshop 1992). According to this classification, complementary therapies are divided into the following categories: diet and nutrition (e.g., macrobiotics, Gerson diet, antioxidants); mind-body interventions (e.g., meditation, imagery, hypnosis, support groups); bioelectromagnetics (e.g., electromagnetics, electroacupuncture); traditional and folk remedies (e.g., naturopathy, Ayurveda, Traditional Chinese Medicine, homeopathy); pharmacological and biological treatments (e.g., antineoplaston, chelation therapy, immuno-augmentation therapy, shark cartilage); manual healing methods (e.g., massage, chiropractic, therapeutic touch); and herbal medicine.

Complementary and alternative medicines are a significant subset of healthcare practices not integral to conventional western care but used by people in their healthcare decisions (Lewith 2001). Though lacking biomedical explanation, some of them (physical therapies, diet, acupuncture) have become widely accepted, but others, such as those interventions linked to the theory of humours (an old term to describe liquids within the body - an example of which was the ’letting’ of blood as a form of treatment) and radium therapy, quietly fade away (Lewith 2001).

Traditional Chinese Medicine (TCM), a traditional healthcare system that is based on the beliefs and practices of Chinese culture and ancient philosophy, includes herbal medicine; acupuncture or moxibustion (combustion of the moxa or mugwort herb); massage; cupping therapy; therapeutic exercise, such as tai chi; and dietary therapy. Traditional Chinese Medicine is one of the most important components of complementary and alternative medicines.
How the intervention might work

Acne develops as a result of increased sebum production, hyperkeratinisation, increase in *Propionibacterium acnes*, and inflammation (Spencer 2009), and treatments aim to address some or all of these elements (Webster 2002).

Chinese herbal medicine, manual healing therapies (such as acupuncture and massage), and other traditional and folk remedies may follow similar mechanisms in the treatment of acne. According to the theory of Traditional Chinese Medicine, several factors may cause acne, including the following: overheating of the lung or stomach, damp and heat toxin with blood stasis, and stagnation of Qi (the life force, or vital energy, of a living thing) and blood. As the condition becomes protracted, heat may rise and lodge in the skin and tissues, thus, producing the lesions (Shen 1995). All of the above therapies may help the body to regulate the Qi and blood, eliminate dampness, relieve heat toxicity, and enhance the immunologic function to improve the remission of acne (Shen 1995). Some studies also mention that acupuncture can stimulate and balance androgen levels to inhibit the over-secretion of the sebaceous gland (Li 2009).

It is usually recommended that people with acne restrict their consumption of chocolate and oily or fatty foods (El-Akawi 2006). One review concluded that some components of western diets, particularly dairy products, may be associated with an increased risk of acne (Spencer 2009). Some researchers have concluded that genetic predisposition and hormonal influences play a more important role in acne than diet (Magin 2005; Wolf 2004). However, despite the genetic regulation of sebum excretion and other determinants of acne, diet may act as a modifier of gene expression that may account for the increased acne risk (Walton 1988). The effect of other kinds of complementary therapies and medicines on treating acne are currently unclear due to insufficient evidence. Commonly used treatments aim to reduce the number of inflammatory lesions, inhibit comedones (Webster 2002), suppress the growth of *Propionibacterium acnes* (Toyoda 1998), or reduce sebaceous gland size and secretory activity (Enders 2003). Topical retinoids (such as tretinoin, adapalene, or tazarotene) can usually inhibit comedonal acne, the non-inflammatory type of acne. These medications may reduce the number of inflammatory lesions, but local irritation can accompany them (Webster 2002). Benzoyl peroxide (BP) alone or combined with either clindamycin or retinoid, which exert a synergistic and antimicrobial effect, can treat mild papulopustular acne. Oral antibiotics (Simonart 2005) are also used to suppress the growth of acne and reduce the production of inflammatory factors (Toyoda 1998), while oral doxycycline (Garner 2009) or minocycline plus topical retinoid can be used in treating severe papulopustular or nodular acne. Although isotretinoin (optimal dosage 0.5 to 1 mg/kg/day) (Katsambas 2004) may be effective in reducing sebaceous gland size and secretory activity, decreasing comedone formation, and reducing follicular colonisation with acne (Enders 2003), its teratogenicity and adverse effects profile (such as dry skin, hyperlipidaemia, and proposed increased risk of depression) is a concern (Marqueling 2007; Webster 2002).

Because of the inadequate treatment response or potential side-effects of current topical treatments for acne, there is increasing interest in the use of complementary therapies as adjuvant or single therapies alone. In America, 9% of people reported having skin conditions
in the past 12 months, 7% reported that they had used a complementary medicine, and 2% reported seeing a complementary medicine practitioner for their condition (Eisenberg 1998).

Traditional Chinese Medicine has been widely used to treat acne for many years. Herbal medicine, including decoction and patent medicine, is used based on a diagnosis from a TCM perspective according to the different syndromes of acne (Shen 1995).

Although there are no systematic reviews of herbal medicine for the treatment of acne, there has been a systematic summary of the therapeutic effect of herbal medicine for the treatment of bacterial infections (Martin 2003), where the authors found similar results to those for conventional treatments. Another evaluation assessed 17 TCM randomised controlled trials (RCTs) (Li 2009), and the findings from the analysis suggested acupuncture and moxibustion were better than routine western medicine at reducing symptoms of acne. A systematic review was conducted (Magin 2006), which included 23 trials of topical and oral CAM to treat acne.

Why it is important to do this review

Despite the widespread use of complementary and alternative medicines (CAM), there is no systematic review comprehensively assessing the evidence of CAM. In particular, a publication bias exists with the inclusion of English-language texts only. There is a need to undertake a comprehensive and systematic review of the effectiveness and safety of CAM for the treatment of acne.

OBJECTIVES

To assess the effects and safety of any complementary therapies in people with acne vulgaris.

METHODS

Criteria for considering studies for this review

Types of studies—We included parallel-group randomised controlled trials (RCT) and only the first phase data of randomised cross-over trials in any data analysis.

Types of participants—We assessed participants of any age and gender with a diagnosis of acne vulgaris or papulopustular, inflammatory, juvenile, or polymorphic acne.

Types of interventions—Eligible interventions included any kind of complementary and alternative medicine, including diet and nutrition; mind-body interventions; bioelectromagnetics; traditional and folk remedies; biological treatments; manual healing methods; and herbal medicine, compared with no treatment; placebo; or other active therapies. Comparisons included a combination of CAM plus other therapies versus other active therapies alone.

Types of outcome measures—According to the report of the Consensus Conference on Acne Classification 1990 (Pochi 1991), the evaluation of lesions and their complications are
important to assess the severity of acne. Psychosocial impact, failure to respond to previous therapies, and occupational disability are three additional factors used in grading acne (Pochi 1991).

The following were timing of outcomes where data were available:

- short-term data - data collected within 30 days after randomisation;
- medium-term data - data collected between 31 and 90 days after randomisation; and
- long-term data - data collected 90 days after randomisation.

**Primary outcomes**

1. Improvement of clinical signs assessed through skin lesion counts (total of inflamed and non-inflamed counted separately) and acne severity scores.

2. Adverse effects assessed by reporting early study discontinuations, the worsening of acne in participants, and other adverse events during the treatment and follow-up period.

**Secondary outcomes**

1. Physicians’ global evaluation (after treatment).

2. Participants’ self assessment of change in specific types of lesion (such as comedones, papules, pustules, or nodules).

3. Psychosocial function outcomes (such as the Hamilton Depression Rating Scale (HAMD)).

4. Quality of life (QoL).

We combined the Physicians’ global evaluation and Participants’ self assessment of change in specific types of lesion and expressed them as the ‘Number of participants with remission’ as this had a clear definition and was easy to assess. The word “remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine” (Zheng 2002), which means lesions totally faded (or > 95% faded) and only mild pigmentation and scars remaining.

**Search methods for identification of studies**

We aimed to identify all relevant randomised controlled trials (RCTs) regardless of language or publication status (published, unpublished, in press, or in progress).

**Electronic searches**—We searched the following databases up to 22 January 2014:

- the Cochrane Skin Group Specialised Register using the strategy in Appendix 1;
- the Cochrane Central Register of Controlled Trials (CENTRAL) in *The Cochrane Library* (2014, Issue 1), using the search strategy in Appendix 2;
- MEDLINE (from 1946) using the strategy in Appendix 3;
• Embase (from 1974) using the strategy in Appendix 4;
• PsycINFO (from 1806) using the strategy in Appendix 5;
• AMED (Allied and Complementary Medicine Database, from 1985) using the strategy in Appendix 6;
• CINAHL (Cumulative Index to Nursing and Allied Health Literature, from 1981) using the strategy in Appendix 7; and
• PubMed (from 1966) using the CAM subset and the strategy in Appendix 8.

We searched the following databases up to 20 January 2014:
• Scopus (from 1966 to the present);
• ScienceDirect (from inception to the present);
• MD Consult (from inception to the present);
• BioMed Central (from 1997 to the present);
• Current Contents Connect® (from 1998 to the present); and
• ProQuest Health and Medical Complete (from inception to the present).

We also searched the following Chinese databases up to 24 January 2014:
• China National Knowledge Infrastructure (CNKI, from 1979 to the present);
• VIP Journal Integration Platform (VJIP, from 1989 to the present);
• Wanfang Data Chinese databases (from 1985 to the present); and
• Chinese Biomedical Literature database (CBM, from 1978 to the present).

We searched the following database up to 21 May 2014:
• the Cochrane CAM Field Specialised Register using the search term 'acne'.

**Searching other resources**—We searched the following trials registers up to 24 January 2014:

• The metaRegister of Controlled Trials ([www.controlledtrials.com](http://www.controlledtrials.com)).
• The US National Institutes of Health Ongoing Trials Register ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)).
• The Australian New Zealand Clinical Trials Registry ([www.anzctr.org.au](http://www.anzctr.org.au)).
• The World Health Organization International Clinical Trials Registry platform ([www.who.int/trialsearch](http://www.who.int/trialsearch)).
• CenterWatch ([www.centerwatch.com/](http://www.centerwatch.com/)).

We also searched unpublished postgraduate theses in Chinese databases.

We handsearched the reference lists of all relevant articles found electronically for further references to relevant trials.
**Adverse effects**—We did not perform a separate search for adverse effects of the target interventions. We examined data on adverse effects from the included studies only.

**Data collection and analysis**

**Selection of studies**—Three authors (HC, GY, and YW) evaluated the titles and abstracts independently. We retrieved full-text versions for all potentially relevant studies. The authors (HC, GY, and YW) resolved disagreements by discussion, and another author (JPL) arbitrated when needed.

**Data extraction and management**—Three authors (HC, GY, and YW) extracted the data from the included trials independently, with disagreements resolved by discussion with a fourth author (JPL). They extracted information about the following:

- study methods: type of study design, method of random number generation and allocation concealment, details of blinding methods;
- participants: inclusion/exclusion criteria, sample size, characteristics of participants (such as age, gender, duration of disorder, et al);
- intervention and control: type of complementary therapy, details of treatment and control;
- follow-up data: duration of follow up, reasons and rates for withdrawal in each group;
- outcome data: types of outcome, data for each outcomes per group (with unit if available); and
- analysis data: methods of dealing with missing data, comparability of groups at baseline (yes/no), statistical methods.

**Assessment of risk of bias in included studies**—We used the method for assessment of risk of bias provided by the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011) to generate a 'Risk of bias' assessment table for each study. We assessed the following categories of bias:

a. selection bias (random sequence generation and allocation concealment);

b. performance bias (blinding of participants and personnel);

c. detection bias (blinding of outcome assessment);

d. attrition bias (incomplete outcome data);

e. reporting bias (selective reporting); and

f. other bias.

For each included study, we described any important concerns we had about other possible sources of bias - e.g., was there a potential source of bias related to the specific study design? Was the trial stopped early because of some data-dependent process? Was there extreme baseline imbalance? Had the study been claimed to be fraudulent? (Higgins 2011)
The Cochrane Collaboration’s ‘Risk of bias’ tool consists of six items. There are three potential bias judgements: ‘low risk’, ‘high risk’, or ‘unclear risk’. If the paper reported insufficient detail regarding what happened in the study, the judgement was usually ‘unclear’. We also made an ‘unclear’ judgement if we knew what happened in the study but the risk of bias was unknown or if an item was not relevant to the study at hand (particularly for assessing blinding and incomplete outcome data or when the study had not measured the outcome assessed).

**Measures of treatment effect**—We summarised data using risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes or mean difference (MD) with 95% CI for continuous outcomes.

**Unit of analysis issues**—We planned to include cross-over trials; however, as there were minimal data on the effectiveness of washout periods for treatment, we included only the first phase of intervention.

**Dealing with missing data**—We made contact with the authors of the included trials to acquire missing information.

We conducted intention-to-treat analysis for dichotomous outcomes. We made ‘best-case’ and ‘worst-case’ assumptions for those leaving the study early (Gamble 2005). In best-case assumptions, we analysed participants who dropped out of the intervention group as effective or improved after treatment, and we counted those who dropped out of the control group as having ineffective results. By contrast, for worst-case analysis, we considered missing data in the intervention group as having an ineffective outcome and missing data in the control group as having an effective outcome. We undertook sensitivity analyses to test how prone the primary outcomes were to change under each assumption. We reported completer-only data for continuous outcomes.

**Assessment of heterogeneity**—We assessed clinical heterogeneity according to the characteristics of the included studies and the participants, details of the intervention or control, and types of outcome measurements. We assessed statistical heterogeneity by using the $I^2$ statistic. We assessed heterogeneity as substantial if the $I^2$ statistic was greater than 50%.

**Assessment of reporting biases**—We planned to generate funnel plots (effect size against standard error) if we found a sufficient number of trials. Asymmetry can be due to publication bias, but it can also be due to a relationship between the trial size and effect size (Higgins 2011).

**Data synthesis**—We performed statistical analyses with Cochrane’s Review Manager software. One reviewer (HC) was responsible for entering data into the software, which a second reviewer (YW) checked. We meta-analysed trials if the $I^2$ statistic was less than 85% and characteristics of trials were similar (same intervention or comparison (including drug type)). Forest plots visualised the results of the meta-analysis. We used the random-effects model unless the degree of heterogeneity was readily explainable, or if the measure of
heterogeneity, the $I^2$ statistic, was less than 25%, we used the fixed-effect model was used (Higgins 2011).

We generated 'Summary of findings' (SOF) tables using GRADE-Pro software (Version 3.2 for Windows). The SOF tables evaluated the overall quality of the body of evidence for clinical outcomes only from results of meta-analysis, which used Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria (study limitations, consistency of effect, imprecision, indirectness, and publication bias).

Subgroup analysis and investigation of heterogeneity—We planned to conduct subgroup analyses for different groups split by age; sex; subtypes or severity of acne (inflammatory acne or non-inflammatory acne); or treatment duration (short-term, medium-term, or long-term), to assess whether the treatment effects were different in different subgroups. Because of insufficient data, we only undertook subgroups for different treatment duration.

Sensitivity analysis—Usually at least one characteristic can be found for a study in a meta-analysis that makes it different from the others, i.e., an outlier. Heterogeneity may be due to the presence of one or two outlying studies with results that conflict with the rest of the studies (Higgins 2011). We planned to perform analyses both with and without outlying studies as part of a sensitivity analysis; however, we were unable to do this because of insufficient trials in each meta-analysis.

RESULTS

Description of studies

Results of the search—The searches conducted for the review retrieved a total of 7230 citations, 7222 following deduplication. Title and abstract screening excluded 6635 of these citations. We subsequently obtained full texts of the remaining 587 citations for further inspection. We screened a further 550 citations out with reasons stated in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart (please refer to Figure 1). We deemed no citations to be eligible for inclusion, but required further information on outcome measures. Please refer to the 'Characteristics of studies awaiting classification' tables for further details. After full-text screening, we included 35 studies in the qualitative syntheses and 4 in the quantitative syntheses of this review (please see the 'Characteristics of included studies' tables).

Included studies—Thirty-five trials (from a total of 39 papers), with a total of 3227 participants (average = 46 per group), were eligible for inclusion. Please refer to the 'Characteristics of included studies’ tables for detailed information on the included studies. Three papers reported Smith 2007; two papers reported Chen 2012; and two papers reported Li 2007.

Setting: Thirty of the 35 trials were conducted in China, which included 18 publications in Chinese Journals (Chen 2012; Li 2007; Lin 2013; Liu 2004; Liu 2008; Liu 2012; Mo 2011; Peng 2012; Shi 2012; Song 2007; Tang 2011; Wen 2012; Wu 2008; Wu 2008a; Yu 2008;
Yu 2011; Zhang 2012; Zhu 2007) and 12 unpublished dissertations (Chen 2009; Feng 2005; Han 2010; Huang 2006; Liu 2006; Liu 2007; Ni 2008; Wang 2012; Wei 2012; You 2012; Zhang 2010; Zhou 2009). For the remaining five trials, which were published in English, three were conducted in Korea (Han 2013; Kim 2012; Kwon 2012), one was conducted in Australia (Smith 2007), and the other was conducted in Iran (Enshaieh 2007).

**Design:** There were 4 3-arm trials (Chen 2009; Liu 2007; Liu 2012; Wu 2008) and 1 4-arm trial (Kim 2012); the remaining 30 trials had a parallel 2-arm design.

**Interventions:** We have listed the interventions under the following six headings: Diet, Acupuncture, Herbal medicine, Wet-cupping therapy, Tea tree oil, and Purified bee venom (PBV).

**Diet**—Two trials assessed the daily diet for acne participants (Kwon 2012; Smith 2007). Smith 2007 conducted 1 trial (with 3 publications), which had 12 weeks’ duration, to investigate the therapeutic effect of a low-glycaemic-load diet (LGLD) where glucose is slowly released into the bloodstream compared with a high-glycaemic-load diet for participants with acne. Kwon 2012 also investigated the effect of LGLD for acne (with 10 weeks’ duration). These 2 trials used a similar study design, and the LGLD was composed of 25% energy from protein, 45% from low-glycaemic-index carbohydrates, and 30% from fat.

**Acupuncture**—Three trials assessed the therapeutic effect of acupuncture for acne: Two arms of the four-arm trial, Kim 2012, compared a combination of acupuncture and herbal medicine with herbal medicine alone and also compared acupuncture and a control of four weeks on the waiting list. Han 2010 compared acupuncture with isotretinoin (20 mg daily for the first month and 10 mg daily for the second month) over an 8-week period. Huang 2006 compared acupuncture with azithromycin (500 mg daily) and clindamycin phosphate gel (externally applied) for 3 weeks.

**Herbal medicine**—Twenty trials investigated the therapeutic effect of herbal medicine on improving the clinical symptoms of acne. We list components of each herbal product (extract, patent, or decoction) in Table 2. Half of the four-arm trial, Kim 2012, compared a combination of herbal decoction and acupuncture with acupuncture alone and herbal decoction with a stay on the waiting list, respectively, with four weeks’ treatment duration.

Fifteen trials compared herbal medicine with western medications; of these, Wang 2012 employed herbal decoction applied externally to skin lesions. Another trial, Tang 2011, assessed herbal medicine (taken orally and externally applied) compared with roxithromycin (300 mg daily) and viaminate capsules (150 mg daily). The remaining 12 trials all used herbal decoction administered orally and taken twice daily. In the control groups, seven trials (Feng 2005; Li 2007; Liu 2004; Mo 2011; Tang 2011; Wei 2012; Yu 2008) employed antibiotics, including minocycline, doxycycline, azithromycin, and tetracycline. The dosage for the antibiotic drugs used as controls varied (details are in the Effects of interventions section), as well as the treatment duration from four to eight weeks. Eight out of these trials
used vitamin A acid (including viaminate capsule, viaminate cream, isotretinoin soft capsules, and tretinoin cream) as a control, in which three (Liu 2007; Shi 2012; Wang 2012) used cream or gel for external application. The oral doses in 5 other trials were 20 to 75 mg per day (Chen 2012; Peng 2012; Tang 2011; Zhang 2012; Zhu 2007). The treatment duration varied from two to eight weeks. One of the 15 trials, Wu 2008, used herbal decoction (used singly or combined with staphylococcus injection) compared with staphylococcus injection; the injection was used 0.2 to 0.5 ml daily for 4 weeks.

Yu 2011 observed a combination of herbal decoction and antibiotics compared with antibiotics (doxycycline, 200 mg daily). Liu 2012 investigated the effect of herbal decoction combined with blue and red light-emitting diode (LED) phototherapy compared with LED alone.

The remaining trial, Chen 2009, investigated the combination of herbal medicinal mask and wet-cupping therapy compared with wet-cupping therapy alone. The main treatment principle of herbal medicine was to clear the liver or lung’s heat and dampness, nourishing yin, and removing the blood stasis.

**Wet-cupping therapy**—This is a method involving sterilising the selected points with alcohol and making a very small incision with a triangle-edged needle or a plum-blossom needle and firmly tapping the point for a short time to cause bleeding (Cao 2010), then creation of a vacuum by applying suction with a hot cup or jar on the desired points or the specific affected body surface, in order to increase the blood supply to the area under suction.

Four trials evaluated the therapeutic effect of wet-cupping therapy (Chen 2009; Song 2007; Wu 2008a; Zhou 2009): One trial, Zhou 2009, chose GV14 (Dazhui) and BL13 (Feishu) as pricking point, according to the principle of clearing and expelling the lung’s heat, compared with viaminate cream. Two trials used tetracycline as control treatment (1000 mg daily in Wu 2008a and 1500mg daily in Song 2007); however, Wu 2008a chose the tender point on the back as the target point for pricking and cupping, and Song 2007 used blood-letting on the ear lobe plus wet cupping on the back. One trial, Chen 2009, compared a combination of wet-cupping therapy and herbal decoction with herbal decoction alone. The treatment duration of these four trials was two and four weeks. Six trials observed the therapeutic effect of a combination of wet-cupping therapy and acupuncture for acne (Liu 2006; Liu 2007; Liu 2008; Wen 2012; You 2012; Zhang 2010): Two trials (Liu 2006; Wen 2012) employed minocycline (100 mg daily) as a control treatment, and the other four (Liu 2007; Liu 2008; You 2012; Zhang 2010) used vitamin A acid (viaminate cream, isotretinoin soft capsules 30mg daily, tretinoin cream, or viaminate capsule 150 mg daily, respectively) as control therapy. Both intervention group and control group used a herbal medicinal mask as an additional treatment in one trial (You 2012). The points GV14 (Dazhui) and BL13 (Feishu) were chosen as the main points for wet-cupping therapy in all of these six trials. The treatment duration varied from 4 to 10 weeks.

One trial, Lin 2013, used wet-cupping therapy combined with herbal medicinal mask compared with viaminate capsule (30 mg daily). The treatment duration was four weeks.
One trial, Ni 2008, employed a combination of wet cupping, acupuncture, and massage as intervention therapy and used zinc gluconate oral liquid (40 ml daily) as a control treatment. The treatment duration was three weeks.

**Tea tree oil**—One trial, Enshaieh 2007, compared tea tree oil gel with placebo (vehicle gel alone) in 60 participants. Tea tree oil gel or placebo gel was applied externally to the skin lesion area for 20 minutes daily for 45 days.

**Purified bee venom (PBV)**—One trial, Han 2013, used cosmetics with or without purified bee venom (PBV) as the comparison in 12 participants. Cosmetics were applied topically on the whole face with an amount of 4 mL per day for 2 weeks.

**Excluded studies**—Out of 7230 citations retrieved by the search (7222 after removal of duplicates), our title and abstract screening excluded 6635. We obtained for further inspection the full texts of the remaining 587 citations. We screened out a further 550 citations with reasons stated in the PRISMA flow chart (please refer to Figure 1).

**Studies awaiting classification**—We identified two studies that are awaiting classification because although they were marked as ‘completed’, we were unable to get any more information about them from the authors.

### Risk of bias in included studies

We present the risk of bias of the included studies in Figure 2 and a summary in Figure 3.

**Allocation**—We had strict inclusion criteria that all the included studies should clearly state the method of randomisation, so we judged all the included trials as at a low risk of random sequence generation. According to the reports, a random number table or computer software (such as SPSS, SAS) generated the random numbers. Six trials reported the methods of allocation concealment. Three trials kept the random number in an opaque envelope (Chen 2012; Huang 2006; Wei 2012); in two trials, a third party (research nurse) performed the allocation (Kwon 2012; Smith 2007). The remaining trial, Kim 2012, used two separate databases (participant database and randomisation database) to keep the basic information or allocations, respectively. The participant database was accessible to any researcher; however, the randomisation database was password-protected. We evaluate the other 29 included trials as at an unclear risk of bias because of the insufficient information about the allocation concealment.

**Blinding**—Two trials, Enshaieh 2007; Han 2013, reported sufficient information to permit a judgement of a low risk of bias for performance bias, and three trials, Enshaieh 2007; Kim 2012; Smith 2007, reported sufficient information to permit a judgement for detection bias. One trial, Feng 2005, reported the study as a “single blind” study; another trial provided detailed information of blinding to personnel (Kim 2012). However, in those studies, intervention and control (non-placebo) were not similar in either appearance or taste, so it is hard to believe that blinding of participants or personnel was possible. The remaining trials did not outline the details about blinding methods. Therefore, we evaluated 33 out of 35 of the included trials (except Enshaieh 2007; Han 2013) as at a high risk of performance bias.
We evaluated 1 trial as at a high risk of bias for detection bias, and we evaluated 31 out of 35 included trials as at an unclear risk of bias for this domain.

**Incomplete outcome data**—Six trials had no missing data (Enshaieh 2007; Han 2013; Kwon 2012; Liu 2007; Ni 2008; Wang 2012), and one trial, Huang 2006, stated the reasons for missing data and used intention-to-treat analysis to impute the missing data: We evaluated these seven trials as at a low risk of bias for this domain. We assessed seven trials as at a high risk of bias for this domain because of the outcome-related reason for missing data and the potentially inappropriate application of simple imputation (Chen 2009; Han 2010; Li 2007; Liu 2004; Smith 2007; Wu 2008; Zhang 2012). The other 21 studies reported insufficient information to permit judgement of the risk of bias.

**Selective reporting**—We evaluated only one, Smith 2007, of the 34 included studies evaluated as at a low risk of bias because it provided the registered protocol of the study, and they had reported their prespecified outcomes in the prespecified way.

Kim 2012 also provided the registered protocol of the study but incompletely reported outcome data as was the case in two other trials (Enshaieh 2007; Kwon 2012), so could not be entered in a meta-analysis. However, Enshaieh 2007 provided 95% confidence intervals (CIs) for each primary outcome, and Kwon 2012 reported the P value of 2 groups between baseline and the end of the treatment, which made it possible to calculate standard deviations. Besides Kim 2012, four trials did not report at least one of their prespecified primary outcomes, so we assessed them as at a high risk of bias for this domain (Feng 2005; Li 2007; Wang 2012; Wei 2012).

We judged the other 28 studies as having an unclear risk of bias.

**Other potential sources of bias**—We assessed the following items for other potential bias:

1. whether or not the study addressed the sample size calculation methods;
2. whether or not the inclusion or exclusion criteria (of the trial) was appropriate;
3. whether or not the baseline data between groups were comparable and if not, whether the study applied any statistical methods to adjust for this;
4. whether or not the study clarified the funding source; and
5. whether there was any other potential methodological flaw that may have influenced the overall assessment.

According to the trial reports, no funding issue or methods of sample size calculation were apparent in most of the included trials; it was difficult to determine whether a study was fraudulent. We evaluated all of the trials as at an unclear risk of bias.
**Effects of interventions**

See: Summary of findings for the main comparison Low-glycaemic-load diet versus high-glycaemic-load diet for acne vulgaris; Summary of findings 2 Herbal medicine versus antibiotics for acne vulgaris

In total, the included studies assessed the therapeutic effects of herbal medicine, acupuncture, wet-cupping therapy, low-glycaemic-load diet (LGLD), tea tree oil gel, and purified bee venom (PBV) for acne. As we pre-defined in our protocol, we were going to use intention-to-treat (ITT) methods if data were available. However, after contacting the study authors, we failed to obtain original data, so we could not use ITT methods for continuous data. For dichotomous data, we conducted ITT analysis based on consideration of 'best-case' and 'worst-case' scenarios for trials that had missing data.

None of the trials reported long-term data (as we defined above); we analysed short-term data and medium-term data from relevant included trials separately in different subgroups. We could not conduct other types of subgroup analysis because of insufficient data.

**Primary outcomes**

1. **Improvement of clinical signs assessed through skin lesion counts (change of inflamed and non-inflamed counted separately and change of total skin lesion counts) and acne severity scores**

   We have reported this outcome as 'Change in inflammatory and non-inflammatory lesion counts', 'Change of total skin lesion counts', 'Skin lesion scores', and 'Change of acne severity score'. For trials that did not report the change of skin lesion counts, if the baseline data were available and comparable, we reported the 'Number of inflamed and non-inflamed counted at the end of the treatment' separately.

    Seven trials reported total skin lesion counts (inflammatory or non-inflammatory skin lesion counts) (Enshaieh 2007; Kim 2012; Kwon 2012; Smith 2007; Wei 2012; Wu 2008; Yu 2008). Han 2013 reported Korean Acne Grading System (KAGS) scores based on numbers of inflammatory and non-inflammatory lesions.

2. **Adverse effects assessed by reporting early study discontinuations, the worsening of acne in participants, and other adverse events during the treatment and follow-up period**

   In total, 26 trials reported adverse effects, but none of the trials found any severe adverse effects. Nine trials did not record whether any adverse effects were reported during the treatment and follow-up period (Han 2013; Kwon 2012; Liu 2007; Ni 2008; Shi 2012; Smith 2007; Song 2007; Tang 2011; Wu 2008a). The types of adverse events differed between groups and among trials, so we could not synthesise the results quantitatively. We present a list of the reported adverse effects from the included trials in Table 3.
Secondary outcomes

1. Physicians’ global evaluation (after treatment)
2. Participants’ self assessment of change in specific types of lesion (such as comedones, papules, pustules, or nodules)
   
   We combined these two secondary outcomes and expressed them as the ‘Number of participants with remission’ as this has a clear definition and is easy to assess. We defined the term “remission” according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded) and with only mild pigmentation and scars remaining. All trials that reported the number of participants with remission employed this definition. Thirty trials measured these two secondary outcomes, which we combined and expressed as ‘Number of participants with remission’.

3. Psychosocial function outcomes (such as the Hamilton Depression Rating Scale (HAMD))

   No trial observed the effect of complementary therapies for improving psychosocial function outcomes of participants with acne vulgaris.

4. Quality of life (QoL)

   The QoL-acne is a questionnaire for assessing facial acne status in clinical trials (Martin 2001). It has three subscales that evaluate participants’ social function (five items), self-reported feeling (five items), and emotional function (four items). Each item is scored from one to six, with a higher score indicating better status of quality of life.

   Two studies reported acne quality of life scores: Ni 2008 in a comparison of combination therapy of acupuncture, massage, and wet-cupping therapy with zinc gluconate, and Liu 2007, which compared herbal medicine, or a combination of acupuncture and wet-cupping therapy, with viaminate cream. Both Ni 2008 and Liu 2007 reported the scores of QoL subscales.

Comparisons assessed

Diet

Low-glycaemic-load diet versus high-glycaemic-load diet: Two trials compared low-glycaemic-load diet (LGLD) with high-glycaemic-load diet (HGLD) (Kwon 2012; Smith 2007). We calculated the standard deviation (SD) of mean changes in non-inflammatory counts for both groups in Kwon 2012 according to the mean difference of changes, reduction after treatment, and the P value (which the authors provided). No statistically significant difference was shown for our primary outcome ‘Change in non-inflammatory lesion counts’ (MD −3.89, 95% CI −10.07 to 2.29, \( P = 0.10 \), \( I^2 \) statistic = 62%, 2 trials, random-effects model, 75 participants; Analysis 1.1; Figure 4) from baseline to the end of the treatment at 10 weeks (Kwon 2012) or 12 weeks (Smith 2007). Smith 2007 found statistically significant differences in favour of LGLD in reducing inflammatory lesion counts (MD −7.60, 95% CI −13.52 to −1.68, \( P = 0.01 \), 53 participants; Analysis 1.2) and
total lesion counts (MD −8.10, 95% CI −14.89 to −1.31, P = 0.02, 53 participants; Analysis 1.3) of acne. Data regarding inflammatory and total lesion counts from Kwon 2012 were incomplete and unusable in synthesis.

**Acupuncture:** Two studies reported our primary outcome 'Adverse effects' (Han 2010; Huang 2006), which employed acupuncture and found that 23% and 9.7% participants respectively reported pruritus or redness at the application site for acupuncture or sensations of pain following needle insertion.

**Acupuncture versus waiting list:** Only one four-arm trial evaluated the effect of acupuncture compared with waiting list (Kim 2012). Our primary outcome 'Change in inflammatory and non-inflammatory lesion counts' showed no difference between acupuncture and waiting list in reducing the number of inflammatory (MD −6.30, 95% CI −15.46 to 2.86, 22 participants; Analysis 2.1) or non-inflammatory lesions (MD −0.90, 95% CI −28.53 to 26.73, 22 participants; Analysis 2.2) at 4 weeks.

**Acupuncture versus western drugs:** Two trials assessed the effect of acupuncture compared with western drugs, while the method of acupuncture and the type of drugs were different.

With regard to our secondary outcome 'Number of participants with remission', Huang 2006 showed a statistically significant difference in favour of acupuncture when the acupuncture was compared with the western drugs azithromycin (500 mg daily) combined with clindamycin phosphate gel (external application) at 3 weeks. Intention-to-treat analysis with 'best-' or 'worst-case' assumptions for this trial and outcome demonstrated similar results (RR 3.67, 95%CI 2.22 to 6.06, n = 210; ‘worst case’ Analysis 3.1) (RR 4.38, 95% CI 2.56 to 7.51, n = 210; ‘best case’ Analysis 3.2). The other trial showed that there was no statistically significant difference between acupuncture and isotretinoin (20 mg daily for the first month and 10 mg daily for another month) for this outcome (Han 2010). Intention-to-treat analysis with 'best' or 'worst case' for this outcome demonstrated similar results (RR 0.69, 95% CI 0.44 to 1.09, n = 100; ‘worst case’ Analysis 3.3) (RR 0.96, 95% CI 0.62 to 1.48, n = 100; ‘best case’ Analysis 3.4).

**Herbal medicines:** Fifteen trials compared herbal medicine with western drugs: antibiotics (n = 7), vitamin A acid (n = 7), and staphylococcus injection (n = 1).

For our primary outcome 'Adverse effects', participants who received herbal medicine as their main treatment reported dizziness (2 out of 65 participants), mild nausea (2 out of 35 participants), abdominal pain (12 out of 112 participants), diarrhoea (20 out of 79 participants), or stomach upset (7 out of 105 participants). However, those who used western drugs reported more cases of adverse events. These adverse events included nausea, stomach upset, dizziness, abdominal pain, dry mouth, cheilitis, nosebleed, or loss of appetite. The external application of western creams may cause pruritus, dryness and desquamation of skin, or a burning sensation on application of the drugs (Chen 2012; Feng 2005; Li 2007; Liu 2004; Liu 2012; Wang 2012; Wei 2012; Wu 2008; Yu 2008; Yu 2011; Zhang 2012; Zhu 2007).
**Herbal medicine versus waiting list:** One trial compared herbal medicine with a waiting list control (Kim 2012). This trial combined the data of participants who accepted herbal medicine together with those who accepted both acupuncture and herbal medicine and compared this with those who did not use herbal medicine (whether acupuncture was employed or not) and were the waiting list group. The results showed no difference between herbal medicine and waiting list control for our primary outcome ‘Change in inflammatory or non-inflammatory lesions’ (inflammatory lesions: MD −2.80, 95% CI −12.26 to 6.66, 22 participants; Analysis 4.1) (non-inflammatory lesions: MD −12.10, 95% CI −39.28 to 15.08, 22 participants; Analysis 4.2) at 4 weeks.

**Herbal medicine versus antibiotics:** Two studies reported our primary outcome ‘Change of total skin lesion counts at eight weeks’: 1 trial with 100 participants, Wei 2012, showed a statistically significant difference in favour of herbal medicine when comparing herbal decoction with minocycline (100 mg daily) (MD −5.20, 95% CI −9.45 to −0.95, P = 0.02, 100 participants; Analysis 5.1); the other trial with 48 participants, Yu 2008, showed no difference between Shugan Zishen decoction and tetracycline (1000 mg daily) (MD −3.63, 95% CI −10.08 to 2.82, P = 0.27, 48 participants; Analysis 5.1).

For our secondary outcome ’Number of participants with remission’, results from six studies showed inconsistent effects on whether herbal medicine was statistically significantly better than antibiotics in increasing the number of participants with remission. Four trials reported short-term data for this outcome (Feng 2005; Li 2007; Liu 2004; Mo 2011). According to our meta-analysis, we did not find any difference in the number of participants with remission between those who received Ziyin Qinggan Xiaocuo Granule and those who received minocycline (100 mg daily), and the direction of the effect estimate changed between results of ITT ‘worst-case’ analysis (RR 0.49, 95% CI 0.09 to 2.53, P = 0.08, I² statistic = 68%, 2 trials, random-effects, 206 participants; Analysis 5.2) and ITT ‘best-case’ analysis (RR 2.82, 95% CI 0.88 to 9.06, P = 0.08, I² statistic = 44%, 2 trials, random-effects, 206 participants; Analysis 5.3) at 4 weeks.

For the other two trials (Liu 2004; Mo 2011), we found that Xiaocuo decoction for the ITT ‘worst-case’ analysis was no different to doxycycline (200 mg daily) (RR 1.39, 95% CI 0.83 to 2.34, P = 0.22, 160 participants, Liu 2004), but Yinqiao Liangxue decoction was statistically significantly better than azithromycin (500 mg daily) according to the number of participants with remission at 4 weeks (RR 2.00, 95% CI 1.17 to 3.42, P = 0.01, 80 participants, Mo 2011) (see Analysis 5.2). In the ITT ’best-case’ analysis, both Xiaocuo decoction and Yinqiao Liangxue decoction were statistically significantly better than the respective antibiotics (see Analysis 5.3).

Wei 2012 and Yu 2008 reported medium-term data for this outcome, which found no difference between groups at 8 weeks (see Analysis 5.4).

**Herbal medicine versus vitamin A acid:** Seven trials compared herbal decoction with vitamin A acid alone for our secondary outcome ‘Number of participants with remission’, and four reported short-term data (see Analysis 6.1).
Xiaocuo decoction (plus 0.1% adapalene gel used externally) (RR 5.50, 95% CI 1.31 to 23.03, P = 0.02, 70 participants, Chen 2012) was better than viaminate capsule (75 mg daily, plus 0.1% adapalene gel used externally), with an increased number of participants with remission at 4 weeks. One trial, Shi 2012, showed Jiawei Xiaodu decoction was better than tretinoin cream, with a greater number of participants with remission (RR 5.92, 95% CI 3.18 to 11.01, P < 0.00001, 167 participants) at 2 weeks. Qingbu decoction (RR 1.50, 95% CI 0.84 to 2.69, P = 0.03, 80 participants, Zhang 2012) was no better than viaminate capsule at 4 weeks. However, no difference was shown (RR 1.67, 95% CI 0.43 to 6.51, P = 0.46, 80 participants) between modified Cuochuang decoction and isotretinoin soft capsules (20mg daily) (Zhu 2007). Intention-to-treat with 'best-' or 'worst-case' for these studies for this outcome demonstrated similar results for Chen 2012, Shi 2012, and Zhu 2007, but not Zhang 2012 (see Analysis 6.1 and Analysis 6.2).

The remaining three trials reported medium-term data for this outcome (Liu 2007; Peng 2012; Wang 2012). No statistically significant difference could be found between participants who used Da Huang Zhe Chong Pillso (RR 0.74, 95% CI 0.34 to 1.63, P = 0.45, 99 participants), modified Wuwei Xiaodu yin plus Yinchenhao decoction (RR 2.00, 95% CI 0.19 to 21.06, P = 0.56, 70 participants), or externally applied herbal decoction (RR 1.13, 95% CI 0.67 to 1.88, P = 0.65, 80 participants) and those who received adapalene externally applied, viaminate cream externally applied, and isotretinoin soft capsule (20 mg daily), respectively (see Analysis 6.3).

For our secondary outcome ‘Acne quality of life score’, 1 trial, Liu 2007, showed no difference between modified Wuwei Xiaodu yin plus Yinchenhao decoction compared with viaminate cream applied externally on a quality of life score measuring functioning in society (MD 0.30, 95% CI −0.71 to 1.31, P = 0.56) at 8 weeks. However, a statistically significant difference in favour of herbal medicine was found on 2 other quality of life measures: on feelings of self-worth (RR 1.51, 95% CI 0.88 to 2.14, P < 0.00001) and emotional functionality (RR 2.20, 95% CI 1.75 to 2.65, P < 0.00001) (see Analysis 6.4).

**Herbal medicine versus antibiotics and vitamin A acid:** One trial, Tang 2011, compared a herbal decoction of externally applied Xiaocuo decoction with the antibiotic, roxithromycin (300 mg daily), which they combined with viaminate capsules (150 mg daily). There were a statistically significantly increased number of participants with remission with the herbal decoction (RR 2.00, 95% CI 1.26 to 3.18, P = 0.003, 219 participants; Analysis 7.1) at 5 weeks.

**Herbal medicine versus staphylococcus injection:** One trial, Wu 2008, compared Qingre Twenty-five Pills with staphylococcus injection (0.2 to 0.5 ml daily). A statistically significant difference was found in favour of herbal medicine in reduction of skin lesion score (MD −1.28, 95% CI −2.10 to −0.46, P = 0.002, 171 participants; Analysis 8.1), but no difference was found in the number of participants with remission between the 2 groups (RR 0.93, 95% CI 0.70 to 1.23, P = 0.60, 171 participants; Analysis 8.2) at 4 weeks.

**Herbal medicine plus western drugs versus western drugs:** A combination of Qingre Twenty-five Ingredients pill and staphylococcus Injection was found to be statistically
significantly better than the staphylococcus injection alone for our primary outcome 'Change of total skin lesion counts' (MD −9.54, 95% CI −10.42 to −8.66, P < 0.00001, 173 participants; Analysis 9.1) at 4 weeks (Wu 2008).

Two trials compared herbal decoction plus western drugs versus western drugs alone in increasing the number of participants with remission at four weeks (Wu 2008; Yu 2011). Qingre Twenty-five Ingredients pill plus staphylococcus Injection (0.2 to 0.5 ml daily) was better than staphylococcus Injection alone (RR 1.45, 95% CI 1.17 to 1.81, P = 0.0007, 173 participants) (Wu 2008). Danshen tablet plus doxycycline (200mg daily) was better than doxycycline (200 mg daily) alone (RR 1.82, 95% CI 1.23 to 2.69, P = 0.003, 130 participants; see Analysis 9.2) (Yu 2011).

**Herbal medicine plus other treatment versus other treatment alone:** Another trial compared herbal medicinal mask plus blue and red light-emitting diode (LED) phototherapy with LED alone (Liu 2012). No statistically significant difference was found between the two groups with regard to the number of participants with remission at four weeks. Intention-to-treat with ‘best’ or ‘worst case’ for this outcome gave similar results (see Analysis 10.1 and Analysis 10.2).

**Herbal medicine plus wet cupping versus other treatment alone:** One trial compared individualised herbal decoction plus wet-cupping therapy with wet-cupping therapy alone (Chen 2009). No difference was found between the 2 groups with regard to the number of participants with remission (RR 2.33, 95% CI 0.67 to 8.18, P = 0.19, 60 participants; Analysis 11.1) at 4 weeks.

**Wet cupping:** With regard to our primary outcome ‘Adverse effects’, wet-cupping therapy may leave black and blue spots on the skin after removing the cups. Five trials reported this (Chen 2009; Liu 2006; Liu 2008; You 2012; Zhang 2010).

**Wet cupping versus western drugs:** In the study by Zhou 2009, a statistically significant difference was found in favour of wet cupping for our primary outcome ‘Change in acne severity score’. There was a reduction in the acne severity score, which the Global Acne Grading System (GAGS) measured (MD −5.95, 95% CI −8.28 to −3.62, P < 0.00001, 40 participants; Analysis 12.1) at 4 weeks.

Zhou 2009 compared wet-cupping therapy with externally applied viaminate cream. No difference was found between groups with regard to our secondary outcome ‘Number of participants with remission’ (RR 5.00, 95% CI 0.26 to 98.00, P = 0.29, 40 participants; Analysis 12.2) at 4 weeks. Two other trials showed a statistically significant increase in the number of participants with remission in the wet-cupping group: Wu 2008a, which compared wet-cupping therapy with tetracycline (1000 mg) and ketoconazole cream (external application) (RR 2.50, 95% CI 1.31 to 4.77, P = 0.005, 60 participants), and Song 2007, which compared wet-cupping (with blood-letting on ear points) therapy with tetracycline (1500 mg daily) (RR 2.83, 95% CI 1.29 to 6.22, P = 0.009, 76 participants) at 2 weeks and at 4 weeks (See Analysis 12.2).
Wet cupping plus herbal medicine versus herbal medicine alone: One trial, Chen 2009, showed no difference between wet-cupping therapy plus individualised herbal decoction compared with individualised herbal decoction alone with regard to the number of participants with remission (RR 2.33, 95% CI 0.67 to 8.18, P = 0.19, 60 participants; Analysis 13.1) at 4 weeks.

Wet cupping plus acupuncture versus western drugs: Six trials assessed the therapeutic effect of wet-cupping therapy plus acupuncture compared with western drugs (Liu 2006; Liu 2007; Liu 2008; Wen 2012; You 2012; Zhang 2010). Two trials used antibiotics (including minocycline 100 mg daily and tetracycline 1500 mg daily) as controls, and 4 trials used vitamin A acid (including internal or external application) as a control, respectively.

Our primary outcome ‘Skin lesion score’ showed no difference between cupping with acupuncture compared with antibiotics at four weeks (see Analysis 14.1). Except for 2 trials (Liu 2007, RR 8.00, 95% CI 1.06 to 60.63, 70 participants; Zhang 2010, RR 2.50, 95% CI 1.12 to 5.56, 60 participants), results from each of the remaining 4 trials consistently showed no difference between the combination therapies and vitamin A acid (including viaminate capsule, viaminate cream, tretinoin cream, and isotretinoin soft capsules) with regard to our secondary outcome ‘Number of participants with remission’ (see Analysis 14.2).

For our secondary outcome ‘Acne quality of life score’, 1 trial showed wet cupping plus acupuncture was better than vitamin A acid cream for 3 quality of life measures (Liu 2007): functioning in society (MD 4.51, 95% CI 3.95 to 5.07, P < 0.00001, 70 participants), feelings of self-worth (MD 4.97, 95% CI 4.39 to 5.55, P < 0.00001), and emotional functionality (MD 4.73, 95% CI 4.31 to 5.15, P < 0.00001, 70 participants) at 8 weeks (see Analysis 14.3).

Wet cupping plus herbal medicine versus western drugs: One trial, Lin 2013, showed no difference between wet-cupping therapy plus herbal medicinal mask and viaminate capsule (30 mg daily) in the number of participants with remission (RR 1.80, 95% CI 0.67 to 4.85, P = 0.24, 72 participants; Analysis 15.1) at 4 weeks.

Combination of wet cupping, acupuncture, and massage versus zinc gluconate: One trial, Ni 2008, compared the combination of wet-cupping therapy, acupuncture, and massage, with zinc gluconate oral liquid (40ml daily). A statistically significant difference was found in favour of combination therapies with regard to the primary outcome ‘Skin lesion scores’ (MD −3.87, 95% CI −6.97 to −0.77, P = 0.01; 46 participants; Analysis 16.1).

There was a borderline statistical significant difference between the 2 groups with regard to the secondary outcome ‘Number of participants with remission’ (RR 4.13, 95% CI 1.00 to 17.04, P = 0.05, 46 participants; Analysis 16.2).

There was a statistically significant difference also in favour of combination therapies for our secondary outcome ‘Acne quality of life score’. Three quality of life measures: functioning in society (MD 1.47, 95% CI 0.29 to 2.65, P = 0.01, 46 participants), feelings of self-worth (MD 1.26, 95% CI 0.20 to 2.32, P = 0.02, 46 participants), and emotional...
functionality (MD 0.93, 95% CI 0.17 to 1.69, \( P = 0.02 \), 46 participants) at 3 weeks (see Analysis 16.3).

**Tea tree oil**

**Tea tree oil versus placebo:** For our primary outcome ‘Change of total skin lesion counts’, one trial, Enshaieh 2007, compared tea tree oil gel with placebo (vehicle gel alone) in 60 participants with acne. A statistically significant difference was found in favour of tea tree oil gel (MD \(-7.53\), 95% CI \(-10.40\) to \(-4.66\), \( P < 0.00001 \), 60 participants; Analysis 17.1).

For our primary outcome ‘Change in acne severity score’, there was an improvement in the acne severity index (MD \(-5.75\), 95% CI \(-9.51\) to \(-1.99\), \( P = 0.003 \), 60 participants; Analysis 17.2) in the tea tree oil gel group compared with the placebo gel group, from baseline to the end of 45 days of treatment.

For our primary outcome ‘Adverse effects’, Enshaieh 2007 reported minimal pruritus (3 out of 30 participants in the tea tree oil group and 2 out of 30 participants in the control group), a little burning sensation on the skin area where the oil was applied (1/30 participants in the intervention group and 2/30 participants in the control group), and minimal scaling (1 case in the tea tree oil group).

**Purified bee venom (PBV)**

**Cosmetics containing PBV versus cosmetics without PBV:** For our primary outcome ‘Change of skin lesion scores’, Han 2013 compared cosmetics with or without PBV (0.06 mg/mL) in 12 participants. Purified bee venom was found to be statistically significantly better than the no PBV control when the post-treatment Korean Acne Grading System (KAGS) scores were measured, which were based on the number of lesions (MD \(-1.17\), 95% CI \(-2.06\) to \(-0.28\), \( P = 0.01 \), 12 participants; Analysis 18.1).

**DISCUSSION**

**Summary of main results**

This review included 35 studies: 23 published studies and 12 unpublished studies. The included studies measured effectiveness of herbal medicine, acupuncture, wet-cupping therapy, low-glycaemic-load diet, tea tree oil, and purified bee venom (PBV); however, because of the clinical heterogeneity between trials and incomplete data reporting, we could only conduct two meta-analyses, with two trials in each meta analysis.

For our pre-defined primary outcomes (including improvement of skin lesion counts and adverse events), the results showed no statistically significant difference between low-glycaemic-load diet (LGLD) and high-glycaemic-load diet (HGLD) on reducing non-inflammatory lesion counts (mean difference (MD) \(-3.89\), 95% CI \(-10.07\) to \(2.29\), 2 trials, 75 participants) at 12 weeks. Results from single trials showed potential benefit of LGLD (MD \(-7.60\), 95% CI \(-13.52\) to \(-1.68\), 43 participants, 1 trial), tea tree oil (MD \(-7.53\), 95% CI \(-10.40\) to \(-4.66\), 60 participants, 1 trial), and PBV (MD \(-1.17\), 95% CI \(-2.06\) to \(-0.28\), 12 participants, 1 trial) in reducing inflammatory skin lesion counts, total skin lesion counts, and skin lesion scores, respectively. Other trials showed inconsistent effects as to whether

*Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.*
herbal medicine, acupuncture, or wet cupping were superior to controls in terms of the number of participants with remission or reduction in the total number of skin lesions.

We created 'Summary of findings' tables for comparisons of LGLD and HGLD (Summary of findings for the main comparison) and comparisons between Ziyin Qinggan Xiaocuo Granule and minocycline (Summary of findings 2). We found low-quality evidence for both LGLD and Ziyin Qinggan Xiaocuo Granule compared with control in improving the clinical symptoms of acne (reducing the number of skin lesions or improving the number of participants with remission) because of the small sample sizes and poor methodological quality of the included studies.

None of the studies reported severe adverse effects. Adverse effects of herbal medicine and orally taken western drugs included dizziness; dry mouth; and mild gastrointestinal effects, such as nausea, diarrhoea, or stomach upset. Wet-cupping therapy may leave black and blue spots on the skin after removing the cups. Itch or redness and pain following needle insertion were reported as potential adverse effects from acupuncture. For tea tree oil gel or western drugs, adverse effects, which were anticipated, included itchiness, dryness and flaking of the skin, or even a little burning sensation at the application site of the drugs.

Thirty trials measured the secondary outcome 'Number of participants with remission'. Low-quality evidence from a meta-analysis comparing Ziyin Qinggan Xiaocuo Granule and the antibiotic minocycline (100 mg daily) showed no difference between the groups (risk ratio (RR) 0.49, 95% CI 0.09 to 2.53, P = 0.08, I² statistic = 68%, 2 trials, random-effects, 206 participants at 4 weeks). No trial assessed 'Psychosocial function'. Two trials assessed 'Quality of life' according to a QoL-acne questionnaire, and significant differences in favour of complementary and alternative medicine (CAM) were found in both of them for feelings of self-worth (MD 1.51, 95% CI 0.88 to 2.14, P < 0.00001, 1 trial, 70 participants) (MD 1.26, 95% CI 0.20 to 2.32, 1 trial, 46 participants) and emotional functionality (MD 2.20, 95% CI 1.75 to 2.65, P < 0.00001, 1 trial, 70 participants) (MD 0.93, 95% CI 0.17 to 1.69, 1 trial, 46 participants).

Overall completeness and applicability of evidence

We searched a comprehensive range of databases, including Chinese-language databases and ongoing trials registration systems. We placed no language restrictions on the search and screening stages. Subsequently, we included 18 Chinese-language publications, 12 Chinese-language unpublished studies, and 5 English publications in this review. We retrieved two trials, which are awaiting assessment. Both the English and Chinese searches were updated before finalisation of the review.

Three trials out of the 35 included studies did not provide complete data (Enshaieh 2007; Kim 2012; Kwon 2012). These authors did not, or could not, respond to requests for additional information. We analysed the data from these three studies as reported; however, these trials are at risk of bias from incomplete reporting. Because of the clinical or statistical heterogeneity of the included studies, we only performed meta-analyses for the outcomes 'Change in inflammatory lesion counts' and 'Number of participants with remission' for the comparisons between LGLD and HGLD and between herbal medicine
and western drugs from four studies. This may also downgrade the level of evidence of the review.

We included 18 types of comparisons between CAM and control groups, including herbal medicine, acupuncture, and cupping. Within these interventions, there was significant variation in the design of the intervention - for example, herbal medicine (e.g., dosage, forms, prescription), wet-cupping therapy (e.g., method of blood-letting, time of retaining the cups), and acupuncture (e.g., methods of hand stimulation, depth or strength of insertion, numbers of needling points). The dosage and treatment duration of western drugs are unlikely to be exactly the same in clinics between China and other countries. As such, the results of this review are more clinically relevant for application in traditional Chinese medicine and potentially less clinically relevant for application within western medicine.

**Quality of the evidence**

Although all of the included trials had a low risk of bias for the “random sequence generation” domain, only six trials reported the methods of allocation concealment. The lack of blinding of participants for 33 studies was a source of potential bias. Only two published studies used placebo as the control (Enschaieh 2007; Han 2013); these studies were assessed as unclear risk of bias for “allocation concealment”, “selective reporting”, and “other bias” domains.

We employed in this review the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria ratings to assess the quality of the evidence; factors that may downgrade the quality level include imprecision, inconsistency, indirectness, limitations, and bias of the evidence. Factors that may upgrade the quality level could be large effect, plausible confounding, and dose-response gradient. For two meta-analyses in this review, we downgraded the level of the evidence because of the potential performance, attrition, and reporting bias and the inconsistency of the results between the included studies. Thus, we could find only low-quality evidence for LGLD in reducing non-inflammatory lesion counts and for herbal medicine (Ziyin Qinggan Xiaocuo Granule) in improving the number of participants with remission. Overall, because of limitations and concerns about the quality of the included studies, we cannot draw a robust conclusion for consistency, size, and direction of outcome effects in this review.

**Potential biases in the review process**

We did not include over 500 studies (the majority of which were conducted in China) in this review due to insufficient information describing the process of randomisation; our judgement on reading the full text of these articles was that they were not randomised (Figure 1).

Twenty included studies evaluated the effect of herbal medicine, 12 trials assessed the effect of acupuncture or wet-cupping therapy, and 3 trials assessed diet and the role of tea tree oil. It is only recently that research in traditional Chinese medicine has used a placebo or control group as a standard feature of clinical studies, for which significant criticism has been made in the past. For 32 out of our 35 included trials, lack of blinding was an important issue.
Agreements and disagreements with other studies or reviews

Two other reviews were found on this topic. One review assessed acupuncture and moxibustion compared with western drugs on treating acne vulgaris (Li 2009). All of the 17 included trials in that review were conducted and published in China. The results of their meta-analysis showed that acupuncture (and moxibustion) or a combination of acupuncture and western drugs were better than western drugs alone at increasing the number of participants with remission. However, there is insufficient high-quality evidence to determine the effectiveness and efficacy of CAM. In our review, we included only three of the trials included in the Li 2009 review. We did not include the other 14 studies because of insufficient information about random sequence generation. However, in our review, we did not conduct meta-analysis for these three trials (Huang 2006; Liu 2006; Song 2007), because of the obvious clinical heterogeneity (different kind or usage of western drugs in control groups among studies).

Another review examined the effect of a broad range of CAM treatments (Magin 2006). We included 23 trials of topical and oral CAM to treat acne; evidence from the review suggested that many of these therapies are biologically plausible. However, most included trials in Magin’s review were of poor methodological quality, only English databases were searched, and that review included studies from no other languages. Our review reached similar conclusions on the effect of tea tree oil for acne improvement.

There are some studies concerning the safety of herbal medicine that reported that herbal supplements may contain no active ingredients (O’Connor 2013) or unlabelled toxins, such as arsenic, mercury, or lead (Mail Online 2013; Starling 2013). However, those conclusions are mainly based on findings from case reports (Wu 2013) or a cross-sectional study (Buettner 2009), and similar conclusions could not be drawn directly from our review. We only found dizziness, dry mouth, and mild gastrointestinal effects as mild adverse events of herbal medicine. More research (including experimental studies and clinical studies) with regard to the safety of herbal products should be done to testify the active ingredients and the potential adverse effects of herbal supplements.

AUTHORS’ CONCLUSIONS

Implications for practice

Some evidence from single studies showed that low-glycaemic-load diet, tea tree oil, and pollen bee venom (PBV) may have an effect on reducing total skin lesion counts and acne severity scores for people with acne vulgaris. However, small sample sizes and poor methodological quality limited the strength of the evidence. Evidence from other existing randomised controlled trials does not support the use of herbal medicine, acupuncture, or wet-cupping therapy for the treatment of acne vulgaris. The evidence for a secondary outcome of this review ‘Number of participants with remission’ for herbal medicine versus antibiotic was uncertain. There were mixed findings regarding total skin lesion counts and number of participants with remission from each single included study. However, two trials that reported quality of life showed the benefit of herbal medicine compared with western drugs.
Our review highlights potential adverse effects from herbal medicine, e.g., dizziness, dry mouth, nausea, diarrhoea, or stomach upset; acupuncture may cause pain following needle insertion, itchiness, or redness of skin; wet-cupping therapy may leave black and blue spots for two weeks after removing the cups; and tea tree oil gel may cause pruritus, dryness and flaking of the skin, and even a little burning sensation on application of the drugs.

Methodological and reporting quality limitations weaken the evidence base for treating acne with several kinds of complementary therapies (including herbal medicine, acupuncture, wet-cupping therapy, low-glycaemic-load diet, PBV, and tea tree oil). This review evaluated herbal medicine, wet-cupping therapy, and acupuncture in a traditional Chinese medicine context; therefore, results might be less generalisable to western medicine.

Implications for research

Research into the efficacy and safety of complementary therapies for the treatment of acne vulgaris is in its infancy (especially in China). Much of the research conducted thus far is difficult to evaluate because of poor-quality reporting. Future studies should be designed to ensure low risk of bias and meet current reporting standards for clinical trials. Although blinding of participants and practitioners is difficult for studies of complementary therapies (such as herbal medicine, acupuncture, cupping therapy, etc.), blinding of outcome assessors and statisticians is recommended. Recommendations to improve the evidence base of complementary therapies for acne vulgaris include the following: increasing the sample size for each study and evaluating efficacy in people by measuring the total number of skin lesion counts or total number of inflammatory and non-inflammatory lesions, respectively. Standard usage of control drugs (such as antibiotics or vitamin A acid) within a reasonable, consistent treatment duration is recommended in future studies. There is a need for collection and full reporting of adverse events.

ACKNOWLEDGEMENTS

The authors wish to thank the Cochrane Skin Group editorial team and Ms Jun Xia from the Cochrane Schizophrenia Group for their assistance in the preparation of this review.

This work was partially funded by Grant Number R24 AT001293 from the National Center for Complementary and Alternative Medicine (NCCAM). The contents of this systematic review are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM or the National Institutes of Health.

The Cochrane Skin Group editorial base wishes to thank Robert Dellavalle, who was the Cochrane Dermatology Editor for this review; Matthew Grainge, who was the Statistical Editor; Ching-Chi Chi, who was Methods Editor; the clinical referees, Alison Devine and Parker Magin; and the consumer referee, Karen Thomas.

SOURCES OF SUPPORT

Internal sources

- Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
- The research capacity establishment grant of Beijing University of Chinese Medicine (grant number 201207007 and 2011-CXTD-09), China.

External sources

- Grant No R24 AT001293 from the National Center for Complementary and Alternative Medicine (NCCAM) of the US National Institutes of Health, USA.
  www.nih.gov/about/almanac/organization/NCCAM.htm
REFERENCES

* Indicates the major publication for the study

References to studies included in this review


Han, B.; Mi, JP. Dissertation for a masters degree from Guangzhou University of Chinese Medicine. 2010. A clinical study on abdominal acupuncture for acne by conditioning liver and kidney.


Li, ZZ.; Chi, FH.; Fan, RQ. Dissertation for a masters degree of Guangzhou University of Chinese Medicine. 2007. Clinical observation on Ziyan Qinggan Xiaocuo Prescription combined with Cuo Ling Tincture for adult female acne vulgaris with yin deficiency and liver heat.


Liu, W.; Sun, Y.; Jiang, Y.; Li, XP. Clinical observation on Xiaocuoyin in treatment of acne; Conference proceedings of dermatology branch of Chinese medicine association; 2004.


Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.


Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.
References to studies awaiting assessment


Additional references


Garner SE, Eady A, Popescu CM, Newton J, Li Wan Po A. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database of Systematic Reviews. 2009; (1)


Reporter. Chinese medicines contain 'dangerously high' levels of lead, mercury and arsenic, warns health watchdog. www.dailymail.co.uk/health/article-2398192/Health-watchdog-warns-dangerously-high-leve.html


APPENDICES

Appendix 1. Skin Group Specialised Register search strategy

Two searches run as there were too many terms for one search string:

1. acne and (diet* or nutrition* or macrobiotic* or Gerson or antioxidant* or “mind-body” or meditation or imagery or hypnosis or “support group*” or bioelectromagnetic* or electromagnetic* or electroacupuncture or traditional or folk or naturopathy or ayurved* or “Traditional Chinese Medicine” or TCM or homeopathy or antineoplastic or chelation or immunoaugmentation or shark or “manual healing” or massage or chiropractic or “therapeutic touch” or herb* or “physical therap*” or acupuncture or moxibustion or “cupping therapy” or “therapeutic exercise*” or “Tai Chi” or complementary or alternative or aromatherapy or reflexology or reiki or cam or yoga or music or “tea tree” or “aloe vera”)

2. acne and (anthroposophy or “auricular therapy” or “holistic health” or “horticultural therapy” or Arabic or Asian or African or Kampo or unani or shamanism or mesotherapy or psychology or “breathing exercise*” or “laughter therapy” or “mental healing” or psychodrama or psychophysiology or “relaxation therapy” or Taiji or acupressure or kinesiology or manipulation or “tissue therapy” or eclecticism or reflexotherapy or rejuvenation or “acoustic stimulation” or “art therapy” or “colour therapy” or “dance therapy” or Speleotherapy or “faith healing” or magic or occultism or Radiesthesia or witchcraft or biofeedback or “immuno augmentation therapy” or “natural remed*” or “drama therapy” or visualisation)

Appendix 2. CENTRAL (The Cochrane Library) search strategy

#1 (diet* or nutrition* or macrobiotic* or Gerson or antioxidant* or “mind-body” or meditation or imagery or hypnosis or “support group*” or bioelectromagnetic* or electromagnetic* or electroacupuncture or traditional or folk or naturopathy or ayurved* or “Traditional Chinese Medicine” or TCM or homeopathy or antineoplastic or chelation or immunoaugmentation or shark or “manual healing” or massage or chiropractic or “therapeutic touch” or herb* or “physical therap*” or acupuncture or moxibustion or
“cupping therapy” or “therapeutic exercise*” or “Tai Chi” or complementary or alternative or aromatherapy or reflexology or reiki or cam or yoga or music or “tea tree” or “aloe vera”)

#2 (anthroposophy or “auricular therapy” or “holistic health” or “horticultural therapy” or Arabic or Asian or African or Kampo or unani or shamanism or mesotherapy or psychology or “breathing exercise*” or “laughter therapy” or “mental healing” or psychodrama or psychophysiology or “relaxation therapy” or Taiji or acupressure or kinesiology or manipulation or “tissue therapy” or eclecticism or reflexotherapy or rejuvenation or “acoustic stimulation” or “art therapy” or “colour therapy” or “dance therapy” or Speleotherapy or “faith healing” or magic or occultism or Radiesthesia or witchcraft or biofeedback or “immuno augmentation therapy” or “natural remed*” or “drama therapy” or visualisation)

#3 (#1 OR #2)

#4 (acne):ti,ab,kw

#5 MeSH descriptor Acne Vulgaris explode all trees

#6 (#4 OR #5)

#7 (#3 AND #6)

**Appendix 3. MEDLINE (OVID) search strategy**

1. acoustic stimulation.mp. or exp Acoustic Stimulation/
2. acupressure.mp. or exp Acupressure/
3. exp Acupuncture/ or acupuncture.mp.
4. exp Medicine, African Traditional/
5. anthroposophy.mp. or exp Anthroposophy/
6. antioxidants.mp. or exp Antioxidants/
7. arabic medicine.mp. or exp Medicine, Arabic/
8. aromatherapy.mp. or exp Aromatherapy/
9. art therapy.mp. or exp Art Therapy/
10. auricular therapy.mp.
11. exp Medicine, Ayurvedic/
12. ayurved$.mp.
13. biofeedback.mp. or exp Biofeedback, Psychology/
14. breathing exercise$.mp. or exp Breathing Exercises/
15. exp Color Therapy/
16. (color therap$ or colour therap$).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]

17. exp complementary therapies/ or exp acupuncture therapy/ or exp anthroposophy/ or exp auriculotherapy/ or exp holistic health/ or exp homeopathy/ or exp horticultural therapy/ or exp medicine, traditional/ or exp mesotherapy/ or exp mind-body therapies/ or exp musculoskeletal manipulations/ or exp naturopathy/ or exp organotherapy/ or exp phytotherapy/ or exp reflexotherapy/ or exp rejuvenation/ or exp sensory art therapies/ or exp speleotherapy/ or exp spiritual therapies/

18. dance therapy.mp. or exp Dance Therapy/

19. exp Medicine, East Asian Traditional/

20. eclecticism.mp. or exp Eclecticism, Historical/

21. electroacupuncture.mp. or exp Electroacupuncture/

22. faith healing.mp. or exp Faith Healing/

23. holistic health.mp.

24. homeopathy.mp.

25. horticultural therapy.mp.

26. hypnosis.mp. or exp Hypnosis/

27. exp “Imagery (Psychotherapy)”/

28. kampo.mp. or exp Medicine, Kampo/

29. exp Kinesiology, Applied/ or kinesiology.mp.

30. laughter therapy.mp. or exp Laughter Therapy/

31. magic.mp. or exp Magic/

32. manipulation.mp. or exp Manipulation, Chiropractic/

33. exp Massage/ or massage.mp.

34. meditation.mp. or exp Meditation/

35. mental healing.mp. or exp Mental Healing/

36. mesotherapy.mp. or exp Mesotherapy/

37. moxibustion.mp. or exp Moxibustion/

38. music therapy.mp. or exp Music Therapy/

39. exp Naturopathy/ or naturopath$.mp.

40. natural remedi$.mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]
41. occultism.mp. or exp Occultism/
42. exp Psychodrama/ or psychodrama.mp.
43. drama therapy.mp.
44. Psychology/ or psychology.mp.
45. psychophysiology.mp. or exp Psychophysiology/
46. mind body relation$.mp.
47. radiesthesia.mp. or exp Radiesthesia/
48. reflexotherapy.mp. or exp Reflexotherapy/
49. rejuvenation.mp. or exp Rejuvenation/
50. relaxation therapy.mp. or exp Relaxation Therapy/
51. shamanism.mp. or exp Shamanism/
52. speleotherapy.mp. or exp Speleotherapy/
53. Tai Ji/
54. tai chi.mp.
55. therapeutic touch.mp. or exp Therapeutic Touch/
56. exp Medicine, Unani/ or unani.mp.
57. witchcraft.mp. or exp Witchcraft/
58. yoga.mp. or exp Yoga/
59. visualisation.mp.
60. immunoaugmentation.mp.
61. Tissue Therapy/
62. Medicine, Chinese Traditional/
63. tcm.mp.
64. antineoplaston.mp.
65. chelation.mp.
66. shark.mp.
67. electromagnetic$.mp.
68. “Tea Tree Oil”/
69. Aloe/
70. reflexology.mp.
71. reiki.mp.
72. herb$.mp.
Appendix 4. Embase (OVID) search strategy

1. exp *acne vulgaris/
2. acne.ti,ab.
3. 1 or 2
4. random$.mp.
5. factorial$.mp.
6. (crossover$ or cross-over$).mp.
7. placebo$.mp. or PLACEBO/
8. (doub$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

9. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

10. (assign$ or allocat$).mp.

11. volunteer$.mp. or VOLUNTEER/

12. Crossover Procedure/

13. Double Blind Procedure/

14. Randomized Controlled Trial/

15. Single Blind Procedure/

16. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15

17. acoustic stimulation.mp. or auditory stimulation/

18. diet/

19. nutrition/

20. exp alternative medicine/ or macrobiotic diet/

21. antioxidant/

22. psychophysiology/

23. meditation/

24. imagery/

25. hypnosis/

26. support group/

27. acupuncture/ or electroacupuncture/

28. exp traditional medicine/

29. Ayurveda/

30. Chinese medicine/

31. homeopathy/

32. chelation/

33. massage/

34. chiropractic/

35. herbal medicine/

36. physiotherapy/
37. moxibustion/
38. Tai Chi/ or kinesiotherapy/
39. aromatherapy/
40. reflexology/
41. Reiki/
42. yoga/
43. music therapy/
44. “tea tree oil”/
45. Aloe vera/
46. horticultural therapy/
47. African medicine/
48. kampo/
49. psychology/
50. breathing exercise/
51. psychodrama/
52. relaxation training/
53. acupressure/
54. eclecticism/
55. rejuvenation/
56. art therapy/
57. speleotherapy/
58. spiritual healing/
59. magic/
60. mysticism/
61. witchcraft/
62. feedback system/

63. (diet$ or nutrition$ or macrobiotic$ or Gerson or antioxidant$ or mind-body or meditation or imagery or hypnosis or support group$ or bioelectromagnetic$ or electromagnetic$ or electroacupuncture or traditional or folk or naturopathy or ayurved$ or Traditional Chinese Medicine or TCM or homeopathy or antineoplaston or chelation or immunoaugmentation or shark or manual healing or massage or chiropractic or therapeutic touch or herb$ or physical therap$ or acupuncture or moxibustion or cupping therapy or therapeutic exercise$ or Tai Chi or complementary or alternative or aromatherapy or reflexology or reiki or cam or
Appendix 5. PsycINFO (OVID) search strategy

1. nutrition/
2. antioxidant/
3. psychophysiology/
4. meditation/
5. imagery/
6. hypnosis/
7. massage/
8. physiotherapy/
9. yoga/
10. music therapy/
11. psychology/
12. art therapy/
13. (diet$ or nutrition$ or macrobiotic$ or Gerson or antioxidant$ or mind-body or meditation or imagery or hypnosis or support group$ or bioelectromagnetic$ or electromagnetic$ or electroacupuncture or traditional or folk or naturopathy or ayurved$ or Traditional Chinese Medicine or TCM or homeopathy or antineoplaston or chelation or immunoaugmentation or shark or manual healing or massage or chiropractic or therapeutic touch or herb$ or physical therap$ or acupuncture or moxibustion or cupping therapy or therapeutic exercise$ or Tai Chi or complementary or alternative or aromatherapy or reflexology or reiki or cam or yoga or music or tea tree or aloe vera or anthroposophy or auricular therapy or holistic health or horticultural therapy or Arabic or Asian or African or Kampo or unani or shamanism or mesotherapy or psychology or breathing exercise$ or laughter therapy or mental healing or psychodrama or psychophysiology or relaxation therapy or Taiji or acupressure or kinesiology or manipulation or tissue therapy or eclecticism or reflexotherapy or rejuvenation or acoustic stimulation or art therapy or colour therapy or dance therapy or Speleotherapy or faith healing or magic or occultism or Radiesthesia or witchcraft or biofeedback or immuno augmentation therapy or macrobiotic$ or natural remed$ or drama therapy or visualisation).ti,ab.

64. or/17–63

65. 3 and 16 and 64
relaxation therapy or Taiji or acupressure or kinesiology or manipulation or tissue
therapy or eclecticism or reflexotherapy or rejuvenation or acoustic stimulation or
art therapy or colour therapy or dance therapy or Speleotherapy or faith healing or
magic or occultism or Radiesthesia or witchcraft or biofeedback or immuno
augmentation therapy or macrobiotic$ or natural remed$ or drama therapy or
visualisation).ti,ab.

14. Faith healing/
15. Acupuncture/
16. Shamanism/
17. Psychology/
18. Dance therapy/
19. Visualization/
20. Diets/
21. Support Groups/
22. exp Alternative Medicine/ or exp Folk Medicine/
23. Holistic Health/
24. Aromatherapy/
25. exp Horticulture Therapy/
26. Shamanism/
27. Relaxation Therapy/
28. Biofeedback/
29. Psychodrama/
30. Occultism/
31. Witchcraft/
32. or/1–31
33. acne.mp.
34. double-blind.tw.
35. random$ assigned.tw.
36. control.tw.
37. 34 or 35 or 36
38. 32 and 33 and 37

**Appendix 6. AMED (OVID) search strategy**

1. diet/
2. nutrition/
3. antioxidant/
4. psychophysiology/
5. meditation/
6. imagery/
7. hypnosis/
8. exp traditional medicine/
9. homeopathy/
10. chelation/
11. massage/
12. chiropractic/
13. physiotherapy/
14. moxibustion/
15. reflexology/
16. Reiki/
17. yoga/
18. music therapy/
19. “tea tree oil”/
20. Aloe vera/
21. psychology/
22. breathing exercise/
23. acupressure/
24. art therapy/
25. (diet$ or nutrition$ or macrobiotic$ or Gerson or antioxidant$ or mind-body or meditation or imagery or hypnosis or support group$ or bioelectromagnetic$ or electromagnetic$ or electroacupuncture or traditional or folk or naturopathy or ayurved$ or Traditional Chinese Medicine or TCM or homeopathy or antineoplaston or chelation or immunoaugmentation or shark or manual healing or massage or chiropractic or therapeutic touch or herb$ or physical therap$ or acupuncture or moxibustion or cupping therapy or therapeutic exercise$ or Tai Chi or complementary or alternative or aromatherapy or reflexology or reiki or cam or yoga or music or tea tree or aloe vera or anthroposophy or auricular therapy or holistic health or horticultural therapy or Arabic or Asian or African or Kampo or unani or shamanism or mesotherapy or psychology or breathing exercise$ or laughter therapy or mental healing or psychodrama or psychophysiology or
relaxation therapy or Taiji or acupressure or kinesiology or manipulation or tissue therapy or eclecticism or reflexotherapy or rejuvenation or acoustic stimulation or art therapy or colour therapy or dance therapy or Speleotherapy or faith healing or magic or occultism or Radiesthesia or witchcraft or biofeedback or immuno augmentation therapy or macrobiotic$ or natural reme$ or drama therapy or visualisation).
ti,ab.

26. acoustic stimulation.mp.
27. exp Complementary medicine/ or exp Complementary therapies/
28. Social support/
29. Ayurvedic medicine/
30. Traditional medicine chinese/
31. Aroma therapy/
32. Horticulture/
33. Herbal drugs/ or Plants medicinal/
34. Medicine kampo/
35. Drama/
36. Acupuncture therapy/
37. Relaxation/ or Biofeedback/
38. Faith healing/
39. Folk remedies/
40. Naturopathy/
41. Therapeutic touch/ or Holistic health/
42. Applied kinesiology/
43. Tai chi/
44. Acupuncture/
45. Anthroposopphical medicine/
46. Shamanism/
47. Psychology/
48. Laughter therapy/
49. Mental healing/
50. Manipulation/
51. Color therapy/
52. Dance therapy/
53. Visualization/
54. or/1–53
55. exp Acne vulgaris/ or acne.mp.
56. randomized controlled trial$/
57. random allocation/
58. double blind method/
59. single blind method.mp.
60. exp Clinical trials/
61. (clin$ adj25 trial$).mp. [mp=abstract, heading words, title]
62. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$ or dummy)).mp. [mp=abstract, heading words, title]
63. (placebo$ or random$).mp. [mp=abstract, heading words, title]
64. research design/ or clinical trials/ or comparative study/ or double blind method/ or random allocation/
65. prospective studies.mp.
66. cross over studies.mp.
67. Follow up studies/
68. control$.mp.
69. (multicent$ or multi-cent$).mp. [mp=abstract, heading words, title]
70. ((stud or design$) adj25 (factorial or prospective or intervention or crossver or cross-over or quasi-experiment$)).mp. [mp=abstract, heading words, title]
71. 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70
72. 54 and 55 and 71

Appendix 7. CINAHL (EBSCO) search strategy

S1 (MM “Acne Vulgaris”)
S2 TI acne
S3 AB acne
S4 S1 or S2 or S3
S5 (MH “Clinical Trials+”)
S6 PT clinical trial

Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.
S7 TX (clinic* n1 trial*)
S8 (MH “Random Assignment”)
S9 TX random* allocat*
S10 TX placebo*
S11 (MH “Placebos”)
S12 (MH “Quantitative Studies”)
S13 TX allocat* random*
S14 “randomized control* trial***
S15 TX ((singl* n1 blind*) or (singl* n1 mask*)) or TX ((doubl* n1 blind*) or (doubl* n1 mask*)) or TX ((tripl* n1 blind*) or (tripl* n1 mask*)) or TX ((trebl* n1 blind*) or (trebl* n1 mask*))
S16 S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15
S17 (MH “Alternative Therapies”) OR (MH “Color Therapy”) OR (MH “Manual Therapy”)
S18 (MH “Diet”) OR (MH “Macrobiotic Diet”)
S19 (MH “Nutrition”)
S20 (MH “Antioxidants”)
S21 (MH “Meditation”) OR (MH “Yoga”)
S22 (MH “Mental Healing”)
S23 (MH “Hypnosis”)
S24 (MH “Support Groups”)
S25 (MH “Medicine, Chinese Traditional”) OR (MH “Medicine, African Traditional”) OR (MH “Medicine, Arabic”) OR (MH “Medicine, Ayurvedic”) OR (MH “Medicine, Oriental Traditional”) OR (MH “Medicine, Herbal”)
S26 (MH “Naturopathy”)
S27 (MH “Homeopathy”)
S28 (MH “Chelation Therapy”)
S29 (MH “Massage”)
S30 (MH “Chiropractic”)

Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.
S31 (MH “Therapeutic Touch”) 
S32 (MH “Physical Therapy”) 
S33 (MH “Acupuncture”) 
S34 (MH “Moxibustion”) 
S35 (MH “Therapeutic Exercise”) 
S36 (MH “Tai Chi”) 
S37 (MH “Aromatherapy”) 
S38 (MH “Reflexology”) 
S39 (MH “Reiki”) 
S40 (MH “Music Therapy”) 
S41 (MH “Tea Tree Oil”) 
S42 (MH “Aloe”) 
S43 (MH “Anthroposophy”) 
S44 (MH “Holistic Health”) 
S45 (MH “Shamanism”) 
S46 (MH “Psychology”) 
S47 (MH “Breathing Exercises”) 
S48 (MH “Psychodrama”) 
S49 (MH “Psychophysiology”) OR (MH “Biofeedback”) 
S50 (MH “Acupressure”) OR (MH “Auriculotherapy”) 
S51 (MH “Kinesiology”) 
S52 (MH “Rejuvenation”) 
S53 (MH “Acoustic Stimulation”) 
S54 (MH “Art Therapy”) 
S55 (MH “Dance Therapy”) 
S56 (MH “Spiritual Healing”)
S57 (MH “Magic”)

S58 (MH “Occultism”)

S59 (MH “Witchcraft”)

S60 TX diet* or nutrition* or macrobiotic* or Gerson or antioxidant* or “mind-body” or meditation or imagery or hypnosis or “support group*” or bioelectromagnetic* or electromagnetic* or electroacupuncture or traditional or folk or naturopathy or ayurved* or “Traditional Chinese Medicine” or TCM or homeopathy or antineoplaston or chelation or immunoaugmentation or shark or “manual healing” or massage or chiropractic or “therapeutic touch” or herb* or “physical therap*” or acupuncture or moxibustion or “cupping therapy” or “therapeutic exercise*” or “Tai Chi” or complementary or alternative or aromatherapy or reflexology or reiki or cam or yoga or music or “tea tree” or “aloe vera” or anthroposophy or “auricular therapy” or “holistic health” or “horticultural therapy” or Arabic or Asian or African or Kampo or unani or shamanism or mesotherapy or psychology or “breathing exercise*” or “laughter therapy” or “mental healing” or psychodrama or psychophysiology or “relaxation therapy” or Taiji or acupressure or kinesiology or manipulation or “tissue therapy” or eclecticism or reflexotherapy or rejuvenation or “acoustic stimulation” or “art therapy” or “colour therapy” or “dance therapy” or Speleotherapy or “faith healing” or magic or occultism or Radiesthesia or witchcraft or biofeedback or “immuno augmentation therapy” or macrobiotic* or “natural remed*” or “drama therapy” or visualisation

S61 S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49 or S50 or S51 or S52 or S53 or S54 or S55 or S56 or S57 or S58 or S59 or S60

S62 S4 and S16 and S61

**Appendix 8. PubMed search strategy (Using CAM subset)**

#4 Search #3 Limits: Complementary Medicine

#3 Search #1 and #2

#2 Search (acne vulgaris[MeSH Terms]) OR acne[Text Word]

#1 Search ((randomized controlled trial[Publication Type] OR controlled clinical trial[Publication Type]) OR randomized[Title/Abstract]) OR placebo[Title/Abstract] OR “clinical trials as topic”[MeSH Terms:noexp] OR randomly[Title/Abstract] OR trial[Title] NOT (animals[MeSH Terms] NOT (humans[MeSH Terms]) AND animals[MeSH Terms])
DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We changed the Data extraction and management section from the protocol, but it is now more concise. We created ‘Summary of findings’ tables and used GRADE criteria to evaluate the overall quality of the body of evidence.

Our primary outcome is 'Improvement of clinical signs assessed through skin lesion counts (total of inflamed and non-inflamed counted separately) and acne severity scores'. We decided to report this as 'Change in inflammatory and non-inflammatory lesion counts', 'Change of total skin lesion counts', 'Skin lesion scores', and 'Change of acne severity score'.

When we assessed the secondary outcomes, we combined the 'Physicians’ global evaluation' and 'Participants’ self assessment of change in specific types of lesion' and expressed them as the 'Number of participants with remission' as this had a clear definition and was easy to assess. We added description in the Methods section to clarify this type of outcome.

For missing data, we mentioned in the protocol that 'we planned to use the method of last observation carried forward for continuous data if available'; however, we could not obtain original individual participant data to carry out last observation carried forward (LOCF). Thus, we only applied intention-to-treat analyses to dichotomous outcomes.
Figure 1.
Study flow diagram
Figure 2.
'Risk of bias' graph: review authors’ judgements about each 'Risk of bias' item presented as percentages across all included studies.
Figure 3.
’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each included study
**Figure 4.**
Forest plot of comparison: 1. Low-glycaemic-load diet versus high-glycaemic-load diet, outcome: 1.1 Primary outcome: change in non-inflammatory lesion count (medium-term data)
### Analysis 1.1.
Comparison 1 Low-glycaemic-load diet versus high-glycaemic-load diet, Outcome 1
Primary outcome: change in non-inflammatory lesion count (medium-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>LGLD</th>
<th>HGLD</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
<td>IV(Random,95% CI)</td>
</tr>
<tr>
<td>Kwon 2012</td>
<td>17</td>
<td>-2.29 (4.65)</td>
<td>15</td>
<td>-1.15 (7.41)</td>
<td>56.8 %</td>
</tr>
<tr>
<td>Smith 2007</td>
<td>23</td>
<td>-16 (10.6375)</td>
<td>20</td>
<td>-8.5 (10.4698)</td>
<td>43.2 %</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>40</strong></td>
<td><strong>35</strong></td>
<td>-3.89</td>
<td>100.0 %</td>
<td><strong>-3.89 [-10.07, 2.29]</strong></td>
</tr>
</tbody>
</table>

Heterogeneity: $\tau^2 = 12.56$; $\chi^2 = 2.64$, df = 1 ($P = 0.10$); $I^2 = 62$
Test for overall effect: $Z = 1.23$ ($P = 0.22$)
Test for subgroup differences: Not applicable
### Analysis 1.2.
Comparison 1 Low-glycaemic-load diet versus high-glycaemic-load diet, Outcome 2
Primary outcome: change in inflammatory lesion counts (medium-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>LGLD N</th>
<th>Mean(SD)</th>
<th>HGLD N</th>
<th>Mean(SD)</th>
<th>Mean Difference IV/Fixed 95% CI</th>
<th>Weight</th>
<th>Mean Difference IV/Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smith 2007</td>
<td>23</td>
<td>-16 (9.9438)</td>
<td>20</td>
<td>-8.4 (9.8288)</td>
<td>-7.60 [-13.52, -1.68]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>0</strong></td>
<td><strong>0</strong></td>
<td></td>
<td></td>
<td>0.0 [ 0.0, 0.0 ]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
Analysis 1.3.
Comparison 1 Low-glycaemic-load diet versus high-glycaemic-load diet, Outcome 3
Primary outcome: change of total lesion counts (medium-term data).
Analysis 2.1.
Comparison 2 Acupuncture versus waiting list, Outcome 1 Primary outcome: change of inflammatory lesion count (short-term data).
Analysis 2.2.
Comparison 2 Acupuncture versus waiting list, Outcome 2 Primary outcome: change of non-inflammatory lesion count (short-term data).
Analysis 3.1.
Comparison 3 Acupuncture versus western drugs, Outcome 1 Secondary outcome: number of participants with remission (ITT-worst case, short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Acupuncture</th>
<th>Western drugs</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Fire acupuncture versus Clindamycin phosphate gel and aizithromycin capsule</td>
<td>55/105</td>
<td>15/105</td>
<td>3.67 [2.22, 6.06]</td>
<td></td>
</tr>
</tbody>
</table>

Favours western drug | Favours acupuncture

0.2 | 0.5 | 1 | 2 | 5
Analysis 3.2.
Comparison 3 Acupuncture versus western drugs, Outcome 2 Secondary outcome: number of participants with remission (ITT-best case, short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Acupuncture n/N</th>
<th>Western drugs n/N</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fire acupuncture versus Clindamycin phosphate gel and azithromycin capsule Huang 2006</td>
<td>57/105</td>
<td>13/105</td>
<td>4.38 [ 2.56, 7.51 ]</td>
</tr>
</tbody>
</table>

Favours western drug Favours acupuncture
### Analysis 3.3.
Comparison 3 Acupuncture versus western drugs, Outcome 3 Secondary outcome: number of participants with remission (ITT-worst case, medium-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Acupuncture</th>
<th>Western drugs</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Acupuncture versus isotretinoin soft capsules</td>
<td>18/50</td>
<td>26/50</td>
<td>0.69 [0.44, 1.09]</td>
<td></td>
</tr>
</tbody>
</table>

*Favours western drug*  
*Favours acupuncture*
### Analysis 3.4.
Comparison 3 Acupuncture versus western drugs, Outcome 4 Secondary outcome: number of participants with remission (ITT-best case, medium-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Acupuncture n/N</th>
<th>Western drugs n/N</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acupuncture versus isotretinoin soft capsules Han 2010</td>
<td>22/50</td>
<td>23/50</td>
<td>0.96 [0.62, 1.48]</td>
<td></td>
</tr>
</tbody>
</table>

0.5 0.7 1 1.5 2
Favours western drug  Favours acupuncture
### Analysis 4.1.

Comparison 4 Herbal medicine versus waiting list, Outcome 1 Primary outcome: change of inflammatory lesion count (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbal medicine</th>
<th>Waiting list</th>
<th>Mean Difference IV/Fixed, 95% CI</th>
<th>Mean Difference IV/Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean (SD)</td>
<td>N</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Kim 2012</td>
<td>11</td>
<td>8 (5.6)</td>
<td>11</td>
<td>10.8 (13.5)</td>
</tr>
</tbody>
</table>

-2.80 [-12.26, 6.66]
Analysis 4.2.
Comparison 4 Herbal medicine versus waiting list, Outcome 2 Primary outcome: change of non-inflammatory lesion count (short-term data).
Analysis 5.1.
Comparison 5 Herbal medicine versus antibiotics, Outcome 1 Primary outcome: change of total skin lesion counts at the end of the treatment (medium-term data).
### Analysis 5.2.
Comparison 5 Herbal medicine versus antibiotics, Outcome 2 Secondary outcome: number of participants with remission (ITT-worst case, short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbal medicine</th>
<th>Antibiotics</th>
<th>Risk Ratio H-Random 95% CI</th>
<th>Weight</th>
<th>Risk Ratio H-Random 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhi-Yin-Qinggan-Xiaocuo Granule versus minocycline (at 4 weeks)</td>
<td>5/57</td>
<td>2/29</td>
<td>1.27 [0.26, 6.16]</td>
<td>43.5%</td>
<td>1.27 [0.26, 6.16]</td>
</tr>
<tr>
<td>Li 2007</td>
<td>4/60</td>
<td>17/60</td>
<td>0.24 [0.08, 0.66]</td>
<td>56.5%</td>
<td>0.24 [0.08, 0.66]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>117</strong></td>
<td><strong>89</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>0.49 [0.09, 2.53]</strong></td>
<td><strong>100.0%</strong></td>
</tr>
<tr>
<td>Xioacuo decoction versus doxycycline (at 4 weeks)</td>
<td>25/80</td>
<td>18/80</td>
<td>1.39 [0.83, 2.34]</td>
<td>100.0%</td>
<td>1.39 [0.83, 2.34]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>80</strong></td>
<td><strong>80</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>1.39 [0.83, 2.34]</strong></td>
<td><strong>100.0%</strong></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>40</strong></td>
<td><strong>40</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>2.00 [1.17, 3.42]</strong></td>
<td><strong>100.0%</strong></td>
</tr>
</tbody>
</table>
### Analysis 5.3.
Comparison 5 Herbal medicine versus antibiotics, Outcome 3 Secondary outcome: number of participants with remission (ITT-best case, short-term data).
### Analysis 5.4.
Comparison 5 Herbal medicine versus antibiotics, Outcome 4 Secondary outcome: number of participants with remission (medium-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbal medicine</th>
<th>Antibiotics</th>
<th>Risk Ratio (M-H,Fixed,95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Herbal decoction versus minocycline hydrochloride capsules (at 8 weeks)</td>
<td>Wei 2012, 10/50</td>
<td>6/50</td>
<td>1.67 [0.66, 4.24]</td>
</tr>
<tr>
<td>2 Shugan Zishen decoction versus tetracycline (at 8 weeks)</td>
<td>Yu 2008, 10/28</td>
<td>3/20</td>
<td>2.38 [0.75, 7.56]</td>
</tr>
</tbody>
</table>
### Analysis 6.1.

Comparison 6 Herbal medicine versus vitamin A acid, Outcome 1 Secondary outcome: number of participants with remission (ITT-worst case, short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbal medicine</th>
<th>Vitamin A acid</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Xiaocuo decoction plus 0.1% adapalene gel versus viamine capsule plus 0.1% adapalene gel (at 4 weeks) Chen 2012</td>
<td>11/35</td>
<td>2/35</td>
<td>5.50 [1.31, 23.03]</td>
</tr>
<tr>
<td>2 Jiawei Xiaodu decoction versus tretinoin cream (at 2 weeks) Shi 2012</td>
<td>72/96</td>
<td>9/71</td>
<td>5.92 [3.18, 11.01]</td>
</tr>
<tr>
<td>3 Qingbu decoction versus viamine capsule (at 4 weeks) Zhang 2012</td>
<td>18/40</td>
<td>12/40</td>
<td>1.50 [0.84, 2.69]</td>
</tr>
<tr>
<td>4 Modified Cuo Chuang decoction versus isotretinoin (at 4 weeks) Zhu 2007</td>
<td>5/40</td>
<td>3/40</td>
<td>1.67 [0.43, 6.51]</td>
</tr>
</tbody>
</table>

Favours vitamin A acid  Favours herbal medicine
### Analysis 6.2.

Comparison 6 Herbal medicine versus vitamin A acid, Outcome 2 Secondary outcome: number of participants with remission (ITT-best case, short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbal medicine</th>
<th>Vitamin A acid</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Xiaocuo decoction plus 0.1% adapalene gel versus viaminate capsule plus 0.1% adapalene gel (at 4 weeks)</td>
<td>11/35</td>
<td>2/35</td>
<td>---</td>
<td>5.50 [1.31, 23.03]</td>
</tr>
<tr>
<td>Chen 2012</td>
<td>72/96</td>
<td>9/71</td>
<td>---</td>
<td>5.92 [3.18, 11.01]</td>
</tr>
<tr>
<td>Shi 2012</td>
<td>19/40</td>
<td>7/40</td>
<td>---</td>
<td>2.71 [1.29, 5.73]</td>
</tr>
<tr>
<td>4 Modified Cuo Chuang decoction versus isotretinoin soft capsules (at 4 weeks)</td>
<td>5/40</td>
<td>3/40</td>
<td>---</td>
<td>1.67 [0.43, 6.51]</td>
</tr>
</tbody>
</table>
### Analysis 6.3.

Comparison 6 Herbal medicine versus vitamin A acid, Outcome 3 Secondary outcome: number of participants with remission (medium-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbal medicine</th>
<th>Vitamin A acid</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Fixed, 95% CI</td>
<td>M-H, Fixed, 95% CI</td>
</tr>
<tr>
<td>1 Da Huang Zhe Chong Pills versus isotretinoin soft capsule (at 8 weeks)</td>
<td>9/52</td>
<td>11/47</td>
<td>-</td>
<td>0.74 [0.34, 1.63]</td>
</tr>
<tr>
<td>Peng 2012</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Modified Wuwei Xiaodu Yin % Yinchen Hao decoction versus viaminate Cream (at 8 weeks)</td>
<td>2/35</td>
<td>1/35</td>
<td>-</td>
<td>2.00 [0.19, 21.06]</td>
</tr>
<tr>
<td>Liu 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Herbal decoction external application versus adapalene external application (at 6 weeks)</td>
<td>18/40</td>
<td>16/40</td>
<td>-</td>
<td>1.13 [0.67, 1.88]</td>
</tr>
<tr>
<td>Wang 2012</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Analysis 6.4.
Comparison 6 Herbal medicine versus vitamin A acid, Outcome 4 Secondary outcome: QoL-acne score (medium-term data).
**Analysis 7.1.**

Comparison 7 Herbal medicine versus antibiotics and vitamin A acid, Outcome 1 Secondary outcome: number of participants with remission (medium-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbal medicine</th>
<th>Antibiotic % vit A acid</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
<th>Risk Ratio M-H,Fixed 95% Cl</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xiaocuo Granule + herbal decoction externally used versus roxithromycin % viaminate capsules (at 5 weeks) Tang 2011</td>
<td>46/120</td>
<td>19.99</td>
<td>2.00 [1.26, 3.18]</td>
<td></td>
</tr>
</tbody>
</table>

Favours western drugs
Favours herbal medicine
### Analysis 8.1.
Comparison 8 Herbal medicine versus staphylococcus Injection. Outcome 1 Primary outcome: skin lesion score (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbal medicine</th>
<th>Mean(SD)</th>
<th>N</th>
<th>Mean(SD)</th>
<th>N</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wu 2008</td>
<td>84</td>
<td>16.36 (2.18)</td>
<td>87</td>
<td>17.64 (3.21)</td>
<td>-1.28</td>
<td>[-2.10, -0.46]</td>
<td></td>
</tr>
</tbody>
</table>

Favours herbal medicine  Favours Staphylococcus Injection
**Analysis 8.2.**

Comparison 8 Herbal medicine versus staphylococcus Injection. Outcome 2 Secondary outcome: number of participants with remission (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbal medicine n/N</th>
<th>Staphylococcus Toxoid Injection n/N</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wu 2008</td>
<td>43/84</td>
<td>48/87</td>
<td></td>
<td>0.93 [0.70, 1.23]</td>
</tr>
</tbody>
</table>

Favours Staphylococcus Toxoid Injection, Favours herbal medicine.
Analysis 9.1.
Comparison 9 Herbal medicine plus western drugs versus western drugs, Outcome 1
Primary outcome: change of total skin lesion counts at the end of the treatment (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbs % western drugs</th>
<th>Western drugs</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean(SD)</td>
<td>N Mean(SD)</td>
<td>IV(Fixed,95% CI)</td>
<td>IV(Fixed,95% CI)</td>
</tr>
<tr>
<td>Qingre 25-medicines pill + Staphylococcus inj versus Staphylococcus inj (at 4 weeks) Wu 2008</td>
<td>86 8.1 (2.68)</td>
<td>87 17.64 (3.21)</td>
<td>-9.54 [-10.42, -8.66]</td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 9.2.
Comparison 9 Herbal medicine plus western drugs versus western drugs, Outcome 2
Secondary outcome: number of participants with remission (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbs % western drugs</th>
<th>Western drugs</th>
<th>Risk Ratio (M-H-Fixed, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Qingre 25- Ingredients Pill + staphylococcus Inj versus staphylococcus Inj (at 4 weeks) Wu 2008</td>
<td>69/86</td>
<td>48/87</td>
<td>1.45 [1.17, 1.81]</td>
</tr>
<tr>
<td>2 Danshen tablet plus doxycycline versus doxycycline (at 4 weeks) Yu 2011</td>
<td>40/65</td>
<td>22/65</td>
<td>1.82 [1.23, 2.69]</td>
</tr>
</tbody>
</table>
### Analysis 10.1.

Comparison 10 Herbal medicine plus LED versus LED, Outcome 1 Secondary outcome: number of participants with remission (ITT-worst case, short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbal medicine plus LED n/N</th>
<th>LED n/N</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liu 2012</td>
<td>14/31</td>
<td>12/31</td>
<td>1.17 [0.65, 2.10]</td>
<td></td>
</tr>
</tbody>
</table>

Favours LED  
Favours herbs plus LED
### Analysis 10.2.
Comparison 10 Herbal medicine plus LED versus LED, Outcome 2 Secondary outcome: number of participants with remission (ITT-best case, short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbal medicine plus LED</th>
<th>LED</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liu 2012</td>
<td>15/31</td>
<td>11/31</td>
<td>1.36 [0.75, 2.48]</td>
<td></td>
</tr>
</tbody>
</table>

Favours LED, Favours herbs plus LED
Analysis 11.1.
Comparison 11 Herbal medicine plus wet cupping versus wet cupping, Outcome 1
Secondary outcome: number of participants with remission (short-term data).
Analysis 12.1.
Comparison 12 Wet cupping versus western drugs. Outcome 1 Primary outcome: change in acne severity score at the end of treatment (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Wet cupping</th>
<th>Mean(SD)</th>
<th>Western drugs</th>
<th>Mean(SD)</th>
<th>Mean Difference</th>
<th>IV/Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wet cupping versus viaminate cream (at 4 weeks)</td>
<td>20</td>
<td>4.05 (2.84)</td>
<td>20</td>
<td>10 (4.5)</td>
<td>-5.95 [-8.28, -3.62]</td>
<td></td>
</tr>
</tbody>
</table>
Analysis 12.2.
Comparison 12 Wet cupping versus western drugs. Outcome 2 Secondary outcome: number of participants with remission (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Wet cupping n/N</th>
<th>Western drugs n/N</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Wet cupping versus vianimate cream (at 4 weeks) Zhou 2009</td>
<td>2/20</td>
<td>0/20</td>
<td>5.00 [0.26, 98.00]</td>
</tr>
<tr>
<td>2 Wet cupping versus achromycin (at 4 weeks) Wu 2008a</td>
<td>20/30</td>
<td>8/30</td>
<td>2.50 [1.31, 4.77]</td>
</tr>
<tr>
<td>3 Wet cupping versus tetracycline (at 2 weeks) Song 2007</td>
<td>21/42</td>
<td>6/34</td>
<td>2.83 [1.29, 6.22]</td>
</tr>
</tbody>
</table>
### Analysis 13.1.
Comparison 13 Wet cupping plus herbal medicine versus herbal medicine, Outcome 1
Secondary outcome: number of participants with remission (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Wet cupping plus herbs n/N</th>
<th>Herbal medicine n/N</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen 2009</td>
<td>7/30</td>
<td>3/30</td>
<td>2.33 [0.67, 8.18]</td>
<td></td>
</tr>
</tbody>
</table>

Cao et al.  
Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.
Analysis 14.1.
Comparison 14 Wet cupping plus acupuncture versus western drugs, Outcome 1 Primary outcome: skin lesion score (medium-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Cupping and acupuncture</th>
<th>Antibiotics</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N  Mean(SD)</td>
<td>N  Mean(SD)</td>
<td>IV/Fixed, 95% CI</td>
<td>IV/Fixed, 95% CI</td>
</tr>
<tr>
<td>I Wet cupping plus acupuncture versus minocycline (at 10 weeks)</td>
<td>30  11.85 (7.82)</td>
<td>30  13.4 (6.39)</td>
<td>-1.55 [-5.16, 2.06]</td>
<td></td>
</tr>
</tbody>
</table>

Favours cupping and acupuncture  Favours minocycline
**Analysis 14.2.**

Comparison 14 Wet cupping plus acupuncture versus western drugs, Outcome 2 Secondary outcome: number of participants with remission (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Cupping plus acupuncture</th>
<th>Western drugs</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
<th>Risk Ratio M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Wet cupping plus acupuncture versus antibiotics (at 4 weeks)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liu 2006</td>
<td>3/20</td>
<td>1/20</td>
<td>3.00 [0.34, 26.45]</td>
<td>2.50 [0.53, 11.89]</td>
</tr>
<tr>
<td>Wen 2012</td>
<td>5/30</td>
<td>2/30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Wet cupping plus acupuncture versus vitamin A acid (at 4 weeks)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liu 2007</td>
<td>8/35</td>
<td>1/35</td>
<td>8.00 [1.06, 60.63]</td>
<td></td>
</tr>
<tr>
<td>Liu 2008</td>
<td>3/26</td>
<td>4/26</td>
<td>0.75 [0.19, 3.03]</td>
<td></td>
</tr>
<tr>
<td>You 2012</td>
<td>8/30</td>
<td>3/30</td>
<td>2.67 [0.78, 9.09]</td>
<td></td>
</tr>
<tr>
<td>Zhang 2010</td>
<td>15/30</td>
<td>6/30</td>
<td>2.50 [1.12, 5.56]</td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 14.3.
Comparison 14Wet cupping plus acupuncture versus western drugs, Outcome 3 Secondary outcome: QoL-acne score (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Herbal medicine</th>
<th>Vitamin A acid cream</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>IV Fixed 95% CI</td>
</tr>
<tr>
<td>1 Functioning in society (at 4 weeks)</td>
<td>Liu 2007 35</td>
<td>27.17 (1.16)</td>
<td>4.51 [3.95, 5.07]</td>
</tr>
<tr>
<td>3 Emotional functionality (at 4 weeks)</td>
<td>Liu 2007 35</td>
<td>25.81 (1.2)</td>
<td>4.73 [4.31, 5.15]</td>
</tr>
</tbody>
</table>
Analysis 15.1.
Comparison 15: Wet cupping plus herbal medicine versus western drugs, Outcome 1
Secondary outcome: number of participants with remission (short-term data).
Analysis 16.1.
Comparison 16 Combination of wet cupping, acupuncture and massage versus western drug - zinc gluconate, Outcome 1 Primary outcome: skin lesion score (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Combination</th>
<th>N</th>
<th>Mean (SD)</th>
<th>Mean (SD)</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IV/Fixed, 95% CI</td>
<td>IV/Fixed, 95% CI</td>
</tr>
<tr>
<td>N: 2008</td>
<td>Combination</td>
<td>24</td>
<td>3.58 (4.65)</td>
<td>22</td>
<td>7.45 (5.93)</td>
<td>-3.87 [-6.97, -0.77]</td>
</tr>
</tbody>
</table>

Cao et al. Page 87
Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.
### Analysis 16.2.
Comparison 16 Combination of wet cupping, acupuncture and massage versus western drug - zinc gluconate, Outcome 2 Secondary outcome: number of participants with remission (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Combination group</th>
<th>Zinc gluconate</th>
<th>Risk Ratio M-H,Fixed</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ni 2008</td>
<td>9/24</td>
<td>2/22</td>
<td>4.13</td>
<td>[1.00, 17.04]</td>
</tr>
</tbody>
</table>

Note: The table above shows the comparison of two treatment groups in terms of remission rates. The remission rate for the combination group was significantly higher than that for the zinc gluconate group, with a risk ratio of 4.13 and a 95% confidence interval of [1.00, 17.04]. This suggests that the combination therapy is more effective in achieving remission compared to zinc gluconate alone.
Analysis 16.3.
Comparison 16 Combination of wet cupping, acupuncture and massage versus western drug - zinc gluconate, Outcome 3 Secondary outcome: QoL-acne score (short-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Combination</th>
<th>N</th>
<th>Mean(SD)</th>
<th>N</th>
<th>Mean(SD)</th>
<th>Mean Difference IVFixed 95% CI</th>
<th>Mean Difference IVFixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Functioning in society (at 3 weeks)</td>
<td>Wet cupping, acupuncture and massage</td>
<td>24</td>
<td>20.79 (2.08)</td>
<td>22</td>
<td>19.32 (2.01)</td>
<td>1.47 [ 0.29, 2.65 ]</td>
<td></td>
</tr>
<tr>
<td>2 Feelings of self-worth (at 3 weeks)</td>
<td>Wet cupping, acupuncture and massage</td>
<td>24</td>
<td>27.21 (1.22)</td>
<td>22</td>
<td>25.95 (2.24)</td>
<td>1.26 [ 0.20, 2.32 ]</td>
<td></td>
</tr>
<tr>
<td>3 Emotional functionality (at 3 weeks)</td>
<td>Wet cupping, acupuncture and massage</td>
<td>24</td>
<td>25.29 (1.37)</td>
<td>22</td>
<td>24.36 (1.26)</td>
<td>0.93 [ 0.17, 1.69 ]</td>
<td></td>
</tr>
</tbody>
</table>
Analysis 17.1.
Comparison 17 Tea tree oil versus placebo, Outcome 1 Primary outcome: change of total skin lesion counts (medium-term data).
### Analysis 17.2.
Comparison 17 Tea tree oil versus placebo, Outcome 2 Primary outcome: change of acne severity score (medium-term data).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Tea tree oil gel</th>
<th>Placebo gel</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
<td>IV/Fixed, 95% CI</td>
</tr>
<tr>
<td>Enshaieh 2007</td>
<td>30</td>
<td>-6.54 (5.45)</td>
<td>30</td>
<td>-0.79 (8.97)</td>
</tr>
</tbody>
</table>

-10 -5 0 5 10
Favours tea tree oil Favours placebo
Analysis 18.1.
Comparison 18 Cosmetics with PBV versus cosmetics without PBV, Outcome 1 Primary outcome: change in KAGS scores based on number of inflammatory and non-inflammatory acne lesions.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>PBV</th>
<th>Control</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td></td>
</tr>
<tr>
<td>Han 2013</td>
<td>6</td>
<td>0.667 (0.817)</td>
<td>-1.17 [-2.06, -0.28]</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>1.83 (0.753)</td>
<td></td>
</tr>
</tbody>
</table>

Scores range from -2 to 2, with a score of 2 indicating a 2 point increase in KAGS scores, and a score of -2 indicating a 2 point decrease. A negative difference indicates greater improvement in the PBV group compared to the control group.
Table 1

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follicular hyperkeratinisation</td>
<td>A chronic skin disease characterised by small follicular papules; disseminated reddish-brown scaly patches; and often, palmoplantar hyperkeratosis. The papules are about the size of a pin and topped by a horny plug.</td>
</tr>
<tr>
<td>Gerson diet</td>
<td>A specific diet that was designed by Dr Max B Gerson for cancer and other ailments to detoxify the body while boosting the immune system and improving metabolism.</td>
</tr>
<tr>
<td>Antineoplaston</td>
<td>A mixture of sodium salts of phenylacetic acid and phenylacetylglutamine in the ratio 4:1.</td>
</tr>
<tr>
<td>Chelation therapy</td>
<td>Therapy of heavy metal poisoning using agents that sequester the metal from organs or tissues and bind it firmly within the ring structure of a new compound, which can be eliminated from the body.</td>
</tr>
<tr>
<td>Immunoaugmentation therapy</td>
<td>A treatment aimed to restore the immune system to enable it to destroy cancer cells, by evaluation-measuring deficiencies of the immune systems and therapy-replenishing deficient factors by self-injection of sera.</td>
</tr>
<tr>
<td>Hyperlipidaemia</td>
<td>Conditions with excess lipids in the blood</td>
</tr>
<tr>
<td>Teratogenicity</td>
<td>Ability to cause birth defects</td>
</tr>
<tr>
<td>Decoction</td>
<td>The extraction of the water-soluble substances of a drug or medicinal plants by boiling</td>
</tr>
</tbody>
</table>
Table 2
Components of the herbal medicine in relevant trials

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Name</th>
<th>Components</th>
<th>Methods of use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen 2012</td>
<td>Xiaocuo decoction</td>
<td>Flos Lonicereae, Fructus forsythiae, Herba taraxaci, Herba violae, Flos chrysanthemi indici, Herba oldenlandiae, Herba lobeliae chinensis, Gypsum fibrosum, Radix scutellariae, Semen coicis, Fructus crataegi, Cortex mori, Radix glycyrrhizae, Radix salviae multiarhizae</td>
<td>40 ml every time, 3 times daily for 4 weeks</td>
</tr>
<tr>
<td>Chen 2009</td>
<td>Individualised herbal decoction</td>
<td>For Wind-heat Syndrome: Rhizoma seu radix notoperygii 10 g, Radix saposhnikoviae 10 g, Fructus gardeniae 6 g, Rhizoma chuanxiong 10 g, Fructus tribuli 10 g, Radix glycyrrhizae 10 g, Flos chrysanthemi 10 g</td>
<td>Twice daily for 4 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>For Damp-heat Syndrome: Fructus forsythiae 10 g, Radix angelicae dahuricae 10 g, Fructus gardeniae 10 g, Radix scutellariae 10 g, Rhizoma coptidis 10 g, Radix sophorae flavescents 10 g, Herba schizonepetae 10 g, Rhizoma chuanxiong 6 g, Bulbus frilllariae thunbergii 10 g, Cortex mori 10 g, Radix glycyrrhizae 10 g</td>
<td></td>
</tr>
<tr>
<td>Feng 2005</td>
<td>Ziyin Qinggan Xiaocuo Granule</td>
<td>Herba Houttuyniae 15 g, Radix bupleuri 12 g, Radix rehmannia 20 g, Radix glycyrrhizae 6 g, Radix salviae multiarhizae 30 g,  Radix curcumae 20 g, Fructus ligustri lucidi 20 g, Herba equilatae 20 g</td>
<td>Once daily for 4 weeks</td>
</tr>
<tr>
<td>Kim 2012</td>
<td>Keigai-rengyo-to-extract (KRTE)</td>
<td>Schizonepetae herba 0.27 g, Forsythiae fructus 0.34 g, Ledebouriellae radix 0.65 g, Angelicae gigantis radix 0.70 g, Cnidii rhizoma 0.65 g, Paonieae radix 0.32 g, Bupleuri radix 0.59 g, Aurantii fructus 0.86 g, Scutellariae radix 0.67 g, Gardeniae fructus 0.89 g, Angelicae dahuricae radix 0.35 g, Platycodi radix 0.51 g, Glycyrrhizae radix 0.67 g, Total amount is 7.4 g</td>
<td>3 times daily after meals for 4 weeks</td>
</tr>
<tr>
<td>Lin 2013</td>
<td>Herbal medicinal mask</td>
<td>Radix Angelicae Dahuricae, Rhizoma Bleilae, Cortex Dictamni, Herba Taraxaci, Fructus Forsythiae, et al</td>
<td>30 minutes every time, once every 2 days for 4 weeks</td>
</tr>
<tr>
<td>Liu 2012</td>
<td>Herbal medicinal mask</td>
<td>Flos Lonicereae, Herba Violae, Flos chrysanthemi indici, Herba oldenlandiae, Radix angelicae dahuricae, Cortex moutan, Radix acanthic lateralis preparata, Margarita. Total amount is 35 g</td>
<td>30 minutes every time, twice per week for 4 weeks</td>
</tr>
<tr>
<td>Liu 2004</td>
<td>Xiaocuo decoction</td>
<td>Herba Taraxaci 20 g, Radix scutellariae 30 g, Rhizoma coptidis 9 g, Radix et rhizoma rhei 6 g, Radix glycyrrhizae 6 g, Radix salviae multiarhizae 30 g, Fructus ligustri lucidi 20 g, Herba equilatae 20 g</td>
<td>50 ml every time, twice daily for 4 weeks</td>
</tr>
<tr>
<td>Liu 2007</td>
<td>Modified Wuwei Xiaodu Yin and</td>
<td>Flos Lonicereae 20 g, Fructus forsythiae 10 g, Herba Violae 15 g, Flos chrysanthemi indici 10 g, Folium isatidis 15 g, Herba oldenlandiae 30 g, Herba portulacae 15 g, Rhizoma coptidis 9 g, Radix et rhizoma rhei 6 g, Herba artemisiae scopariae 15 g, Radix glycyrrhizae 6 g, Radix salviae multiarhizae 30 g, Fructus ligustri lucidi 20 g, Herba equilatae 20 g</td>
<td>100 ml every time, twice daily for 8 weeks</td>
</tr>
<tr>
<td>Lin 2011</td>
<td>Yinxiao Liangxue decoction</td>
<td>Flos Lonicereae 20 g, Fructus forsythiae 20 g, Folium isatidis 20 g, Herba oldenlandiae 15 g, Radix trichosanthes 15 g, Cortex moutan 20 g, Radix paeoniae rubra 15 g, Bulbus frilllariae thunbergii 12 g, Cortex mori 12 g, Rhizoma anemarrhena 15 g</td>
<td>50 ml every time, twice daily for 4 weeks</td>
</tr>
<tr>
<td>Study ID</td>
<td>Name</td>
<td>Components</td>
<td>Methods of use</td>
</tr>
<tr>
<td>----------</td>
<td>------</td>
<td>------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Peng 2012</td>
<td>Da Huang Zhe Chong Pills</td>
<td>Radix et Rhizoma Rhei, Eupolyphaga seu Stelleophaga, Hirudo, Tabanus, Grub, Resina Toxicondriniai, Semen Persicae, Semen Armeniacae Amarum, Radix Scutellariae, Radix Rehmanniae, Radix Paeoniae Alba, Radix Glycyrrhizae</td>
<td>3 g half hour before meal, taken with Dan Quan rice wine 10 ml (Guangxi Dan Quan wine industry limited by share Ltd.), twice daily for 8 weeks</td>
</tr>
<tr>
<td>Shi 2012</td>
<td>Jiawei Xiaodu Yin</td>
<td>Flos Lonicerae 10 g, Herba Taraxaci 10 g, Herba Violae 10 g, Flos chrysanthemi indici 10 g, Radix angelicae dahuricae 10 g, Radix scutellariae 10 g, Medulla retractanacis 10 g, Bulbus frullarii thunbergii 12 g, Cortex mori 10 g, radix astragali 30 g, Spina gleditsiae 10 g</td>
<td>Twice daily for 15 days</td>
</tr>
<tr>
<td>Tang 2011</td>
<td>Xiaocuo Granule</td>
<td>Herba Violae 15 g, Flos chrysanthemi indici 12 g, Herba oldenlandiae 15 g, Radix bupleuri 10 g, Radix angelicae dahuricae 10 g, Radix scutellariae 15 g, Radix salviae miltiorrhziae 15 g, Herba menthae 6 g</td>
<td>Twice daily for 5 weeks</td>
</tr>
<tr>
<td>Wang 2012</td>
<td>Modified Cuochuang decoction</td>
<td>Herba Taraxaci 30 g, Herba Violae 30 g, Herba oldenlandiae 10 g, Herba portulacae 30 g, Radix scutellariae 10 g, Radix rehmanniae 15 g, Radix paoniae rubra 10 g, Herba artemisiae scopariae 15 g, Bulbus frullarii thunbergii 30 g, Folium eriobotryae 15 g, Cortex mori 10 g, Radix glycyrrhizae 5 g, Radix angelicae sinensis 5 g, Radix salviae miltiorrhziae 30 g, Flos chrysanthemi 30 g</td>
<td>Twice daily for 6 weeks</td>
</tr>
<tr>
<td>Wei 2012</td>
<td>Herbal decoction aim to clear liver heat and dampness</td>
<td>Herba Taraxaci 20 g, Radix bupleuri 6 g, Fructus gardeniae 10 g, Radix scutellariae 10 g, Radix gentianae 10 g, Radix scutellariae 10 g, Semen coicis 20 g, Semen plantaginis 10 g, Rhizoma alismatis 10 g, Rhizoma atracylodis macrocephalae 10 g, Radix glycyrrhizae 5 g, Radix paoniae alba 10 g, Radix salviae miltiorrhziae 10 g, Radix angelicae sinensis 10 g</td>
<td>200 ml every time, twice daily after meals for 8 weeks</td>
</tr>
<tr>
<td>Wu 2008</td>
<td>Qingre Twenty-five Ingredient pills</td>
<td>Lignum santali albi, Fructus toosendan, Semen euphorbiae, Flos carthami, Fructus amomum rotundus, Flos caryophylli, Fructus alpiniae oxyphyllae, Fructus tsaooko, Pericarpium citri reticulate viride, Borneolium synthenticum, Radix aucklandiae, Caulis clematidis armandii, Gypsum fibrosum, Fructus aurantii immaturus, Fructus chebulae, Fructus gardeniae, Cortex phellodendri, Flos chrysanthemi, Lignum aquilariae resinaltum, Rhizoma belamcandae, et al</td>
<td>2 g every time, twice daily for 30 days</td>
</tr>
<tr>
<td>Yu 2011</td>
<td>Compound Danshen tablet</td>
<td>Guangdong Yikang Pharmaceutical Ltd Co (Z44020873). Main ingredient: Radix salviae miltiorrhziae, Radix notoginseng, Borneolium synethicunm</td>
<td>0.412 g/tablet, 3 tablets every time, 3 times daily for 4 weeks</td>
</tr>
<tr>
<td>Yu 2008</td>
<td>Shugan Ziyin decoction</td>
<td>Fructus toosendan, Rhizoma cyperi, Radix salviae miltiorrhziae, Semen cuscutae, Fructus ligustri lucidi, Herba ecaiptae, Radix scutellariae</td>
<td>50 ml once daily for 8 weeks</td>
</tr>
<tr>
<td>Zhang 2012</td>
<td>Qingbu decoction</td>
<td>Fructus forsythiae 15 g, Herba Taraxaci 30 g, Herba oldenlandiae 30 g, Spica prunellae 10 g, Fructus gardeniae 9 g, Radix bupleuri 10 g, Semen coicis 30 g, Herba artemisiae scopariae 15 g, Fructus aurantii 10 g, Radix pseudostellariae 30 g, Radix glycyrrhizae 6 g, Radix salviae miltiorrhziae 30 g, Fructus ligustri lucidi 12 g, Herba ecaiptae 12 g, Spina gledistsiae 10 g</td>
<td>150 mg every time, twice daily after meals for 4 weeks</td>
</tr>
<tr>
<td>Zhu 2007</td>
<td>Modified Cuochuang decoction</td>
<td>Radix scutellariae 10 g, Cortex phellodendri 10 g, Folium eriobotryae 10 g, Cortex mori 10 g, Radix glycyrrhizae 10 g, Radix salviae miltiorrhziae 30 g, Flos carthami 10 g, Semen persicae 10 g, Rhizoma anemarrhenae 10 g</td>
<td>Twice daily for 6 weeks</td>
</tr>
</tbody>
</table>
### Table 3

#### Adverse events

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Intervention group</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Description of adverse events</td>
<td>Sample size</td>
</tr>
<tr>
<td>Chen 2012</td>
<td>2 participants had mild nausea 2 participants reported dry skin and desquamation</td>
<td>35</td>
</tr>
<tr>
<td>Chen 2009</td>
<td>15 participants had violaceous mark on application of the cupping, which faded away a few days later</td>
<td>20</td>
</tr>
<tr>
<td>Enshaieh 2007</td>
<td>3 participants had minimal pruritus 1 participant reported a little burning sensation on application of the drug 1 participant had minimal scaling</td>
<td>30</td>
</tr>
<tr>
<td>Feng 2005</td>
<td>19 participants reported loose stools once or twice daily</td>
<td>29</td>
</tr>
<tr>
<td>Han 2010</td>
<td>4 participants reported topical pruritus 7 participants reported subcutaneous black and blue spot 5 participants felt a sharp prick when the needle went into their skin</td>
<td>46</td>
</tr>
<tr>
<td>Huang 2006</td>
<td>10 participants reported slight redness of skin where the acupuncture applied 24 hours after the treatment</td>
<td>105</td>
</tr>
<tr>
<td>Kim 2012</td>
<td>No adverse events were reported in both groups</td>
<td></td>
</tr>
<tr>
<td>Kwon 2012</td>
<td>Unknown: Adverse events were not mentioned in the report</td>
<td></td>
</tr>
<tr>
<td>Li 2007</td>
<td>3 participants reported mild abdominal pain and diarrhoea 4 participants reported sore throat 3 participants terminated the treatment due to adverse events</td>
<td>60</td>
</tr>
<tr>
<td>Lin 2013</td>
<td>No adverse events were reported in the intervention group</td>
<td>36</td>
</tr>
<tr>
<td>Liu 2006</td>
<td>7 participants had violaceous mark on application of the cupping, which faded away in 2 weeks</td>
<td>20</td>
</tr>
<tr>
<td>Liu 2008</td>
<td>2 participants had a violaceous mark on application of the cupping, which faded away in 2 weeks</td>
<td>26</td>
</tr>
<tr>
<td>Liu 2012</td>
<td>6 out of 94 participants in 2 groups reported redness, dry, and burning sensation after LED therapy; the feelings disappeared after externally using viaminate cream</td>
<td></td>
</tr>
<tr>
<td>Liu 2004</td>
<td>20 participants reported redness, pruritus, pain, and burning sensation of skin 4 participants reported stomach upset</td>
<td>80</td>
</tr>
<tr>
<td>Liu 2007</td>
<td>Unknown: Adverse events were not mentioned in the report</td>
<td></td>
</tr>
<tr>
<td>Mo 2011</td>
<td>No adverse events were reported in both groups</td>
<td></td>
</tr>
<tr>
<td>Ni 2008</td>
<td>Unknown: Adverse events were not mentioned in the report</td>
<td></td>
</tr>
<tr>
<td>Peng 2012</td>
<td>9 participants reported mild abdominal pain and increased stool frequency</td>
<td>52</td>
</tr>
<tr>
<td>Study ID</td>
<td>Intervention group</td>
<td>Control group</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Description of adverse events</td>
<td>Description of adverse events</td>
</tr>
<tr>
<td></td>
<td>Sample size</td>
<td>Sample size</td>
</tr>
<tr>
<td>Shi 2012</td>
<td>Unknown: Adverse events were not mentioned in the report</td>
<td>1 participant reported mild gastrointestinal reaction</td>
</tr>
<tr>
<td>Smith 2007</td>
<td>Unknown: Adverse events were not mentioned in the report</td>
<td></td>
</tr>
<tr>
<td>Song 2007</td>
<td>Unknown: Adverse events were not mentioned in the report</td>
<td></td>
</tr>
<tr>
<td>Tang 2011</td>
<td>Unknown: Adverse events were not mentioned in the report</td>
<td></td>
</tr>
<tr>
<td>Wang 2012</td>
<td>No adverse events were reported in the intervention group</td>
<td>5 participants reported redness, desquamation, and burning sensation of the skin</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>Wei 2012</td>
<td>1 participant reported mild diarrhoea</td>
<td>5 participants reported mild nausea and vomiting</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>2 participants reported mild dizziness</td>
</tr>
<tr>
<td>Wen 2012</td>
<td>No adverse events were reported in the intervention group</td>
<td>7 participants reported stomach upset</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>3 participants reported nausea</td>
</tr>
<tr>
<td></td>
<td>4 participants reported dizziness</td>
<td>4 participants reported dizziness</td>
</tr>
<tr>
<td></td>
<td>3 participants reported loss of appetite</td>
<td></td>
</tr>
<tr>
<td>Wu 2008</td>
<td>Combination group: 21 participants reported chills and fever; 9 participants reported red and swollen skin after injection</td>
<td>Western drug group: 15 participants reported chills and fever; 8 participants reported red and swollen skin after injection</td>
</tr>
<tr>
<td></td>
<td>86</td>
<td>87</td>
</tr>
<tr>
<td></td>
<td>Herbal medicine group: No adverse events were reported</td>
<td></td>
</tr>
<tr>
<td></td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>Wu 2008a</td>
<td>Unknown: Adverse events were not mentioned in the report</td>
<td></td>
</tr>
<tr>
<td>You 2012</td>
<td>23 participants had a violaceous mark on application of the cupping, which faded away in 2 weeks</td>
<td>25 participants reported desquamation and burning sensation of skin</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>Yu 2011</td>
<td>4 participants reported stomach upset</td>
<td>2 participants reported a little nausea</td>
</tr>
<tr>
<td></td>
<td>65</td>
<td>3 participants reported dizziness</td>
</tr>
<tr>
<td></td>
<td>2 participants reported dizziness</td>
<td></td>
</tr>
<tr>
<td>Yu 2008</td>
<td>No adverse events were reported in the intervention group</td>
<td>Some participants reported a little nausea and stomach upset</td>
</tr>
<tr>
<td></td>
<td>28</td>
<td>20</td>
</tr>
<tr>
<td>Zhang 2012</td>
<td>No adverse events were reported in intervention group</td>
<td>7 participants reported stomach upset</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>3 participants reported nausea</td>
</tr>
<tr>
<td></td>
<td>4 participants reported dizziness</td>
<td>4 participants reported dizziness</td>
</tr>
<tr>
<td></td>
<td>3 participants reported loss of appetite</td>
<td></td>
</tr>
<tr>
<td>Zhang 2010</td>
<td>14 participants had a violaceous mark on application of the cupping, which faded away in 2 weeks</td>
<td>21 participants reported pruritus, dry skin, and desquamation</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>Zhou 2009</td>
<td>No adverse events were reported in both groups</td>
<td></td>
</tr>
<tr>
<td>Zhu 2007</td>
<td>2 participants reported dry mouth, cheilitis, dry skin, and desquamation</td>
<td>35 participants reported dry mouth, cheilitis, dry skin, and desquamation</td>
</tr>
<tr>
<td></td>
<td>3 participants reported mild stomach upset</td>
<td>2 participants reported mild stomach upset</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>1 participant had raised alanine aminotransferase, which went back to normal level after they stopped taking drugs</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>3 participants had raised triglycerides, which went back to normal level after they stopped taking drugs</td>
</tr>
</tbody>
</table>

*Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.*
### SUMMARY OF FINDINGS FOR THE MAIN COMPARISON

**Low-glycaemic-load diet versus high-glycaemic-load diet for acne vulgaris**

**Patient or population:** people with acne vulgaris  
**Settings:** university hospital  
**Intervention:** low-glycaemic-load diet versus high-glycaemic-load diet

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustartive comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High-glycaemic-load diet</td>
<td>The mean primary outcome: change in non-inflammatory lesion count (medium-term data) in the control groups was −1.15</td>
<td>The mean primary outcome: change in non-inflammatory lesion count (medium-term data) in the intervention groups was 3.89 lower (10.07 lower to 2.29 higher)</td>
<td>75 (2 studies)</td>
<td>⊕⊕○○ low</td>
<td>Only results from a meta-analysis with 2 poor-quality trials contributed to the assessment of quality of the evidence for this comparison, which showed a low level of evidence. No conclusion could be drawn for safety outcomes of this intervention</td>
</tr>
</tbody>
</table>

*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval.

**GRADE Working Group grades of evidence**

- **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.
- **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- **Very low quality:** We are very uncertain about the estimate.

1 downgraded by one point due to serious study limitations: There were potential risk of performance and attrition bias. (Blinding of participants and personnel was not applied; missing data in one of the trials were treated inappropriately).  
2 downgraded by one point due to inconsistency results between trials: Result from each individual trial showed different estimate effect of interventions, and there was potential statistical heterogeneity between trials ($I^2$ statistic >50%).
**ADDITIONAL SUMMARY OF FINDINGS [Explanation]**

**Herbal medicine versus antibiotics for acne vulgaris**

**Patient or population:** people with acne vulgaris  
**Settings:** outpatient dermatology department of Chinese Hospital  
**Intervention:** herbal medicine versus antibiotics

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antibiotics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary outcome: number of participants with remission (ITT-best case, short-term data) - Ziyin-Qinggan-Xiaocuo Granule versus minocycline (at 4 week) Follow-up: mean 4 weeks</td>
<td>79 per 1000</td>
<td>222 per 1000 (69 to 713)</td>
<td>RR 2.82 (0.88 to 9.06)</td>
<td>206 (2 studies)</td>
<td>⬤⬤⬤⬤ low¹</td>
</tr>
<tr>
<td><strong>Herbal medicine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary outcome: number of participants with remission (ITT-worst case, short-term data) - Ziyin-Qinggan-Xiaocuo Granule versus minocycline (at 4 week) Follow-up: mean 4 weeks</td>
<td>213 per 1000</td>
<td>105 per 1000 (19 to 540)</td>
<td>RR 0.49 (0.09 to 2.53)</td>
<td>206 (2 studies)</td>
<td>⬤⬤⬤⬤ low¹</td>
</tr>
</tbody>
</table>

*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  
GRADE Working Group grades of evidence  
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  
Very low quality: We are very uncertain about the estimate.  

¹downgraded by two points due to very serious study limitations: There were high risk of performance, detection, and reporting bias. (Blinding of participants, personnel, and outcome assessors were not applied; there was a difference between the trial protocol and final report).
CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Studies</th>
<th>Methods</th>
<th>Participants</th>
<th>Diagnostic criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen 2009</td>
<td>Randomised controlled trial</td>
<td>There were 90 participants in the study, with 30 participants in each group</td>
<td>- Guiding principle of clinical research on new drug of traditional Chinese medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Guiding principle of new drug of traditional Chinese medicine in treating acne vulgaris</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Inclusion criteria:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- met the diagnostic criteria for acne</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- received any internally used anti-acne medicine within 30 days or externally used medicine within 7 days before enrolment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Exclusion criteria:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- pregnant or lactating</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- had occupational or pharmaceutical acne</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- had other severe original disease or mental disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- would be exposed to sun or ultraviolet radiation for a long time during treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- did not meet inclusion criteria or comply with treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- with incomplete data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:</td>
<td>Average age (years): I = 22.93 (6.03); C-A = 21.37 (5.12); C-B = 21.83 (6.07)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Duration of disease (years): I = 4.31 (3.24); C-A = 2.98 (2.40); C-B = 2.60 (1.92)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Interventions</strong></td>
<td>Intervention:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1. Chinese herbal medicine according to syndromes, orally taken;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2. blood-letting plus cupping by a 0.65 mm * 3.5 mm blood collection needle for bleeding of 3 cc, then cupping for 10 min; 3. acupuncture was done during retaining cupping according to syndromes by a 0.35mm* 40 mm filiform needle, manipulated with neutral supplementation and drainage method, twice per week for 4 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Control A: blood-letting - dose and method were the same as for the treatment group</td>
<td>Control B: Chinese herbal medicine according to syndromes - 1 decoction daily for 4 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Outcomes</strong></td>
<td>- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Adverse events</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Notes</strong></td>
<td>*&quot;remission&quot; was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or &gt; 95% faded), and only mild pigmentation and scars remained</td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “...using random number table to gain the random number” Comment: The study reported enough detailed information to indicate that random sequence generation was appropriate</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: “...using sequentially numbered, opaque, sealed envelope...” Comment: The study reported enough detailed information to indicate that allocation concealment was appropriate</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>The study did not outline any blinding details. However, because participants in the intervention group were given a TCM decoction plus cupping and blood-letting, while participants in control A group were given only cupping and blood-letting, and the control B group were only given TCM decoction, it seems likely that there was no blinding of participants and personnel</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of 'low' or 'high' risk of bias</td>
</tr>
</tbody>
</table>
Incomplete outcome data (attrition bias) | High risk
---|---
The study randomised 90 participants, which were all included in the analysis: “During the follow-up of 3 months after treatment, there was no recurrence reported among the seven remission cases in treatment group, while for remission cases in control A and B, two out of the three remission cases recurred in both groups.” It seems likely that there were no incomplete outcome data in this study. However, as the exclusion criteria noted “…participants with incomplete data will be excluded” and follow-up only focused on the remissions, it is probable that the study had incomplete outcome data

Selective reporting (reporting bias) | Unclear risk
---|---
Since we could not find the protocol for this trial, it was difficult to judge whether the study reported all of the primary outcomes in the article

Other bias | Unclear risk
---|---
No funding issue was apparent
No sample size calculation was provided

Chen 2012

Methods
Randomised controlled trial

Participants
There were 70 participants in the study, with 35 participants in each group

Diagnostic criteria:
- Guiding principle of clinical research on new drugs of clinical Chinese Medicine
- Diagnostic and effectiveness assessment criteria of disease and syndrome of Chinese medicine

Inclusion criteria:
- met the diagnostic criteria for acne
- met the Chinese Medicine’s criteria for lung-stomach heat-type acne and aged 18 to 35 years old
- did not receive any anti-acne treatment (including externally used) in the last month before enrolment

Exclusion criteria:
- allergic to the experimental drug
- pregnant or lactating
- had pharmaceutical acne
- had other severe original disease
- had cyst type acne

Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:
Average age (years): I = 23.54 (4.64); C = 23.34 (4.37)
Sex ratio, male/female: I = 14/21; C = 13/22
Duration of disease (years): I = 4.48 (2.58), C = 4.31 (2.47)

Interventions

**Intervention:** Xiao Cuo decoction (hospital preparation by the First Affiliated Hospital of Hunan University of Chinese Medicine) taken orally - 40 ml per time, 3 times daily for 4 weeks - plus 0.1% adapalene gel externally used on lesion area per night

**Control:** viaminate capsules (Wei An Zhi capsules, Chong Qing Hua Bong pharmaceutical limited by share Ltd.) - 25 mg, 3 times daily - plus 0.1% adapalene gel externally used on lesion area once per night

Outcomes
- Skin lesions integral (according to “severity classification and effectiveness evaluation standard for acne vulgaris”)
- Symptom scores (according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”)
- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
- Blood routine examination
- Routine urinalysis
- Routine inspection
- Liver function test (for alanine transaminase)
- Kidney function test (for blood urea nitrogen and creatinine)
- Adverse events
- Incidence of adverse events

Notes
*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained
## Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to intervention and control groups, with 35 patients [in] each group...the random numbers were generated by random number table...” Comment: Even though the study provided no more detailed information to describe how randomisation was assigned, it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>The study did not outline any blinding details; however, as the intervention and control medicines were not similar in appearance and taste, it seems unlikely that blinding of participants and personnel was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>70 participants were randomised, and all were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, due to the exclusion criteria, participants who dropped out during the treatment were excluded, so there was insufficient information about this item</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>In the methods section, the study authors mentioned that the blood test, liver/kidney function test would be measured, but these were not reported in the results section. However, this information may not have influenced the final analysis since they were not primary outcomes. As we could not find the protocol for this trial, it was hard to judge whether they reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent No sample size calculation was provided</td>
</tr>
</tbody>
</table>

### Enshaieh 2007

#### Methods

**Randomised controlled trial**

**Participants**

- There were 60 participants in the study, with 30 participants in each group
  - **Diagnostic criteria:**
    - Acne diagnosis and management, USA
  - **Inclusion criteria:**
    - had mild to moderate facial acne vulgaris
    - signed informed consent
  - **Exclusion criteria:** unclear
  - **Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:**
    - Average age (years): I = 19.3 (3.1); C = unclear
    - Sex ratio, male/female: I = 7/23; C = 6/24
    - Duration of disease (years): unclear

**Interventions**

- **Intervention:** applied 5% tea tree oil gel (provided by Cinere Company, Iran) over the affected area for 20 mins and then washed it off with tap water twice daily for 45 days
- **Control:** vehicle gel (Cinere Company, Iran) composed of the carbomer that had no anti-acne activities per se, which was the same colour, texture, package size, but different label than the intervention drug, applied twice daily over the affected area for 20 min, then washed off with tap water

**Outcomes**

- Measured every 15-day period
  - **Primary outcome:**
    - ASI = papules + (2 * pustules) + (comedones/4)
  - **TLC = papules + pustules + comedones + nodules**
  - **Secondary outcome:**
    - Change in mean number of comedones, papules, and pustules

**Notes**

- Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation  | Low risk           | Quote: “Patients were randomly assigned to intervention and control groups… the random numbers were generated by random allocation software…”  
Comment: Even though no more detailed information was provided to describe how randomisation was assigned, it was probably generated appropriately |
| Allocation concealment      | Unclear risk       | There was insufficient information about the allocation concealment to permit judgement of 'low' or 'high' risk of bias |
| Blinding of participants and personnel | Low risk | Quote: “Both investigators and the patients were blinded to the type of treatment”  
Quote: “Tea tree oil and placebo gels were composed the same colour, texture, package size but with different label”  
Comment: It seems unlikely that blinding of participants and personnel was maintained |
| Blinding of outcome assessment | Low risk          | Quote: “A second investigator blinded to the type of treatment was responsible for counting the lesions before and after the treatment”  
Quote: “At the end of the study, the data were analysed by the third investigator using SPSS program and then the labels were revealed” |
| Incomplete outcome data     | Low risk           | All of the participants completed the study according to the authors’ report |
| Selective reporting         | Unclear risk       | No standard deviation was reported for all the outcome data in the results section |
| Other bias                  | Unclear risk       | Cinere company financial supported the study, which also provided the intervention and control drugs for the study  
No sample size calculation was provided |

### Feng 2005

#### Methods

Randomised controlled trial (2:1 randomised)

#### Participants

There were 86 participants in the study, with 57 participants in the intervention group and 29 participants in the control group

**Diagnostic criteria:**

- Chinese textbook: Clinical Dermatology

**Inclusion criteria:**

- met the diagnostic criteria
- did not use anti-acne drug in previous 2 weeks
- aged from 18 to 25 years old

**Exclusion criteria:**

- younger than 18 or over 25 years old
- allergic to tetracycline
- had ever used anti-acne drug in previous 2 weeks
- pregnant or lactating
- had severe heart, liver, or kidney disease
- refused to participate in the trial

**Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:**

- Average age (years): I = 24.67 (4.53); C = 24.52 (4.54)
- Sex ratio, male/female: I = 0/57; C = 0/29
- Duration of disease (years): I = 4.25 (3.63), C = 4.95 (3.12)

#### Interventions

**Intervention:** herbal decoction (Zi Yin Qing Gan Xiao Cuo decoction: particle-free granules from Jiangyin Tianjiang Pharmaceutical Company) - 250 ml administered orally once daily for 4 weeks - plus Sanhuang lotion externally applied on lesion area twice daily

**Control:** minocin capsule - 50 mg twice daily (Jiangsu Suzhou Lida Pharmaceutical Company) - plus Sanhuang lotion externally applied on lesion area twice daily
### Outcomes

Measured at weeks 0, 1, 2, and 4
- Type of lesion
- Number of lesions
- Skin lesion integral
- Symptom scores
- Laboratory test (for serum testosterone and estradiol level)

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to intervention and control groups by random number table...” Comment: No more detailed information was provided to describe how randomisation was assigned; it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of 'low' or 'high' risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Authors reported the study as “single blind” without details; however, as the intervention and control medicines were not similar in appearance and taste, it seems likely that blinding of participants and personnel was not maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>High risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of 'low' or 'high' risk of bias; however, authors reported the study as “single blind” with regard to participants. Therefore, the outcome assessors may not be blinded</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>86 participants were recruited and analysed according to the report; however, there was insufficient information about whether all participants completed the study to permit judgement of 'low' or 'high' risk of bias</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>Skin lesion integral was reported as a primary outcome, but was not reported after the treatment finished</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent</td>
</tr>
</tbody>
</table>

Han 2010

### Methods

Randomised controlled trial

Participants
There were 100 participants in the study, with 50 participants in each group

**Diagnostic criteria:**
- Chinese text book: Clinical Dermatology

**Inclusion criteria:**
- met the diagnostic criteria
- had mild to moderate acne
- had not used an anti-acne drug in the previous 2 weeks
- aged from 14 to 40 years old

**Exclusion criteria:**
- had severe acne
- younger than 14 or older than 40 years old
- had taken an anti-acne drug in the previous 2 weeks
- pregnant or lactating
- have severe damage of liver, heart, or kidney

_Cochrane Database Syst Rev._ Author manuscript; available in PMC 2016 January 19.
• refused to participate in the trial

Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:
Average age (years): I = 25.83 (5.25); C = 24.68 (4.36)
Sex ratio, male/female: I = 18/28; C = 14/33
Duration of disease (years): I = 2.35 (0.86), C = 2.15 (0.82)

Interventions

Intervention: acupuncture on abdomen point (CV13, CV12, CV4, CV6, K13, R6, E24) for 30 minutes, once every 2 days for 8 weeks
Control: isotretinoin soft capsules (Shanghai Donghai Pharmaceutical Company) - 10 mg twice daily for a month, then once daily for the second month

Outcomes

Outcomes measured at weeks 0, 4, and 8, and 1 month after treatment
• Skin lesion integral: assessed according to number, location, and colour of lesion, and pain
• Symptom improvement: assessed according to the “Guiding principle of clinical research on new drug of Traditional Chinese Medicine”

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk | Quote: “Patients were randomly assigned to intervention and control groups by random number table…”
Comment: No more detailed information was provided to describe how randomisation was assigned; it was probably generated appropriately |
| Allocation concealment (selection bias) | Unclear risk | There was insufficient information about the allocation concealment to permit judgement of 'low' or 'high' risk of bias |
| Blinding of participants and personnel (performance bias) All outcomes | High risk | No blinding details were outlined; however, the intervention and control medicines were totally different therapies, so it seems unlikely that blinding was maintained |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | There was insufficient information about the blinding method of outcome assessors to permit judgement of 'low' or 'high' risk of bias |
| Incomplete outcome data (attrition bias) All outcomes | High risk | 100 participants were randomised into 2 groups: 4 in the intervention group and 3 in the control group dropped out of the study due to personal reasons. These 7 participants’ data were not included in the statistical analysis |
| Selective reporting (reporting bias) | Unclear risk | We could not find any protocol information to assist us with judgement |
| Other bias | Unclear risk | No funding issue was apparent No sample size calculation was provided |

Han 2013

Methods

Randomised controlled trial

Participants

There were 12 participants in the study, with 6 participants in each group

Diagnostic criteria: not reported

Inclusion criteria:
• had mild to moderate acne, as graded by the Korean Acne Grading System (KAGS)
• had signed a certification that they had no allergy or sensitivity to bees or bee sting
• aged from 12 to 35 years old
• agreed to sign a written informed consent and complete a brief demographic medical history form

Exclusion criteria:
• with dermatological conditions that could interfere with treatment or evaluation

Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:
Average age (years): not reported
Sex ratio, male/female: not reported
Duration of disease (years): not reported

### Interventions

**Intervention:** cosmetics containing PBV twice daily in the morning and evening for 2 weeks. Cosmetics were applied topically on the whole face with an amount of 4 mL per day. The concentration of PBV was 0.06 mg/mL in PBV-containing cosmetics

**Control:** cosmetics without PBV were applied twice daily in the morning and evening for 2 weeks. The usage method was the same as in the intervention group

### Outcomes

Outcomes measured at weeks 0 and 2
- KAGS scores based on numbers by lesion counts for inflammatory and non-inflammatory
- The average decrement of skin micro-organism (ATP) level

### Notes

The severity of acne was assessed using KAGS, proposed by the consensus conference in 2004. The severity score (grades 1 to 6) was as follows: grade 1, papules ≤10; grade 2, papules 11 to 30; grade 3, papules ≥31, nodules ≤10; grade 4, nodules 11 to 20, ± mild ongoing scars; grade 5, nodules 21 to 30, ± moderate ongoing scars; grade 6, nodules ≥30, ± severe ongoing scars and ± sinus tract

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ Judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk | Quoted “Korean female and male subjects…participated in a double-blind, placebo-controlled, split face study with left-right randomisation that was carried out June 2012”
Comment: No more detailed information was provided to describe how randomisation was assigned; it was probably generated appropriately |
| Allocation concealment (selection bias) | Unclear risk | There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias |
| Blinding of participants and personnel (performance bias) All outcomes | Low risk | Quoted “Korean female and male subjects…participated in a double-blind, placebo-controlled, split face study with left-right randomisation that was carried out June 2012”
Comment: Cosmetics with or without PBV were applied in the intervention or control group; usage method of cosmetics and treatment frequency was exactly the same in both groups. Though details of blinding were not mentioned, it seems that blinding of participants and personnel could be conducted successfully |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | 12 participants were included in the trial; no-one dropped out of the study during treatment. The number of participants in the per-protocol set and intention-to-treatment analysis was 6 per group |
| Selective reporting (reporting bias) | Unclear risk | We could not find any protocol information to assist us with judgement |
| Other bias | Unclear risk | No funding issue was apparent
No baseline information was provided to determine comparability
No sample size calculation was provided |

### Methods

Multicentre randomised controlled trial

### Participants

There were 210 participants in the study, with 105 participants in each group

**Diagnostic criteria:**
- Guiding principle of clinical research on new drug of Traditional Chinese Medicine
- Chinese textbook: Clinical Dermatology

**Inclusion criteria:**
- met the diagnostic criteria
- aged from 16 to 45 years old
- had not used anti-acne drugs or other relative therapies recently
- agreed to participate in the trial
### Exclusion criteria:
- had allergic constitution or scar diathesis
- scared of needling
- had severe mental disease
- had diabetes or haemophilia
- pregnant

### Participants' baseline data presented as mean (SD) for intervention (I) and control (C) groups:

<table>
<thead>
<tr>
<th>Average age (years)</th>
<th>I = 23.52 (5.38); C = 24.94 (6.26)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex ratio, male/female</td>
<td>I = 73/32; C = 62/43</td>
</tr>
<tr>
<td>Duration of disease (months)</td>
<td>I = 49.93 (43.58); C = 51.27 (54.12)</td>
</tr>
</tbody>
</table>

### Interventions

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Intervention: acupuncture on lesion points BL 13 and BL 20; the needle was inserted and kept for 5 seconds before withdrawal - done 5 times for each point, once every 4 days for 3 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control: clindamycin phosphate gel (Suzhou Pharmaceutical Company) - 10 g externally applied on lesion area twice daily - plus 0.5 g azithromycin capsule (Shandong Lukang Medical Company) once daily for 3 weeks</td>
</tr>
</tbody>
</table>

### Outcomes

- Skin lesion integral: assessed according to the “Guiding principle of clinical research on new drug of Traditional Chinese Medicine”
- Symptom improvement: assessed according to the “Guiding principle of clinical research on new drug of Traditional Chinese Medicine”

### Notes

- Risk of bias
  - **Random sequence generation (selection bias)**: Low risk
    - Quote: “…random number was generated by SPSS software…”
    - Comment: It was probably generated appropriately
  - **Allocation concealment (selection bias)**: Low risk
    - Quote: “…random number was kept in envelope, then sent to each clinical centre…”
    - Comment: It was probably concealed appropriately
  - **Blinding of participants and personnel (performance bias)**: High risk
    - No blinding details were outlined; however, the intervention and control medicines were totally different therapies, so it seems unlikely that blinding was maintained
  - **Blinding of outcome assessment (detection bias)**: Unclear risk
    - There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias
  - **Incomplete outcome data (attrition bias)**: Low risk
    - 4 participants dropped out (2 cases in each group); reasons were outlined; intention-to-treat analysis was also used for a primary outcome
  - **Selective reporting (reporting bias)**: Unclear risk
    - We could not find any protocol information to assist us with judgement
  - **Other bias**: Unclear risk
    - No funding issue was apparent

### Kim 2012

**Methods**

- Randomised controlled trial

**Participants**

- There were 44 participants in the study, with 11 participants in each group

**Diagnostic criteria:**

- Korean Acne Grading System (grade 2 to 4)

**Inclusion criteria:**

- aged from 13 to 35 years old
- had more than 10 papules and less than 20 nodules on the face
had acne for more than 3 months

**Exclusion criteria:**

- had received western medical treatment or oriental medicine for acne within 1 month before entry to the trial
- did not meet the normal range for blood test after screening
- had papules or nodules mainly located on the chest or back
- had keloid acne, corticosteroid acne, or other infectious skin disease
- had an internal disease that required treatment without delay
- unable to comply with the study guideline

**Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:**

<table>
<thead>
<tr>
<th></th>
<th>Intervention (I)</th>
<th>Control (C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average age (years)</td>
<td>21.5 (3.6)</td>
<td>23.3 (4.1)</td>
</tr>
<tr>
<td>Sex ratio, male/female</td>
<td>22/0</td>
<td>22/0</td>
</tr>
<tr>
<td>Duration of disease (years)</td>
<td>5.8 (3.4)</td>
<td>6.6 (4.7)</td>
</tr>
</tbody>
</table>

**Interventions**

**Intervention 1:** Keigai-rengyo-to extract - 3 times daily after meals for 4 weeks

**Intervention 2:** acupuncture on ST2, ST6, LI20, LI11, PC6, HT8, SP3, SP6, SP10, and LR3 for 15 minutes each time; disposable stainless steel needles were inserted at a vertical or oblique angle to a depth of 1 to 5 minutes at each point, twice per week for 4 weeks

**Intervention 3:** Keigai-rengyo-to extract - 3 times daily after meals, plus acupuncture (same points’ selection as intervention 2) twice per week for 4 weeks

**Control:** waiting list for 4 weeks

**Outcomes**

**Primary outcomes:**

- Mean percentage change of inflammatory lesions from baseline to the end of the trial

**Secondary outcomes:**

- Mean percentage change of non-inflammatory lesions from baseline to the end of the trial
- Count of inflammatory and non-inflammatory lesions
- Quality of life scale (Skindex-29)
- Investigator’s Global Assessment (IGA)

**Notes**

- **Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to one of four groups. Random number were generated by a computerized random number generator through the block-randomisation method of a software program…” Comment: It was probably generated appropriately</td>
</tr>
<tr>
<td>(selection bias)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allocation concealment</td>
<td>Low risk</td>
<td>Quote: “…two separate databases were created: a ‘patients’ database, which lists basic information, including patient name, contact details, and so on, and a ‘randomisation’ database, which holds data on which patients have been registered on trial along with their allocations. The ‘patients’ database was accessible to any researcher, whereas the ‘randomisation’ database was password protected, so that it was accessible only by the principal investigator and a nominated statistician…” Comment: The study probably concealed allocation appropriately</td>
</tr>
<tr>
<td>(selection bias)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of participants and</td>
<td>High risk</td>
<td>Quote: “The assessor, who was the acupuncture practitioner and KRTE supplier, and who was blinded to the allocation results until the end of study, performed the outcome assessment” Comment: It seems likely that personnel were blinded, but participants were not blinded to group allocation</td>
</tr>
<tr>
<td>personnel (performance bias)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment</td>
<td>Low risk</td>
<td>Quote: “The assessor, who was the acupuncture practitioner and KRTE supplier, and who was blinded to the allocation results until the end of study, performed the outcome assessment” Comment: The study outcome assessor was blind to group allocation</td>
</tr>
<tr>
<td>(detection bias)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data</td>
<td>Unclear risk</td>
<td>10 participants dropped out during the study, with a total dropout rate of 22.7%. The number of participants that dropped out was different among groups (3:1:2:4), but the reason for dropout was not clarified with detailed information Quote: “The two most common reasons for discontinuation were ‘lost to follow-up’ or ‘personal reason’”</td>
</tr>
<tr>
<td>(attrition bias)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Comment: Though an intention-to-treat analysis was used with LOCF methods, they may have had unclear risk of attrition bias that influenced the overall outcome assessment

<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>High risk</th>
<th>The study provided a protocol, but primary and secondary outcomes were incompletely reported for all groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No sample size calculation was provided</td>
</tr>
</tbody>
</table>

Kwon 2012

Methods

Randomised controlled trial

Participants

There were 17 participants in the intervention group and 15 participants in the control group

Diagnostic criteria: unclear

Inclusion criteria:
- had mild to moderate acne

Exclusion criteria: unclear

Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:
- Average age (years): I = 23.5 (3.2); C = 23.7 (2.6)
- Sex ratio, male/female: I = 13/4; C = 11/4
- Duration of disease (years): unclear

Interventions

Intervention: low-glycaemic-load diet (LGLD) with 25% energy from protein, 45% low-glycaemic-index carbohydrates, and 30% energy from fat - once daily for 10 weeks

Control: carbohydrate-rich foods - once daily for 10 weeks

Outcomes

Primary outcome:
- Changes in the number of inflammatory lesions
- Changes in the number of non-inflammatory lesions
- Histopathological changes in the acne lesions

Secondary outcome:
- Participant’s subjective assessment

Notes

- Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “A blocked random allocation sequence was created by computer-generated random number…” Comment: Random sequence generation was generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: “…allocation to specific groups was performed by a research nurse…” Comment: Allocation was concealed appropriately</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>No blinding details were outlined; however, intervention and control were not similar in colour and taste. It seems likely that participants and personnel were not blind to group allocation</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>All of the participants completed the study according to the authors’ report</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>No standard deviation was reported for all of the outcome data. Also, the mean difference of primary outcome for control group was not provided</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent No sample size calculation was provided</td>
</tr>
</tbody>
</table>

Li 2007

Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.
Methods

Randomised controlled trial

Participants

There were 120 participants, with 60 participants in each group

Diagnostic criteria:

• Chinese textbook: Clinical Dermatology

Inclusion criteria:

• met the diagnostic criteria
• did not receive anti-acne drugs in previous 2 weeks
• women aged from 18 to 50 years old
• had a moderate grade III acne according to “3 degree 4 categories classic”

Exclusion criteria:

• younger than 18 or older than 50 years old
• allergic to alcohol
• had received similar treatment
• had severe damage to liver, kidney, or heart, which may influence the metabolism of the drug
• pregnant or lactating

Participants' baseline data presented as mean (SD) for intervention (I) and control (C) groups:

Average age (years): I = 25.45 (4.45); C = 26.67 (7.06)
Sex ratio, male/female: I = 0/60; C = 0/60
Duration of disease (months): I = 26.40 (18.59), C = 25.60 (18.01)

Interventions

Intervention: herbal medicine Ziyin-Qinggan-Xiaocuo granule (Jiangyin Tianjiang Pharmaceutical Company) - 200 ml given orally once daily for 4 weeks - plus Cuoling Tincture externally used twice daily on the lesion area

Control: 50 mg minocycline capsules taken twice daily (Jiangsu Suzhou Lida Pharmaceutical Company), plus Cuoling Tincture externally used twice daily

Outcomes

Outcomes were measured at weeks 0, 1, 2, 3, and 4

• Number, type, and location of the skin lesion
• Other clinical symptoms
• Adverse events

Notes

- 

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to intervention and control groups by random number table...” Comment: Even though no more detail information was provided to describe how randomisation was assigned, it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of 'low' or 'high' risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>No blinding details were outlined; however, the intervention and control medicines were totally different therapies, so it seems unlikely that blinding was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of 'low' or 'high' risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>A total of 20 participants were excluded from the final analysis; 9 of them were excluded because of the potential adverse effects of the drug, and 11 of them were lost to follow up. No appropriate statistical methods was used to handle the incomplete outcome data</td>
</tr>
</tbody>
</table>

Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.
Selective reporting (reporting bias) | High risk | Primary outcomes including the number, location, and type of the lesion were not reported in the results section
---|---|---
Other bias | Unclear risk | No funding issue was apparent
No sample size calculation was provided

Lin 2013

Methods | Randomised controlled trial
---|---
Participants | There were 72 participants in the study, with 36 participants in each group
Diagnostic criteria: • Chinese textbook “Diagnosis and differential diagnosis of skin disease”
Inclusion criteria: • met the diagnostic criteria for acne who came between September 2010 and October 2012 • aged 18 to 35 years old • did not receive any systematic anti-acne treatment • agreed to attend the trial and sign the informed consent form
Exclusion criteria: • pregnant or lactation • had other severe original disease or mental disease • risk of exposure to the sun or ultraviolet rays
Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:
Average age (years): I = 18 to 35; C = 18 to 28
Sex ratio, male/female: I = 10/26; C = 8/28
Duration of disease (years): I = 0.25 to 3, C = 0.17 to 3
Interventions
Intervention: wet cupping plus herbal mask; pricking with triangle-edged needle on 2 points selected from GV14, BL13, BL15, BL18, BL20, BL21, and BL25; then cups were applied on the points, retained for 5 min - once every 2 days, 4 times as a treatment session for a month; herbal mask for 30 minutes once every 2 days - 15 times as a session for a month
Control group: 10 mg viaminate capsule (brand name: Taiersi, Shanghai Yan’an Pharmaceutical company) taken 3 times daily for a month
Outcomes • Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective) • Adverse events
Notes *"remission" was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ Judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to intervention and control groups by random number table…” Comment: Even though no more detailed information was provided to describe how randomisation was assigned, it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>No blinding details were outlined; however, the intervention and control medicines were totally different therapies, so it seems unlikely that blinding was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
</tbody>
</table>
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to two groups by random number table…” Comment: Even though no more detailed information was provided, it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the sequence generation process to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>No blinding details were outlined; however, the intervention and control medicines were totally different therapies, so it seems unlikely that blinding was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the sequence generation process to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>In total, 160 participants were included, but 4 in the intervention group and 6 in the control group were excluded from the final analysis. 7 of them were excluded due to the potential adverse effects of the drug, and 3 of them were lost follow up. No appropriate statistical methods were used to handle the incomplete outcome data</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent No sample size calculation was provided</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liu 2006</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
</tr>
<tr>
<td>Participants</td>
</tr>
<tr>
<td>Diagnostic criteria:</td>
</tr>
<tr>
<td>• Chinese textbook: Clinical dermatology</td>
</tr>
<tr>
<td>Inclusion criteria:</td>
</tr>
<tr>
<td>• met the western medicine diagnostic criteria for acne</td>
</tr>
<tr>
<td>• aged 14 to 35 years old</td>
</tr>
<tr>
<td>• did not receive any anti-acne drug in the last month before enrolment, and did not apply external anti-acne treatment in the previous 7 days</td>
</tr>
<tr>
<td>• agreed to attend the trial and sign the informed consent form</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
</tr>
<tr>
<td>• pregnant or lactating</td>
</tr>
<tr>
<td>• acne was caused by a chemical substance or drug</td>
</tr>
<tr>
<td>• had other severe original disease or mental disease</td>
</tr>
<tr>
<td>• risk of exposure to the sun or ultraviolet rays</td>
</tr>
<tr>
<td>• did not co-operate during the treatment</td>
</tr>
<tr>
<td>Participants' baseline data presented as mean (SD) for intervention (I) and control (C) groups:</td>
</tr>
<tr>
<td>Average age (years): I = 23.70 (3.11); C = 23.70 (3.83)</td>
</tr>
<tr>
<td>Sex ratio, male/female: I = 6/14; C = 5/15</td>
</tr>
<tr>
<td>Duration of disease (years): I = 4.66 (3.78), C = 3.61 (3.11)</td>
</tr>
<tr>
<td>Interventions</td>
</tr>
<tr>
<td>Intervention group: acupuncture treatment once every other day, 15 times for 1 course, 2 courses in total; prickling and cupping treatment, once every 3 days, 8 times for 1 course, 2 courses in total</td>
</tr>
<tr>
<td>Control group: “Mei man du su” capsule (minocycline), oral administration, 1 capsule once, twice per day, 1 month for 1 course, 2 courses in total</td>
</tr>
<tr>
<td>Outcomes</td>
</tr>
<tr>
<td>• Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)</td>
</tr>
<tr>
<td>• Score of skin lesion</td>
</tr>
<tr>
<td>• Value of serum IL 6</td>
</tr>
<tr>
<td>Notes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bias</td>
</tr>
<tr>
<td>Random sequence generation (selection bias)</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
</tr>
</tbody>
</table>
### Risk of bias

<table>
<thead>
<tr>
<th>Blinding of participants and personnel (performance bias)</th>
<th>High risk</th>
<th>No blinding details were outlined; however, the intervention and control medicines were totally different therapies, so it seems unlikely that blinding was maintained</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of “low” or “high” risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Because there was no information about the dropout and follow-up rate, it was hard to judge whether we should apply a ‘low’ or ‘high’ risk of bias to this domain</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent No sample size calculation was provided</td>
</tr>
</tbody>
</table>

**Methods**

**Participants**

- There were 105 participants in the study, with 35 participants in each group
- **Diagnostic criteria:**
  - Western diagnostic criteria: Chinese textbook: Clinical Dermatology
  - Chinese diagnostic criteria: Guiding principle of clinical research on new drugs of clinical Chinese Medicine for acne vulgaris
  - Classification criteria for acne: Pillsbury classification
- **Inclusion criteria:**
  - met the diagnostic criteria for acne
  - aged 12 to 36 years old
  - complete the trial and be willing to attend
- **Exclusion criteria:**
  - did not meet the diagnostic criteria or inclusion criteria
  - acne was caused by chemical substance or drug
  - had other severe original disease or mental disease
  - pregnant or lactating
  - did not co-operate during the treatment

**Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:**

- Average age (years): I = 19.16, C1 = 19/16, C2 = 19/16
- Sex ratio, male/female: I = 20/15; C1 = 19/16; C2 = 19/16
- Duration of disease (months): 20.23

**Interventions**

- **Western medicine group:** drug for exterior use: viaminate cream (vitamin A acid cream, Chongqing Huabang Pharmaceutical Co. Ltd), used once per day before sleeping for 8 weeks in total
- **Chinese medicine group:** Qingre Chushi Jiedu decoction, 100 ml per time, taken once every morning and night for 8 weeks in total
- **Acupuncture group:** acupuncture, once per day, 5 times from Monday to Friday; pricking and cupping, twice per week for 8 weeks in total

**Outcomes**

- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
- Score of GAGS
- Scores of QoL (measured with 3 components: society function, self-feeling, and emotional function)

**Notes**

*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained
Cao et al.

**Bias** | **Authors’ judgement** | **Support for judgement**
--- | --- | ---
Random sequence generation (selection bias) | Low risk | A random number table generated the random sequence.

Allocation concealment (selection bias) | Unclear risk | There was insufficient information about the sequence generation process to permit judgement of ‘low’ or ‘high’ risk of bias.

Blinding of participants and personnel (performance bias) | High risk | No blinding details were outlined; however, the intervention and control medicine were totally different therapies, so it seems unlikely that blinding was maintained.

Blinding of outcome assessment (detection bias) | Unclear risk | There was insufficient information about the sequence generation process to permit judgement of ‘low’ or ‘high’ risk of bias.

Incomplete outcome data (attrition bias) | Low risk | 105 participants were randomly divided into 3 groups, and all were included in the analysis. Quote: “All participants completed the study.”

Selective reporting (reporting bias) | Unclear risk | Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article.

Other bias | Unclear risk | No funding issue was apparent.

No sample size calculation was provided.

Liu 2008

**Methods** | Randomised controlled trial

**Participants** | There were 52 participants in the study, with 26 participants in each group.

**Diagnosis criteria:**
- Chinese textbook: Clinical Dermatology

**Inclusion criteria:**
- met the diagnostic criteria for acne
- aged 14 to 35 years old
- did not receive any anti-acne drug in the previous month before enrolment
- did not apply external anti-acne treatment in the previous 7 days
- agreed to attend the trial and sign the informed consent form

**Exclusion criteria:**
- pregnant or lactating
- acne was caused by chemical substance or drug
- had other severe original disease or mental disease
- risk of exposure to the sun or ultraviolet rays
- did not co-operate during the treatment

**Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:**
- Average age (years): I = 23.25 (1.25); C = 22.75 (1.96)
- Sex ratio, male/female: I = 8/18; C = 10/16
- Duration of disease (years): I = 2.79 (2.01); C = 2.57 (2.36)

**Interventions**
- **Intervention:** acupuncture plus pricking and cupping, twice per week, 4 weeks in total.
- **Control:** isotretinoin soft capsules, orally administered, 10mg per time, 3 times per day, 4 weeks in total.

**Outcomes**
- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
- Value of serum IL 6
- Adverse effects

---

*C* indicates the best outcome.
**remission** was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to two groups by random number table…” Comment: Even though no more detailed information was provided, it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the sequence generation process to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>No blinding details were outlined; however, the intervention and control medicine were totally different therapies, so it seems unlikely that blinding was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Because there was no information about the dropout and follow-up rate, it was hard to judge whether we should apply a ‘low’ or ‘high’ risk of bias to this domain</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent</td>
</tr>
</tbody>
</table>

### Liu 2012

Methods

Randomised controlled trial

Participants

There were 94 participants in the study, with 31, 31, or 32 participants in the intervention, control 1, and control 2 group, respectively.

Inclusion criteria: unclear

- met regular diagnostic criteria for acne
- classified as I, II, or III by Pillsbury criteria

Exclusion criteria:

- used antibiotic and tretinoin in last 4 weeks
- allergic dermatitis on the face
- pregnant or lactating
- classified as IV by Pillsbury criteria

Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:

- Average age (years): I = 22.3, C1 = 9.8, C2 = 21.3
- Sex ratio, male/female: I = 15/16, C1 = 17/14, C2 = 14/18

Interventions

3 groups were all treated with “Fu Fang Zhen Zhu An Chuang” tablets and lotion for acne vulgaris. 

**Intervention** traditional Chinese medical mask combined with blue and red LED phototherapy - 15 minutes for blue LED, 15 minutes for red LED, after that, using traditional Chinese medical mask twice per week, 8 times for 1 course

Control group 1 blue and red LED phototherapy

Control group 2 traditional Chinese medical mask twice per week 3 groups were all treated for 4 weeks

Outcomes

- Counting the numbers of acne through each participant’s photograph
- Total effective rate = (number of remission* participants + number of markedly effective participants)/total number of participants *100%
**Notes**

**“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained.**

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “94 patients were randomly divided into 3 groups by number”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the sequence generation process to permit judgement of “low” or “high” risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>No blinding details were outlined; however, the intervention and control medicines were totally different therapies, so it seems unlikely that blinding was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of “low” or “high” risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>1 participant in each group failed to follow-up</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No sample size calculation was provided</td>
</tr>
</tbody>
</table>

### Methods

**Mo 2011**

**Participants**

There were 80 participants in the study, with 40 participants in each group

**Diagnostic criteria:**
- Chinese diagnostic criteria: Guiding principle of clinical research on new drugs of clinical Chinese Medicine for acne vulgaris
- Classification criteria for acne: Pillsbury classification

**Inclusion criteria:**
- met the diagnostic criteria for acne
- aged 12 to 36 years old
- complete the trial and be willing to attend

**Exclusion criteria:**
- aged under 18 or over 35
- acne is caused by chemical substance or drug
- have other severe original disease or mental disease
- did not meet inclusion criteria

**Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:**
- Average age (years): I = 22.35 (5.55); C = 21.20 (5.48)
- Sex ratio, male/female: I = 12/28; C = 14/26
- Duration of disease (years): I = 2.50 (3.52); C = 2.60 (3.60)

**Interventions**

**Intervention group:** (Chinese medicine) modified Yin Qiao Liang Xue Tang, oral administration, once daily externally applied drug: Sheng Ji Zhen Hua San 2 g, Qing Ha San 5 g, Xiao Yan Xuan Shi Gao 7.5 g. 2 h per time, once daily

**Control group:** (western medicine) azithromycin, 0.5 g per time, oral administration

**Outcomes**

- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
Notes

*"remission" was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “80 patients were randomised into two groups”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: Even though no more detailed information was provided, it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>No blinding details were outlined; however, the intervention and control medicine were totally different therapies, so it seems unlikely that blinding was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>80 participants were randomised, and all were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, because there was no information about the dropout and follow-up rate, it was hard to judge whether there was ‘low’ or ‘high’ risk of bias for this domain</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No sample size calculation was provided</td>
</tr>
</tbody>
</table>

Methods

Randomised controlled trial

Participants

There were 46 participants in the study, with 24 participants in the intervention group and 22 participants in the control group.

Diagnostic criteria:

- Guiding principle of clinical research on new drugs of clinical Chinese Medicine

Inclusion criteria:

- people with acne
- diagnosed as 'Accumulation of Heat in Lung and Stomach'
- able to complete the trial and be willing to attend

Exclusion criteria:

- did not co-operate during the treatment
- did not receive any anti-acne drug in the previous 4 weeks before enrolment
- had other severe original disease or mental disease
- did not meet inclusion criteria

Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:

- Average age (years): I = 22.35 (5.55); C = 21.20 (5.48)
- Sex ratio, male/female: I = 12/28; C = 14/26
- Duration of disease (years): I = 2.50 (3.52); C = 2.60 (3.60)

Interventions

**Intervention:** acupuncture, 3 times per week, 3 weeks for a course; pricking and cupping, twice per week, 3 weeks for a course; massage, 3 times per week, 3 weeks for a course

**Control:** (western medicine) zinc gluconate, 20 ml per time, twice per day, 3 weeks for a course

Giving participants some life guides, such as keeping optimistic and avoiding fat, spicy, and sugary foods

Outcomes

- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
The relevance between duration of disease and efficacy in intervention group

The relevance between disease condition and efficacy in intervention group

Score of skin lesion

Scores of QoL (measured with 3 components: society function, self-feeling, and emotional function)

Notes

*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation</td>
<td>Low risk</td>
<td>Quote: “…using the method of block randomizations according to patients’ visiting sequence”</td>
</tr>
<tr>
<td>Allocation concealment</td>
<td>Unclear risk</td>
<td>There was no information to permit judgement of allocation concealment as ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel</td>
<td>High risk</td>
<td>No blinding details were outlined; however, the intervention and control medicine were totally different therapies, so it seems unlikely that blinding was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment</td>
<td>Unclear risk</td>
<td>There was no information to permit judgement of blinding method of outcome assessors as ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data</td>
<td>Low risk</td>
<td>46 participants were randomised, and all were included in the analysis. No participants dropped out or were lost to follow up in either group</td>
</tr>
<tr>
<td>Selective reporting</td>
<td>Unclear risk</td>
<td>Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent</td>
</tr>
</tbody>
</table>

Peng 2012

Methods

Randomised controlled trial

Participants

There were 99 participants in the study, with 52 participants in the intervention group and 47 participants in the control group

Diagnostic criteria:

- Chinese textbook: Clinical Dermatology

Inclusion criteria:

- acne was classified as mild or moderate by Pillsbury classification
- aged 14 to 46 years old
- did not partly receive any anti-acne drug in last 30 days before enrolment, and did not systematically apply external anti-acne treatment in last 10 days
- not pregnant or lactating
- not allergic to alcohol
- did not have occupational acne or acne medicamentosa
- did not have severe liver or kidney disease
- did not have hyperlipaemia or gastritis

Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:

Average age (years): I = 22.70 (4.30); C = 21.70 (3.60)

Sex ratio, male/female: I = 32/20; C = 28/19

Duration of disease (years): I = 2.62 (1.42), C = 2.33 (1.25)
### Interventions

**Intervention:** Da Huang Zhe Chong Pills (Beijing Tongrentang Limited by share Ltd.) 3 g 0.5 h before meal, taken with Dan Quan rice wine 10 ml (Guangxi Dan Quan wine industry limited by share Ltd.) twice daily for 8 weeks  
**Control:** isotretinoin soft capsule (trade name: Taersi, Shanghai Xin Yi Yan’an Pharmaceutical Limited by share Ltd.) 10 mg twice daily for 4 weeks, then 10 mg once daily for another 4 weeks

### Outcomes

- Symptom scores (according to “Guiding principle of clinical research on new drugs of traditional Chinese medicine”)
- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
- Adverse events

### Notes

*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly divided into two groups by random number table”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>No blinding details were outlined; however, the intervention and control medicine were totally different therapies, so it seems unlikely that blinding was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>99 participants were randomised, and all of these were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, because there was no information about the dropout and follow-up rate, it was hard to judge whether there was ‘low’ or ‘high’ risk of bias for this domain</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent</td>
</tr>
</tbody>
</table>

### Methods

**Shi 2012**

- Randomised controlled trial
- There were 167 participants in the study, with 96 participants in the intervention group and 71 participants in the control group
- **Diagnostic criteria:**
  - Western criteria: clinical pathway for acne vulgaris in 2010 edition by ministry of health
  - Chinese criteria: diagnostic and effective criteria for disease of TCM
- **Exclusion criteria:**
  - pregnant or lactating
  - acne was caused by chemical substance or drug
- **Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:**
  - Average age (years): I = 23.3 (3.12); C = 23 (2.43)
  - Sex ratio, male/female: I = 54/42; C = 40/31
- **Interventions**
  - **Intervention:** (Chinese medicine) modified Jia Wei Xiao Du Yin taken twice per day, in the morning and evening - 15 days for a course
  - **Control:** (western medicine) tretinoin cream (Di Wei Cream, Chongqing Huabang Pharmaceutical Co. Ltd) twice per day - 15 days for a course
### Outcomes

- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)

### Notes

*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly divided into two groups by random number table”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of “low” or “high” risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>No blinding details were outlined; however, the intervention and control medicines were totally different therapies, so it seems unlikely that blinding was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of “low” or “high” risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>167 participants were randomised, and all were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, because there was no information about the dropout and follow-up rate, it was hard to judge whether there was ‘low’ or ‘high’ risk of bias for this domain</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent</td>
</tr>
</tbody>
</table>

### Smith 2007

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised controlled trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>There were 54 participants in the study, with 27 participants in each group</td>
</tr>
<tr>
<td>Diagnostic criteria:</td>
<td>The Leeds Acne Grading Technique</td>
</tr>
<tr>
<td>Inclusion criteria:</td>
<td>male participants aged 15 to 25 years</td>
</tr>
<tr>
<td></td>
<td>with mild-moderate facial acne</td>
</tr>
<tr>
<td></td>
<td>had acne for more than 6 months and a severity grade of greater than 0.25 but less than 2.0</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
<td>taking medications known to affect acne or glucose metabolism</td>
</tr>
<tr>
<td></td>
<td>a washout period of 6 months was required for oral retinoids or 2 months for oral antibiotics or topical agents</td>
</tr>
<tr>
<td>Participants' baseline data presented as mean (SD) for intervention (I) and control (C) groups:</td>
<td>Average age (years): I = 18.2 (0.5); C = 18.5 (0.5)</td>
</tr>
<tr>
<td>Interventions</td>
<td>Intervention</td>
</tr>
<tr>
<td></td>
<td>Control</td>
</tr>
<tr>
<td></td>
<td>All participants were provided with a topical cleanser and were advised to use it in place of their normal wash, soap, or cleanser</td>
</tr>
<tr>
<td>Outcomes</td>
<td>The reduction in total lesion counts after 12 weeks</td>
</tr>
<tr>
<td></td>
<td>Inflammatory counts</td>
</tr>
</tbody>
</table>
Weight, BMI, body fat percentage, and waist circumference

- Insulin sensitivity and insulin resistance

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Randomization was carried out by computer-generated random numbers…”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: “…allocation to groups was performed by a third party”</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Quote: “Participants were informed that the study was comparing the carbohydrate to protein ratio in the diet and were not informed of the study’s hypothesis” Comment: It seems likely that the trial blinded participants. However, blinding of personnel may have been hard to do due to the difference between the intervention and control</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>Quote: “This study was designed as a parallel dietary intervention study with investigator-masked dermatology assessments”</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>Quote: “Seven participants did not complete the study (5 in control and 2 in LGL groups), and 4 were removed from data set (two were noncompliant; two began medications known to affect acne, an exclusion criterion)” Comment: The dropout rate was 15% and 25% in the intervention and control groups, respectively. Intention-to-treat analysis was not applied</td>
</tr>
<tr>
<td>Selective reporting (reporting bias) Low risk</td>
<td>We could retrieve the protocol, which reported all primary and secondary outcomes</td>
<td></td>
</tr>
<tr>
<td>Other bias Unclear risk</td>
<td>No funding issues were apparent  The study appeared to be free of other sources of bias</td>
<td></td>
</tr>
</tbody>
</table>

### Methods

#### Participants

There were 76 participants in the study, with 42 participants in the intervention group and 34 participants in the control group.

**Diagnostic criteria:**

- Diagnosed by the dermatological department of the hospital and classified by “classification and treatment choice of ance vulgaris”

**Inclusion criteria:** unclear

**Exclusion criteria:** unclear

**Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:**

- Sex ratio, male/female: I = 24/18; C = 19/15

#### Interventions

**Intervention group** pricking ear point, then pricking the Back-Shu point and cupping, once daily - 15 times for a course

**Control group:** (western medicine) tetracycline, 500 mg per time, 3 times per day cleaning the face, using Cuo Chuang Ping cream, once every morning and night - 15 days for a course

#### Outcomes

- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
- The relevance between courses and the numbers of remission participants

**Notes**

*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to two groups by random number table…” Comment: Even though no more detailed information was provided, it was probably generated appropriately</td>
</tr>
<tr>
<td>Bias</td>
<td>Authors' judgement</td>
<td>Support for judgement</td>
</tr>
<tr>
<td>---------------------------------------------------------------------</td>
<td>--------------------</td>
<td>---------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to two groups by random number table…”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of 'low' or 'high' risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>The study did not outline any blinding details; however, the intervention and control medicines were totally different therapies, so it seems unlikely that blinding of participants and personnel was maintained</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>76 participants were randomised, and all of these were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, because there was no information about the dropout and follow-up rate, it was hard to judge whether there was 'low' or 'high' risk of bias for this domain</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent</td>
</tr>
</tbody>
</table>

Tang 2011

Methods

Randomised controlled trial

Participants

There were 219 participants in the study, with 120 participants in the intervention group and 99 participants in the control group

Diagnostic criteria:

- Diagnostic and effective criteria for diseases of TCM

Inclusion criteria: unclear

Exclusion criteria: unclear

Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:

- Average age (years): I = 24.81 (5.41); C = 23.54 (5.57)
- Duration of disease (years): I = 4.35; C = 4.21

Interventions

**Intervention**: (Chinese medicine) Qin Gan Jie Yu Xiao Cuo particles orally taken, twice per day, 1 bag per time.

- Exterior use Chinese medicine, once every morning and night Chloramphenicol Tincture, external application, twice every morning and night

**Control**: roxithromycin, orally taken, 150 mg, twice daily viaminate capsules, 50 mg, 3 times daily

- Chloramphenicol tincture, external application, twice every morning and night

Outcomes

- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)

Notes

*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.
Cao et al.

Blinding of outcome assessment (detection bias)  
All outcomes  
Unclear risk  
There was insufficient information about the blinding method of outcome assessors to permit judgement of 'low' or 'high' risk of bias  

Incomplete outcome data (attrition bias)  
All outcomes  
Unclear risk  
Because there was no information about the dropout and follow-up rate, it was hard to judge whether there was 'low' or 'high' risk of bias for this domain  

Selective reporting (reporting bias)  
Unclear risk  
Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article  

Other bias  
Unclear risk  
No funding issue was apparent  
No sample size calculation was provided  

Wang 2012

Methods  
Randomised controlled trial  

Participants  
There were 80 participants in the study, with 40 participants in each group  

Diagnostic criteria:  
- Chinese textbook: Clinical Dermatology  

Inclusion criteria:  
- met the diagnostic criteria for acne  
- aged 15 to 45 years old  
- did not receive any internally used anti-acne medicine within 30 days and externally used medicine within 7 days before enrolment  

Exclusion criteria:  
- allergic to experimental drug/ingredient  
- pregnant or lactating  
- received any internally used anti-acne medicine within 30 days and externally used medicine within 7 days  
- had other severe original disease or mental disease  
- had occupational acne or acne caused by drugs  
- had acne fulminans or acne conglobata  

Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:  
Average age (years): I = 24.1 (5.49); C = 24.35 (6.33)  
Sex ratio, male/female: I = 14/26; C = 16/24  
Duration of disease (years): I = 1.99; C = 2.13

Interventions  

Intervention: modified Cuo Chuang Fang, orally taken, 100 ml, 2 times per day; herbs steaming, used Automatic Chinese Medicine Steaming Instrument (provided by Changzhou Zhengrong Medical Equipment Co. Ltd, type: XZQ-V) to prepare herbs for steaming, 15 minutes per time, 2 times per week for 6 weeks  
Control: modified Cuo Chuang Fang; 0.1% adapalene Gel (Vitamin A acid) (trade name: Differin, provided by Laboratoires Galderma S.A.) externally used once per night

Outcomes  

- Symptom scores (according to “Guiding principle of clinical research on new drugs of traditional Chinese medicine”)  
- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)  
- Level of serum testosterone test  
- Incidence of recurrence  
- Adverse events  
- Incidence of adverse events

Notes  
*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

Risk of bias  

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>

Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.
Random sequence generation (selection bias) | Low risk | Quote: “Patients were randomly assigned to two groups by random number table…” Comment: Random sequence generation was probably generated appropriately
---|---|---
Allocation concealment (selection bias) | Unclear risk | There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias
Blinding of participants and personnel (performance bias) | High risk | The study did not outline any blinding details; however, as participants in the treatment group were given steamed TCM, which were not given in the control group, it seems unlikely that blinding of participants and personnel was maintained
Blinding of outcome assessment (detection bias) | Unclear risk | There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias
Incomplete outcome data (attrition bias) | Low risk | 80 participants were randomised, and all of these were included in the analysis Quote: “All participants completed the study”
Selective reporting (reporting bias) | High risk | In the methods section, authors did not mention that the relapse rate would be measured, but they reported it in the results section. As we could not find the protocol for this trial, it might not have reported all of the primary outcomes for this trial
Other bias | Unclear risk | No funding issue was apparent
No sample size calculation was provided

Wei 2012

Methods | Randomised controlled trial
---|---
Participants | There were 100 participants in the study, with 50 participants in each group
Diagnostic criteria:
- Western medicine criteria: Guiding principle of clinical research on new drug of Traditional Chinese Medicine
- Chinese textbook: Clinical Dermatology
- TCM criteria: Guiding principle of clinical research on new drug of Traditional Chinese Medicine and Diagnosis and treatment terminology of Traditional Chinese Medicine
Inclusion criteria:
- met the western medicine diagnostic criteria for acne
- met the Chinese Medicine’s criteria for having 1 primary symptom and 2 secondary symptoms
- aged 13 to 40 years old
- did not receive any internally used anti-acne medicine within 30 days or externally used medicine in the previous 7 days before enrolment
- had no severe original disease or mental disease
- obtained informed consent
Exclusion criteria:
- had Class I acne according to Pillsbury
- allergic to experimental drug
- pregnant or lactating
- had occupational or pharmaceutical acne
- received any internally used anti-acne medicine within 30 days or externally used medicine within 7 days
- had other severe original disease or mental disease
- did not meet the inclusion criteria
Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:
Average age (years): I = 28 (2.02); C = 27 (3.8)
Sex ratio, male/female: I = 25/25; C = 26/24

Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.
### Interventions

**Intervention:** decoction with function of clearing liver and eliminating dampness, 200 ml, orally taken 30 min after meal, twice daily for 8 weeks

**Control:** minocycline hydrochloride capsules (Wyeth Pharmaceutical Company, Ltd., H10960010), 50 mg per time, 2 times daily for 8 weeks

### Outcomes

Measured at 2, 4, and 8 weeks:
- Symptom scores (according to “Guiding principle of clinical research on new drugs of traditional Chinese medicine”)
- Number of rash
- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
- Adverse events

### Notes

**“remission”** was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Using SPSS 17.0 software to generate random number, patients were assigned to two groups…”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: “…took the random number into opaque envelopes…”</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>No blinding details were outlined; however, the intervention and control medicines were totally different therapies, so it seems unlikely that blinding was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>100 participants were randomised, and all of these were included in the analysis. The study reported that during the follow-up of 1 month, there was no recurrence in the treatment group and 2 cases in the control group. It seems likely that there were no incomplete outcome data in this study. However, because there was no detailed information about the dropout and follow-up rate, it was hard to judge whether there was ‘low’ or ‘high’ risk of bias for this domain</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>In the methods section, authors mentioned that skin lesion score would be measured and did not mention that number of rashes. However, in the results section, only skin lesion score before treatment was reported, and the number of rashes before and after treatment of each group were reported. The skin lesion score was the primary outcome. Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>No sample size calculation was provided</td>
</tr>
</tbody>
</table>

### Methods

**Participants**

There were 60 participants in the study, with 30 participants in each group

**Diagnostic criteria:**
- Guiding principle of clinical research on new drug of Traditional Chinese Medicine
- Chinese textbook: Clinical Dermatology

**Inclusion criteria:**
- met the diagnostic criteria for acne conglobata
- aged 20 to 35 years old, regardless of sex
• did not receive any internally used anti-acne medicine within 30 days before enrolment
• did not receive any externally used anti-acne medicine within 7 days before enrolment

**Exclusion criteria:**
• allergic to experimental drug
• pregnant or lactating
• had occupational or pharmaceutical acne
• had other severe original disease
• did not meet the inclusion criteria

**Participants' baseline data presented as mean (SD) for intervention (I) and control (C) groups:**
Average age (years): I = 23.70 (3.11); C = 23.70 (3.83)
Sex ratio, male/female: I = 16/14; C = 12/18
Duration of disease (months): I = 4.66 (3.78); C = 3.61 (3.11)

**Interventions**

**Intervention:** 1. facial blood-letting and quick cupping on the local area of acne by disposable blood collection needle (No. 4) inserting in the centre of the acne, then used quick cupping 3 times for bleeding of 0.5 to 1 ml. Twice per week for 10 weeks. 2. body acupuncture on LI 11, SJ 6, ST 36, ST 40, and ST 44 by filiform needle (0.25 * 40 mm) inserting upright for 0.5 to 1.2 inch, manipulated needles with neutral supplementation and drainage method, and retained the needles for 30 min. Twice per week for 10 weeks

**Control:** minocycline hydrochloride capsules (Wyeth Pharmaceutical Company, Ltd.), 50 mg per time, twice daily for 10 weeks

**Outcomes**

• Score of skin lesions (according to “Global acne grading system, GAGS”)
• Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
• Level of serum IL-1a test
• Adverse events

**Notes**

**“remission”** was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk | Quote: "Patients were randomly assigned to treatment group and control group by random number table..."  
Comment: Even though no more detailed information was provided, it was probably generated appropriately |
| Allocation concealment (selection bias) | Unclear risk | There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias |
| Blinding of participants and personnel (performance bias) All outcomes | High risk | The study did not outline any blinding details; however, because participants in the treatment group were treated by acupuncture plus moving cupping and blood-letting, while participants in the control group were given a capsule, it seems unlikely that blinding of participants and personnel was maintained |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | 60 participants were randomised, and all of these were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, because there was no information about the dropout and follow-up rate, it was hard to judge whether there was ‘low’ or ‘high’ risk of bias for this domain |
| Selective reporting (reporting bias) | Unclear risk | In the methods section, the study authors did not report the outcome measures. In addition, since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the outcomes in the article |
| Other bias | Unclear risk | No sample size calculation was provided |

**Methods**

<table>
<thead>
<tr>
<th>Wu 2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomised controlled trial</td>
</tr>
</tbody>
</table>
There were 270 participants in the study, with 86, 84, or 87 participants in the combination, herbal medicine, or control group, respectively.

**Diagnostic criteria:**
- Chinese textbook: Clinical Dermatology

**Inclusion criteria:**
- did not receive any anti-acne oral drug within 2 weeks before enrolment
- did not receive any anti-acne externally used drug within 1 week before enrolment

**Exclusion criteria:** not reported

**Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:**
- Average age (range), years: 21.78 (16 to 56)
- Sex ratio, male/female: 224/46
- Duration of disease (weeks): 23.7

**Interventions**

**Intervention:** Qingre Twenty-five Ingredients Pill, 2 g per time, twice daily for 30 days

**Control A:** staphylococcus Injection, once daily. The first injection was 0.2 ml, then increased by 0.1 ml till 0.5 ml, for 30 days

**Control B:** staphylococcus Injection plus Qingre Twenty-five Ingredients Pill. Dose and course were the same as for the other 2 groups

**Outcomes**
- Number of skin lesions
- Number of inflammatory papules
- Symptom (pain) scores
- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
- Adverse events

**Notes**
- *"remission" was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “270 patients were randomly assigned to three groups by drawing lots…” Comment: Even though no more detailed information was provided, it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of 'low' or 'high' risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>No blinding details were outlined; however, the intervention and control medicine were totally different therapies, so it seems unlikely that blinding was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of 'low' or 'high' risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>270 participants were randomised, and 3 participants in control A group, 6 participants in intervention group, and 4 participants in control B group dropped out during the treatment. The outcome data of these dropout participants were not included in the data analysis. No ITT analysis was used</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Since in the methods section, the study authors did not report the outcome measures and the protocol for this trial was not available, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent</td>
</tr>
</tbody>
</table>

- No sample size calculation was provided

**Wu 2008a**

**Methods**
- Randomised controlled trial

**Participants**
- There were 60 participants in the study, with 30 participants in each group

**Diagnostic criteria:**
### Inclusion criteria:
- not reported

### Exclusion criteria:
- not reported

### Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:
- Average age (years): I = 26.13 (2.54); C = 24.83 (3.07)
- Sex ratio, male/female: I = 9/21; C = 7/23
- Duration of disease (weeks): I = 15.20 (1.36); C = 14.53 (1.87)

### Interventions

#### Intervention:
- Blood-letting and cupping
  - Selection of points: Ashi points in the first lateral line of bladder channel on the back, or Feishu (BL 13) if no obvious Ashi points
  - Method: pricked the points quickly 10 times with a 3-edged needle, then used cupping on the points for bleeding of 7 to 8 ml - once daily, 10 times as 1 treatment course
  - Course: 1 month

#### Control:
- Achromycin, orally taken, 0.25 g per time, 4 times daily; 2% Cremeorketoconazoli, externally used, once daily

### Outcomes

- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)

### Notes

*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias)   | Low risk           | Quote: “Patients were randomly assigned into intervention group and control group by random number table…”  
Comment: Even though no more detailed information was provided, it was probably generated appropriately |
| Allocation concealment (selection bias)       | Unclear risk       | There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias                                  |
| Blinding of participants and personnel (performance bias) | High risk         | The study did not outline any blinding details; however, because participants in the treatment group were treated by cupping and blood-letting, while participants in the control group were given western medicine, it seems unlikely that blinding of participants and personnel was maintained |
| Blinding of outcome assessment (detection bias) | Unclear risk       | There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias                  |
| Incomplete outcome data (attrition bias)      | Unclear risk       | 60 participants were randomised, and all of these were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, because there was no information about dropout and follow-up rate, it was hard to judge whether there was ‘low’ or ‘high’ risk of bias for this domain |
| Selective reporting (reporting bias)          | Unclear risk       | Since in the methods section, the study authors did not mention outcome measure and we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article |
| Other bias                                    | Unclear risk       | No funding issue was apparent  
No sample size calculation was provided |

### You 2012

#### Methods
- Randomised controlled trial

#### Participants
- There were 60 participants in the study, with 30 participants in each group

#### Diagnostic criteria:
- Chinese textbook: TCM Surgery
- Chinese textbook: Clinical Dermatology

#### Inclusion criteria:
- met the diagnostic criteria for acne
- aged 18 to 32 years old
- did not receive any internally used anti-acne medicine within 30 days or externally used medicine within 7 days before enrolment
Exclusion criteria:
- did not meet the diagnostic criteria
- did not comply with treatment or added some drug personally during treatment
- received any internally used anti-acne medicine within 30 days or externally used medicine within 7 days before enrolment
- pregnant, lactating, or had tumour
- had other severe original disease or mental disease

Participants' baseline data presented as mean (SD) for intervention (I) and control (C) groups:
- Average age (years): I = 24.83 (4.54); C = 24.67 (5.33)
- Sex ratio, male/female: I = 17/13; C = 16/14
- Duration of disease (months): I = 23.36 (9.74); C = 22.81 (8.43)

Interventions
- **Intervention:** 1. acupuncture on EX-HN3, EX-HN5, SI 18, RN 24, BL 13, BL19, BL 20, BL 23, DU 14, LI 11, LI 4, ST 36, and KI 3, with supplement deficiency and unblocking the collaterals method, using “three-three manipulation”, and retained the needles for 30 minutes, once daily; 2. blood-letting by 3-edged needle or No.7 needle for injection to prick the points for bleeding of 3 to 5 ml, once every 5 days, 6 times as 1 treatment course; 3. self-made Chinese herbal facial mask, externally used, once every 3 days for 10 times
- **Control:** 1. self-made Chinese herbal facial mask, external use, once every 3 days for 10 times; 2. tretinoin Cream (provided by Chongqing Huapont Pharm. Co., Ltd, H50021817), externally used every night, 4 weeks as 1 treatment course, 2 courses in total. There was a 5-day break before the next course

Outcomes
- Skin lesions scores (according to “global acne grading system, GAGS”)
- Syndrome of integral (according to “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, classified into remission*, markedly effective, effective, and ineffective)
- Adverse events

Notes
*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to two groups by random number table…” Comment: Even though no more detailed information was provided, it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>The study did not outline any blinding details; however, because participants in the treatment group were treated by acupuncture plus cupping and blood-letting, while participants in the control group were given western medicine and facial mask, it seems unlikely that blinding of participants and personnel was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>60 participants were randomised, and all of these were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, because there was no information about the dropout and follow-up rate, it was hard to judge whether there was ‘low’ or ‘high’ risk of bias for this domain</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Since in the methods section authors did not mention outcome measures, and we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent No sample size calculation was provided</td>
</tr>
</tbody>
</table>

Yu 2008

Methods Randomised controlled trial

Cochrane Database Syst Rev. Author manuscript; available in PMC 2016 January 19.
Participants

There were 48 participants in the study, with 28 participants in the intervention group and 20 participants in the control group.

Diagnostic criteria: not reported

Inclusion criteria:
- met the diagnostic criteria for acne
- met the Chinese Medicine’s criteria for liver constraint and kidney deficiency type acne

Exclusion criteria:
- had acne necrotica
- had acne conglobata
- received anti-acne medicine (including externally used) within 4 weeks
- pregnant or lactating
- had severe liver or kidney disease or haemopathy
- did not meet Chinese medicine’s criteria

Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:
- Average age (years): I = 26.4 (5.8); C = 25.8 (6.7)
- Duration of disease (months): I = 24.8 (12.6); C = 25.2 (14.9)
- Sex: female

Interventions

Intervention: ShuganZishen Fang (prepared in hospital preparation room), orally taken, 100 ml, twice per day for 8 weeks

Control: tetracycline, orally taken, 0.5 g, twice per day for 8 weeks

Outcomes

- Number of skin lesions (according to “severity classification and effectiveness evaluation standard for acne vulgaris”)
- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
- Adverse events

Notes

*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “48 patients were randomly assigned to two groups by random number table…” Comment: Even though no more detailed information was provided, it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>The study did not outline any blinding details; however, because participants in the treatment group were given TCM decoction, while participants in the control group were given western medicine, it seems unlikely that blinding of participants and personnel was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>48 participants were randomised, and all of these were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, because there was no information about the dropout and follow-up rate, it was hard to judge whether there was ‘low’ or ‘high’ risk of bias for this domain</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>In the methods section, authors mentioned the condition of skin lesion including acne, papilla, pustule before and after treatment would be measured, and the result was reported as composite outcome like total effective rate. In addition, since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
</tbody>
</table>
Yu 2011

Methods
Randomised controlled trial

Participants
There were 130 participants in the study, with 65 participants in each group

Diagnostic criteria:
- Chinese textbook: Clinical Dermatology

Inclusion criteria: not reported
Exclusion criteria: not reported

Participants’ baseline data presented in total, not for each group:
- Average age (years): 21 (4)
- Sex ratio, male/female: 73/57

Interventions

Intervention: compound Danshen tablets (provided by Guangdong Yikang Pharm. Co. Ltd.), 3 tablets per time, 3 times daily; Doxycycline Hyclate Tablets (provided by Guangdong Yikang Pharm. Co. Ltd.) 0.1 g per time, twice daily for 4 weeks
Control: Doxycycline Hyclate tablets, 0.1 g per time, twice daily for 4 weeks

Participants in both groups externally used 2% Chloramphenicol for cleaning skin

Outcomes
- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
- Adverse events

Notes
- “remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to two groups by random number table, and 65 cases in each group…” Comment: Even though no more detailed information was provided, it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>The study did not outline any blinding details; however, because participants in the treatment group were TCM patent on the basis of western medicine, while participants in the control group were given only western medicine, it seems unlikely that blinding of participants and personnel was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>130 participants were randomised, and all of these were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, because there was no information about the dropout and follow-up rate, it was hard to judge whether there was ‘low’ or ‘high’ risk of bias for this domain</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No funding issue was apparent</td>
</tr>
</tbody>
</table>

No sample size calculation was provided

Zhang 2010

Methods
Randomised controlled trial

Participants
There were 60 participants in the study, with 30 participants in each group

Diagnostic criteria:
- Guiding principle of clinical research on new drug of Traditional Chinese Medicine

Inclusion criteria:
• met the diagnostic criteria for acne
• aged 14 to 30 years old
• did not receive any internally used anti-acne medicine within 30 days or externally used medicine within 7 days before enrolment

Exclusion criteria:
• did not meet the diagnostic criteria
• did not comply with treatment or received other treatment personally
• received any internally used anti-acne medicine within 30 days or externally used medicine within 7 days before enrolment
• pregnant, lactating or had tumour
• had other severe original disease or mental disease
• had haemorrhage or likely to be subcutaneous haemorrhage
• had venereal disease or infested skin

Participants' baseline data presented as mean (SD) for intervention (I) and control (C) groups:
Average age in total (years): 22.83
Sex ratio, male/female: I = 17/13; C = 16/14
Duration of disease (months): I = 30.65 (9.53); C = 27.63 (8.83)

Interventions
Intervention: 1. acupuncture on EX-HN5, SI 18, ST 7, LI 11, LI 4, and SJ 5 by Huatuo needle inserted the points, and manipulated needles with lifting-thrusting for supplementation/drainage method. Retained the needles for 20 minutes. Once every other day, 6 times as 1 treatment course, 2 courses in total. There was a 3-day break between 2 courses; 2. blood-letting and cupping by 3-edged needle to prick DU 14, BL 13, BL 21, BL 25, BL 20, BL 17 for bleeding of 2 to 3 ml, retained the cupping for 5 min. Once every other day, 6 times as 1 treatment course. 2 courses in total. There was a 3-day break between 2 courses; 3. self-made Chinese herbal facial mask, externally used, once every 3 days, 10 times as 1 treatment course, for 6 weeks
Control: vitamin capsules (provided by Chongqing Huapton Pharm. Co., Ltd., 25 mg*20s/pack) 50 mg per time, 3 times daily for 6 weeks

Outcomes
• Skin lesions score (according to “global acne grading system, GAGS”)
• Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
• Adverse events

Notes
*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to two groups by random number table…”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: Even though no more detailed information was provided, it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>The study did not outline any blinding details; however, because participants in the treatment group were treated by acupuncture plus cupping and blood-letting, while participants in the control group were given western medicine, it seems unlikely that blinding of participants and personnel was maintained</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>60 participants were randomised, and all of these were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, because there was no information about the dropout and follow-up rate, it was hard to judge whether there was ‘low’ or ‘high’ risk of bias for this domain</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Since in the methods section, the authors had not mentioned outcome measures, and we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article.

No funding issue was apparent.

No sample size calculation was provided.

There were 80 participants in the study, with 40 participants in each group.

- Diagnostic criteria:
  - Diagnostic and Effectiveness Criteria of Traditional Chinese Medicine
  - Chinese textbook: Clinical Dermatology

Inclusion criteria:
- met the diagnostic criteria for acne
- aged 18 to 35 years old
- had acne with severity of III or IV

Exclusion criteria:
- received anti-acne treatment (including externally used) within 4 weeks
- received tretinoin agent within 6 months
- pregnant or lactating, or preparing for pregnancy within 2 years
- had severe heart, liver, or kidney disease
- received glucocorticoid or antibiotics within 1 month
- had poor compliance

Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:
- Average age (years): I = 23.60 (3.66); C = 23.5 (3.70)
- Sex ratio, male/female: I = 13/27; C = 15/25
- Duration of disease (months): I = 6.78 (4.34); C = 7.64 (4.30)

Intervention: Qing Bu Tang (herbal medicine), orally taken, 150 ml, twice daily for 4 weeks
Control: viaminate capsules (Wei An Zhi Capsules, provided by Chongqing Huapton Pharm. Co., Ltd.) 25 mg per time, 3 times daily for 4 weeks

Skin lesions score (according to “global acne grading system, GAGS”)
- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
- Level of serum IL-1a
- Adverse events

*R“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained.

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ Judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to two groups by random number table, and 40 case in each group...”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: Even though no more detailed information was provided, it was probably generated appropriately</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>The study did not outline any blinding details; however, because participants in the treatment group were given TCM decoction, while participants in the control group were given western medicine, it seems unlikely that blinding of participants and personnel was maintained</td>
</tr>
</tbody>
</table>
### Blinding of outcome assessment (detection bias)

| All outcomes | Unclear risk | There was insufficient information about the blinding method of outcome assessors to permit judgement of 'low' or 'high' risk of bias |

### Incomplete outcome data (attrition bias)

| All outcomes | High risk | 80 participants were randomised, and “during the treatment 1 case in treatment group dropped out due to no returning visit and 5 cases in control group due to adverse events or no returning visit.” The data of these participants were not included in data analysis. No ITT analysis was used |

### Selective reporting (reporting bias)

| Unclear risk | Since in the methods section, the study authors had not reported outcome measures, and we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes for this trial |

### Other bias

| Unclear risk | No funding issue was apparent No sample size calculation was provided |

---

### Zhou 2009

#### Methods

- **Randomised controlled trial**

#### Participants

- There were 40 participants in the study, with 20 participants in each group

**Diagnostic criteria:**

- Guiding principle of clinical research on new drugs of clinical Chinese Medicine

**Inclusion criteria:**

- met the western diagnostic criteria for acne
- met the Chinese Medicine’s criteria
- aged 18 to 35 years old
- did not receive any anti-acne drug in the previous month before enrolment
- did not apply external anti-acne treatment in the last 7 days

**Exclusion criteria:**

- younger than 18 or over 35 years old
- pregnant or lactating
- had acne caused by chemicals or drugs
- had other severe original disease or mental disease
- did not meet the inclusion criteria

**Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:**

- Average age (years): I = 23.95 (4.58); C = 24.50 (4.35)
- Sex ratio, male/female: I = 11/9; C = 11/9
- Duration of disease (months): I = 18.75 (7.43), C = 18.80 (6.88)

#### Interventions

**Intervention:** wet-cupping therapy. Prick on Dazhui (DU14) and Feishu (BL13) (plus other points selected according to syndrome differentiation), insert the needle 0.2 to 0.5 cm under skin, then apply the cups on the selected area until bleeding 3 to 5 ml - once every 2 days, 6 times a course, 3 days between the courses for 2 courses (27 days).

**Control:** viaminate cream (Chongqing Hua Bong pharmaceutical limited by share Ltd) externally applied on lesion skin, once every night

#### Outcomes

- Skin lesions integral (assessed according to “GAGS”)  
- Symptom improvement evaluated according to “Guiding principle of clinical research on new drugs of traditional Chinese medicine” (classified into remission*, markedly effective, effective, and ineffective)

#### Notes

- *“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to intervention and control groups…sequence was generated by SAS software 6.12…”  Comment: Even though no more detailed information was provided to describe how randomisation was assigned, it was probably generated appropriately</td>
</tr>
</tbody>
</table>
Allocation concealment (selection bias) | Unclear risk | There was insufficient information about the allocation concealment to permit judgement of ‘low’ or ‘high’ risk of bias

Blinding of participants and personnel (performance bias) | High risk | The study did not outline any blinding details; however, as the intervention and control medicines were not similar in appearance and taste, it seems likely that there was no blinding of participants and personnel

Blinding of outcome assessment (detection bias) | Unclear risk | There was insufficient information about the blinding method of outcome assessors to permit judgement of ‘low’ or ‘high’ risk of bias

Incomplete outcome data (attrition bias) | Unclear risk | 40 participants were randomised, and all of these were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, there was insufficient information about this item to permit judgement of ‘low’ or ‘high’ risk of bias

Selective reporting (reporting bias) | Unclear risk | We could not find any protocol information to assist us with judgement

Other bias | Unclear risk | No funding issue was apparent
No sample size calculation was provided

---

Zhu 2007

Methods

Randomised controlled trial

Participants

There were 80 participants in the study, with 40 participants in each group.

Diagnostic criteria:

- Chinese textbook: Clinical Dermatology

Inclusion criteria:

- met the diagnostic criteria for acne
- met the syndrome differentiation for wind-heat lung channel

Exclusion criteria:

- pregnant or lactating
- received any externally or internally used anti-acne treatment (e.g., glucocorticoid)
- had hyperlipaemia
- had abnormal liver or kidney function
- did not comply with treatment

Participants’ baseline data presented as mean (SD) for intervention (I) and control (C) groups:

- Average age (years): I = 22.68; C = 23.30
- Sex ratio, male/female: I = 15/25; C = 12/28
- Duration of disease (years): I = 16.8; C = 19.4

Interventions

Intervention: modified Cuo Chuang Fang, orally taken, twice daily for 6 weeks

Control: isotretinoin soft capsules (trade name: Taiersi, provided by Shanghai Xinyi Yanan Pharm. Co., Ltd.) 10 mg, twice per day, taken after meal for 6 weeks

Outcomes

- Symptom scores
- Syndrome of integral (classified into remission*, markedly effective, effective, and ineffective)
- Adverse events

Notes

*“remission” was defined according to the “Guiding principle of clinical research on new drugs of traditional Chinese medicine”, which means lesions totally faded (or > 95% faded), and only mild pigmentation and scars remained

---

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “80 patients all outpatients, and they were randomly assigned by random number table…”</td>
</tr>
<tr>
<td>Domain</td>
<td>Risk</td>
<td>Comment</td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>---------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the allocation concealment to permit judgement of 'low' or 'high' risk of bias</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>The study did not outline any blinding details; however, because participants in the intervention group were given TCM decoction, while participants in the control group were given western medicine, it seems unlikely that blinding of participants and personnel was maintained</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>There was insufficient information about the blinding method of outcome assessors to permit judgement of 'low' or 'high' risk of bias</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>80 participants were randomised, and all of these were included in the analysis. It seems likely that there were no incomplete outcome data in this study. However, because there was no information about the dropout and follow-up rate, it was hard to judge whether there was 'low' or 'high' risk of bias for this domain</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Since we could not find the protocol for this trial, it was hard to judge whether the study reported all of the primary outcomes in the article</td>
</tr>
</tbody>
</table>

Other bias: Unclear risk
No funding issue was apparent
No sample size calculation was provided

ASI = Acne Severity Index.
ATP = adenosine triphosphate.
I = intervention.
IL = interleukin.
ITT = intention-to-treat.
BMI = body mass index.
BUN = blood urea nitrogen.
C = control group.
h = hour.
intervention = intervention group.
IL = interleukin.
KAGS = Korean Acne Grading System.
GAGS = Global Acne Grading System.
GI = glycaemic index.
KRTE = Keigai-rengyo-to-extract.
mean (SD) = mean (standard deviation).
min = minutes.
No. = number.
LED = light-emitting diode.
LGLD = low-glycaemic-load diet.
LOCF = last observation carried forward.
PBV = purified bee venom.
TCM = Traditional Chinese Medicine.
TLC = total lesion count.
QoL = quality of life.
Characteristics of studies awaiting assessment [ordered by study ID]

<table>
<thead>
<tr>
<th>ACTRN12605000233628</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
</tr>
<tr>
<td><strong>Participants</strong></td>
</tr>
<tr>
<td>Sample size: 18</td>
</tr>
<tr>
<td>Inclusion criteria:</td>
</tr>
<tr>
<td>• people with acne vulgaris lesions.</td>
</tr>
<tr>
<td>• 14 to 18 years</td>
</tr>
<tr>
<td>• both males and females</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
</tr>
<tr>
<td>• no exclusion criteria</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
</tr>
<tr>
<td>Intervention group:</td>
</tr>
<tr>
<td>Control group:</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
</tr>
<tr>
<td>• Decrease in the number of pustules and other lesions</td>
</tr>
<tr>
<td>• Subject perception of changes in acne</td>
</tr>
<tr>
<td><strong>Notes</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ACTRN12607000140459</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
</tr>
<tr>
<td><strong>Participants</strong></td>
</tr>
<tr>
<td>Sample size: 20</td>
</tr>
<tr>
<td>Inclusion criteria:</td>
</tr>
<tr>
<td>• people with mild to moderate inflammatory acne, of any racial/ethnic group</td>
</tr>
<tr>
<td>• 15 years to 35 years</td>
</tr>
<tr>
<td>• both males and females</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
</tr>
<tr>
<td>• oral retinoid use within 2 years of entry into the study</td>
</tr>
<tr>
<td>• systemic acne therapies within 4 weeks of entry into the study</td>
</tr>
<tr>
<td>• people with predominantly comedone acne</td>
</tr>
<tr>
<td>• people with predominant retention acne</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
</tr>
<tr>
<td>Intervention group:</td>
</tr>
<tr>
<td>Control group:</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
</tr>
<tr>
<td>• 2 grade improvement in Investigators Global Assessment (IGA)</td>
</tr>
<tr>
<td>• Reduction in Inflammatory Lesion Count</td>
</tr>
<tr>
<td><strong>Notes</strong></td>
</tr>
</tbody>
</table>